Protocol I8F- MC-GPHK(b)  
 
Efficacy and Safety of Tirzepatide Once Weekly in Participants  
without Type [ADDRESS_318367] Obesity or are Overweight with Weight- 
Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial 
(SURMOUNT -1) 
 
[STUDY_ID_REMOVED]  Approval Date: 04- Oct-2021 
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators.  It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_261708] (LY3298176) , unless such persons are bound by [CONTACT_261722].  
Note to Regulatory Authorities:   This document may contain protected personal data and/or commer cially confidential 
information exempt from public disclosure.  Eli Lilly and Company requests consultation regarding release/redaction prior to any 
public release.  In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exempt ion 4 and may not be 
reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.
Protocol Title: Efficacy and Safet y of Tirzepat ide Once Weekly in Parti cipants 
without Ty pe [ADDRESS_318368] O besityor are Overweight w ith Weight -
Related C omorbidities:A Rando mized, Double -Blind, P lacebo -Controlled T rial 
(SURMOUNT -1)
Protocol Number: I8F-MC-GPHK (b)
Compound Number: LY3298176
Study Phase: Phase 3
Short Title: Efficacy and Saf ety of Tirzepat ide Once Weekly V ersus Pl acebo in Parti cipants 
Who are either Obese or Overweight with Weight -Related Com orbidities(SURMOUNT -1)
Acronym: SURMOUNT -1
Sponsor Name: [CONTACT_134142]: Indianapolis, Indiana ,[LOCATION_003] [ZIP_CODE] 
Regulatory Agency Identifier Number(s)
IND: 139721
Approval Date :  Protocol Amendment ( b) Electronically Signed and Approved by [CONTACT_41378].
Approval Date: 04-Oct-2021 GMT
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 2Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Amendment (a) 24-Jul -2020
Original Protocol 09-Sep -2019
Overall Rationale for Amendment (b):
The overall rationale for the current GPHK protocol  amendment i s to update the key  study  
objectives and endpo intsin Sec tion3;clarify the definit ion of incident diabetes ,add guidance for
retesting , 
confirmation , recording , and adjudicat ionof incident di abetes in Sect ion [IP_ADDRESS] ; add 
guidance i n Secti ons6.6.1 and 6.6.3 for study drug dose modificat ionduring the additional 
2-year treatm entperiod in participants with perceived excessive weight loss ; and to update 
inform ation relevant to stati stical analyses in Sect ion 9 to align wit h recent updates to the SAP .
These and other changes are listed in the below table.
Section # and 
NameDescription of Change Brief Rationa le
1.1.Synopsis
3. Obj ectives and 
EndpointsKey secondary  object iveat 20 weeks was 
modified , chang ingheading from “by [CONTACT_2715]” to 
“pool ed dose” analysis, andediting obj ective 
to reflect the pooled [ADDRESS_318369] iveat 72 week s,by [CONTACT_261723] ,was m odified :
For the body  weight object ive, added the 
endpo int “≥20% body  weight reducti on from 
rando mizat ion”.To better inform clinical 
decisio ns in management 
of peopl e living wi th 
obesit y.
Deleted the object iveand associated endpo int
for SF-36v2 acute form Physical Funct ioning 
domain score for [ADDRESS_318370] ive and associ ated 
endpo int weremoved to 
Key secondary at 72 
weeks, pooled do se
analy sis.
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 3Section # and 
NameDescription of Change Brief Rationa le
1.1. Synopsis
3. Obj ectives and 
Endpoints Revised key secondary  objective at 72 weeks
from “by [CONTACT_2715]” to “ pooled dose”analysis to 
demonstrate that the pooled [ADDRESS_318371] iveat 72 weeks, 
pooled dose analysis for tirzepat ide (all doses 
combined) to dem onstrate superi ority to 
placebo for lipid parameters , the endpo int was 
modified to repl ace “LDL ”with “non -HDL
cholesterol”, and to replace “total” with 
“HDL” cho lesterol .Emerging science 
indicates assessing HDL -
cholesterol  in addit ion to 
non-HDL cho lesterol  
shoul d provi de m ore 
valuable data on CVD risk
in this specific populat ion.
1.1. Synopsis
3. Obj ectives and 
Endpoints Addit ionalsecondary  objective at [ADDRESS_318372] 
“HDL ”with “LDL ”cholesterol , and to add 
“total chol esterol ”.For consistency and to 
reflect the changes to the 
key secondary  object ives.
[IP_ADDRESS].3. 
Addit ional 2-Year 
Treatment Period 
for Parti cipants 
with Predi abetes 
at Ran domizat ion 
(Visits 101 
through 116)Added wording “unless diabetes had been 
diagnosed pri or to t he visits” .For clarity
.
[IP_ADDRESS]. Oral 
Glucose 
Tolerance TestAdded wording regarding use of OGTT for 
confirming diagnosis o f diabetes .For cl arity and 
consistency wit hnew text 
related toconfirmation of 
diabetes di agnosis in
Secti on [IP_ADDRESS] .
[IP_ADDRESS] .Definit ion 
and Management 
of Incident 
DiabetesRevised definit ion of incident diabetes and 
added subsect ions containing clarifying 
inform ation related to “Confirmat ion of 
diabetes di agnosis ”and “Recording ofincident 
diabetes events ”.Definit ion of incident 
diabetes was revised to 
clarify the cri teria 
regarding the requirement 
for 2abnormal test results 
to confirm the diagnosis .
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 4Section # and 
NameDescription of Change Brief Rationa le
6.6.1. Ti rzepati de Added sentence allowing dose modification for 
management of participants with perceived 
excessive weight loss during the additional 2-
year treatm entperiodfor parti cipants wi th 
predi abetes at r andomization .To support patient 
management and retention 
in the additional 2-year 
treatm entperiod .
6.6.3. 
Management of 
Parti cipants wi th 
Perceived
Excessive Weight 
Loss During the 
Addit ional 2-year 
Treatment Period 
for Participants 
with 
Prediabetes 
at Randomizat ionAdded this subsect ion containing informat ion
for managing parti cipants wi th perceived 
excessive weight loss during the additional 2-
year treatm entperiodfor parti cipants wi th
predi abetes at randomization .Provi de cl ear, detailed
inform ation for managing
and retaining participant s
in the additional 2-year 
treatm entperiod .
7.2. Participant 
Discontinuati on/
Withdrawal from 
the StudyAdded bullet point “Female parti cipants will 
be wit hdrawn fro m the study  if the parti cipant 
beco mes pregnant. ”For cl arity in parti cipant 
management .
9.1. Statistical 
Hypothe sesUpdated to reflect the changes specified in the 
key secondary  object ivesand endpo ints in 
Secti on3.For c onsistency .
[IP_ADDRESS]. Primary  
AnalysesUpdated informat ion onestimands and related 
analys e
s.To address and align with 
FDA feedback .
[IP_ADDRESS]. Key  
Secondary  
AnalysesUpdated to reflect the changes specified in the 
key object ivesand endpoints in Sec tion3.For consistency .
[IP_ADDRESS].2. Events 
Related to 
Potenti al Abuse 
Liabi lityUpdated to r eplace current informat ion with 
“To identify AE term s suggest ive of potential 
abuse liabilit y, narrow term s from SMQ of 
Drug abuse and dependence (20000101) will 
be used .
”Based on mechanism o f 
action of  tirzepat ide, 
anticipated gastrointestinal 
adverse events, and low 
likelihood for abuse 
potenti al/psychoact ive 
effects, it isreasonable to 
narrow the list of abuse 
terms use d.
10.1.4. 
Committee 
StructureAdded wording pertaining to adjudicat ion of 
incident diabetes events and cross
-reference to 
related details in Section4.1.2.3 .For cl arityand 
consistency .
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 5Section # and 
NameDescription of Change Brief Rationa le
10.4.Appendix 4 : 
Contraceptive 
Guidance and 
Collect ion of 
Pregnancy 
Inform ationIn subsect ion for “Female Parti cipants who 
become pregnant”, m odified final sentence to 
indicate that if a study  partici pant becom es 
pregnant , the participant will discontinue study  
intervent ion“and” will be withdrawn fro m the 
study.For clarityand to align 
with other changes in 
protocol Secti on7.2.
10.7.Appendix 7: 
Protocol  GPHK 
Standardi zed 
Protocol s for the 
Measurement of 
Height, Wei ght, 
Waist 
Circumference, 
Vital Signs, 
Electrocardiogra
m, and Oral  
Glucose 
Tolerance TestAdded note in the text stating that placement 
of a venous cannula may  not be requi redwhen 
a 2-hour OGTT is repeated to confirm the 
diagnosis of diabetes during the study , and 
only samples at 0 and 120 minutes for glucose 
measurement will be co llected.For cl arityand to align 
with changes in 
Secti on4.1.2.2.
Throughout Usedthe term “additional 2-year treatment
periodfor parti cipants wi th predi abetes at 
rando mizat ion” to repl ace similar but 
inconsistent ly used terms when referring to the 
study  period following primary outcom e at 
Visit 21(Week 72 )
.For clarity and 
consistency .
Throughout Minor ,editorial and document formatting 
revisio ns.Minor, therefore have not 
been summarized.
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 6Table of Contents
1. Protocol Summary ...................................................................................................... [ADDRESS_318373] ivities for additional 2-year treatment period for 
participants wi th predi abetes at randomizat ion............................................................ 22
2. Introduction .............................................................................................................. 29
2.1. Study  Rati onale .......................................................................................................... 29
2.2. Backg round ................................................................................................................ 30
2.3. Benefit/Risk Assessment ............................................................................................ [ADDRESS_318374] ivity........................................................................................................ 55
5.4. Screen Failures ........................................................................................................... 55
6. Study Intervention .................................................................................................... 56
6.1. Study  Intervent ions Administered ............................................................................... 56
6.1.1. Medical Devices ......................................................................................................... 56
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 57
6.3. Measures to Minimize Bias:  Rando mizat ion and Blinding ......................................... 57
6.4. Study  Intervent ion Compliance ................................................................................... 58
6.5. Concomitant Therapy .................................................................................................58
6.6. Dose Modificat ion...................................................................................................... 59
6.6.1. Tirzepati de................................................................................................................. 59
6.6.2. Management of Participants with Gastrointestinal Symptoms ..................................... 59
6.6.3. Management of Participants with Perceived Excessive Weight 
Loss During the Addit ional 2-year Treatment Period for 
Parti cipants wi th Prediabetes at Rando mizat ion.......................................................... 60
6.7. Intervention after the End of the Study ........................................................................ 60
6.7.1. Treatment after Study  Com pletion.............................................................................. 60
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 77. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 61
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 61
7.1.1. Temporary  Study  Drug Di scontinuati on...................................................................... 63
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 64
7.2.1. Parti cipant Disposi tion and Timing of Safet y Follow-up for the 
Primary Endpo int (72 Weeks) ..................................................................................... [ADDRESS_318375] ing AE and SAE 
Inform ation................................................................................................................. 75
8.3.2. Follow-up of  AEs and SAEs ....................................................................................... 75
8.3.3. Regulatory  Reporting Requirements for SAEs ............................................................ 75
8.3.4. Pregnancy ................................................................................................................... 76
8.3.5. Medical Device Incidents (Including Malfunct ions).................................................... 76
8.3.6. Com plaint Handling ................................................................................................... 77
8.4. Treatment of Overdose ............................................................................................... 77
8.5. Pharmacokinet ics........................................................................................................ 78
8.6. Pharmacodynamics ..................................................................................................... 78
8.7. Genet ics..................................................................................................................... 78
8.7.1. Who le Blood Sample(s) for Pharmacogenet ic Research .............................................. 78
8.8. Biomarkers ................................................................................................................. 79
8.9. Heal th Economics ....................................................................................................... 79
9. Statistic al Considerations ......................................................................................... 80
9.1. Statistical Hypotheses .................................................................................................80
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 89.2. Sample Si ze Determinat ion......................................................................................... [ADDRESS_318376] ical Considerat ions............................................................................... 83
9.4.2. Treatment Group Comparabilit y................................................................................. 84
9.4.3. Efficacy Analyses ....................................................................................................... 84
9.4.4. Safety Analyses .......................................................................................................... 86
9.4.5. Pharmacokinet ic/Pharmacodynamic Analyses ............................................................ 88
9.4.6. Evaluat ion of Immunogenicit y.................................................................................... 88
9.4.7. Other Analyses ........................................................................................................... 88
9.5. Interim Analyses ......................................................................................................... 89
10. Supporting Documentation and Operational Considerations ................................ 90
10.1. Appendix 1:  Regulatory , Ethi cal, and Study  Oversight 
Considerations ............................................................................................................ 90
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 90
10.1.2. Inform ed Consent Process .......................................................................................... 90
10.1.3. Data Protection ........................................................................................................... 91
10.1.4. Committees Structure .................................................................................................91
10.1.5. Disseminat ion of Clinical Study  Data ......................................................................... 91
10.1.6. Data Qualit y Assurance .............................................................................................. 92
10.1.7. Data Capture System .................................................................................................. 92
10.1.8. Source Documents ...................................................................................................... 93
10.1.9. Study  and Si te Cl osure ................................................................................................ 93
10.1.10. Publicat ion Policy ....................................................................................................... 93
10.2. Appendix 2:  Clinical Laboratory  Tests ....................................................................... 94
10.3. Appendix 3:  Adverse Events:  Definit ions and Procedures for 
Recording, Evaluat ing, Follow -Up, and Reporting ...................................................... 98
10.3.1. Speci al Safet y Topi [INVESTIGATOR_1102].................................................................................................98
10.4. Appendix 4:  Contraceptive Guidance and Collection of 
Pregnancy Information ............................................................................................. 104
10.5. Appendix 5:  Liver Safet y:  Suggested Acti ons and Follow -Up 
Assessments ............................................................................................................. 108
10.6. Appendix 6:  Medical Device Incidents:  Definit ion and 
Procedures for Recording, Evaluat ing, Fo llow-Up, and Reporting ............................ 109
10.7. Appendix 7:  Protocol GPHK Standardized Protocols for the 
Measurement of Height, Weight, Waist Circumference, Vital 
Signs, El ectrocardi ogram , and Oral  Glucose Tol erance Test ..................................... 111
10.8. Appendix 8:  Suggested Visit Structure ..................................................................... 114
10.9. Appendix 9:  Management of Gastrointest inal Symptoms ......................................... 115
10.10. Appendix 10:  Provi sions f or Changes in Study  Conduct During 
Except ional Circumstances ....................................................................................... 116
10.11. Appendix 11:  Abbreviat ions.................................................................................... 120
10.12. Appendix 12: Protocol Amendment History ............................................................. 125
11. References ............................................................................................................... 127
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 91. Protocol Summary
1.1. Synopsis
Protocol Title:
Efficacy and Safet y of Tirzepat ide Once Weekly in Parti cipants wi thout Type [ADDRESS_318377] Obesity or are Overweight with Weight -Related Com orbidities:A Rando mized, Double-
Blind, Placebo -Controlled Trial (SURMOUNT -1)
Short Title:
Efficacy and Saf ety of Tirzepat ide Once Weekly V ersus Pl acebo in Parti cipants Who are either 
Obese or Overweight with Weight -Related Com orbidit ies (SURMOUNT -1)
Rationale :
Obesit y is a chronic disease and i tsincreasing prevalence is a public healt h concern associated 
with therising incidence of ty pe 2 diabetes mellitus (T2DM) , increased risk for premature death 
and increased risk for some cancers ( Allison et al . 2008 ; AMA 2013 ;Council on Sci ence and 
Public Health2013 ).  Although loss of 5 % to 10% body  weight has been shown to reduce 
complicat ions related to obesit y and improve quality  of life (Mertens and Van Gaal 2000;
Knowl er et al . 2002 ; Jensen et al . 2014 ; Li et al . 2014 ;Warkentin et al. 2014) , lifest yle therapi[INVESTIGATOR_261709] (Dombrowski et al . 
2014).  
The gut i ncretin hormones, glucose -dependent insulinotropic polypept ide (GIP) and glucagon -
like peptide -1 (GLP -1),are secreted after meal ingestion and mediate the incret in effect.  Both 
horm ones have effects on endocrine cells in the pancreas, increasing insulin bio synthesis and 
secretion, and modifying glucagon secret ion (Skow et al. 2016).  Based on these properti es, 
several GLP -1 receptor (GLP -1R) agonists have been approved for pharmaco logical treatm ent of 
T2DM ( Tomlinso n et al . 2016) .
In addit ion to i ts pancreat ic effects, GLP -1R activation decreases gut motilit y, slows gastric 
emptying,and promotes satiet y (presum ably through a combinat ion of GLP -1R act ivation in the 
central  and peri pheral  nervous system s), thereby  [CONTACT_261724](Baggi o 
and Drucker 2007). The US Food and Drug Administration and the European Medicines 
Agency approved the GLP -1R agoni st liraglut ide for the treatment of overweig ht and obesit y 
(SAXENDA ® package insert , 2014; SAXENDA® SmPc , 2015 ).
Preclinical data indicate that GIP also exert seffects on appetite regulat ion and food intake ,
adipose ti ssue,and on peripheral  energy metabo lism. Although studi es evaluating effects of GIP 
on body  weight have yielded equivocal results, GIP receptor (GIPR) activationmay play a role 
in body  weight regul ationand targeting both the GLP -1R and the GIPR simultaneously may
resul t in addi tive or synergist ic effects of the 2 incretins on body weight (Coskun et al. 2018).
Tirzepati de is a [ADDRESS_318378]. Its 
structure is based on the GIP sequence and includes a C20 fatty  diacid m oiety.It is administered 
once -weekly (QW) by [CONTACT_6567] (SC) inject ion(Coskun et al. 2018).
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 10As a dual  GIP/GLP -1R agoni st, tirzepat idecould exceed the efficacy  of select ive GLP -1R 
agonists by [CONTACT_261725] -1R agonists (for 
example, adipose tissue as indicated by [CONTACT_261726]) (Baggio 
and Drucker 2007) and has the potential to reach higher efficacy in target tissues ,such as insulin -
producing pancreatic betacells that express both GIPR and GLP -1R, before reaching its 
therapeuti climitat ion. 
Study  I8F-MC-GPHK (GPHK ; SURMOUNT -1) is a Phase 3, mult icenter, randomized, placebo -
controlled, double -blinded study  of the safet y and efficacy  of 
5-mg, 10-mg and 15-mg tirzepat ide 
QW, com pared withplacebo , 
when used i n conjuncti on wi th a reduced -calorie diet and increased 
physical act ivityfor wei ght m anagement, in participants who do not have T2DM, and have 
obesit y (BMI ≥30kg/m2) or are overwei ght (BMI ≥27kg/m2)with at least one weight -related 
comorbid condi tion (for example , hypertensi on, dyslipi[INVESTIGATOR_035], or cardiovascular disease ).  All 
participants will be rando mized to at least [ADDRESS_318379] potential differences in progression to 
T2DM.
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 11Objectives and Endpoint s
Objectives Endpoints
Primary
at 72 weeks , by [CONTACT_261727] 10 mg QW is superior 
to placebo for :
percent change in body weight AND
percentage of participants with ≥5% body 
weight reduction 
AND/OR
To demonstrate that tirzepatide 15 mg QW is superior 
to placebo for :
percent change in body weight AND 
percentage of participants with ≥5% body 
weight reduction mean percent change in body weight from 
randomization
percentage of study participants who achieve ≥5% 
body weight reduction from randomization  
Key secondary (controlled for Type I error)
at 20 weeks , pooled dose analysis
For pooled tirzepatide 10 mg and 15 mg QW doses, to 
demonstrate superiority to placebo for: 
body weight mean change in body weight (kg) from 
randomization
Key secondary (controlled for Type I error)
at 72 weeks , by [CONTACT_261727] 5 mg QW is superior 
to placebo for :
percent change in body weight AND 
percentage of participants with ≥5% body 
weight reduction  mean percent change in body weight from 
randomization 
percentage of study participants who achieve ≥5% 
body weight reduction from randomization  
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 12Objectives Endpoints
For tirzepatide 10 -mg and/or 15 -mg QW doses , to 
demonstrate superiority to placebo for : 
body weight percentage of participants who achieve :
o≥10% body weight reduction from 
randomization
o≥15% body weight reduction from 
randomization
o≥20% body weight reduction from 
randomization 
waist circumference mean c hange in waist circumference (cm) from 
randomization
Key secondary (controlled for Type I error)
at 72 weeks, pooled dose analysis
To demonstrate that pooled tirzepatide 10 mg and 15 
mg QW is superior to placebo for:
patient -reported outcomes (SF -36v2 acute 
form Physical Functioning domain score)mean change in SF-36v2 acute form Physical 
Functioning domain score from randomization
Key secondary (controlled for Type I error)
at 72weeks, pooled dose analysis
For tirzepatide QW (alldoses combined), to 
demonstrate superiority to placebo for: 
lipid parameters 
SBP
insulin mean change from randomization in 
otriglycerides (mg/dL)
onon-HDL cholesterol (mg/dL)
oHDL cholesterol (mg/dL)
mean c hange in SBP ( mmHg )from randomization
meanchange in fasting insulin (pmol/L) from 
randomization
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 13Objectives Endpoints
Key secondary (controlled for Type I error)
at 176 weeks , by [CONTACT_261728] 10 -mg and/or 15 -mg QW doses , to 
demonstrate superiority to placebo (forparticipants 
with prediabetes at randomization) for: 
body weightmean percent change in body weight from 
randomization
Key secondary (controlled for Type I error)
at 176 or 193 weeks, pooled dose analysis
For tirzepatide QW (all doses combined), to 
demonstrate superiority to placebo (for participants 
with prediabetes at randomization) in :
delayed progression to T2DM at 176 weeks
delayed progression to T2DM at 193 weekstime to onset of T2DM during 176 week s
treatment period
time to onset of T2DM during entire study 
including safety follow up period
Additional secondary at 72 weeks, by [CONTACT_261728] 5-mgQW dose, to demonstrate 
superiority to placebo for:
body weight
waist circumference
patient -reported outcomes (SF -36
v2 Phy sical 
Functioning )
For tirzepatide 5-mg, 10 -mg,and/o r 15-mg QW 
doses, to demonstrate superiority to placebo for :percentage of participants who achieve:
o≥10% body weight reduction from 
randomization
o≥15% body weight reduction from 
randomization
mean change in waist circumference (cm) from 
randomization
meanchange in SF -36
v2 acute form Physical 
Functioning domain score from randomization
body weight  mean c hange in body weight (kg) from 
randomization
mean change in BMI (kg/m2)from randomization
glycemic control mean c hange in HbA1c (%, mmol/mol) from 
randomization
mean change in fasting glucose (mg/dL) from 
randomization
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 14Objectives Endpoints
patient -reported outcomes mean change in IWQOL -Lite-CT Physical 
Function composite score from randomization
Additional secondary at 72 weeks, pooled dose 
analysis
For tirzepatide QW (alldoses combined), to 
demonstrate superiority to placebo for:
DBP mean c hange in DBP ( mmHg ) from 
randomization
lipid parameters mean change from randomization in:
oLDL -cholesterol (mg/dL)
ototal cholesterol (mg/dL)
oVLDL -cholesterol (mg/dL)
o free f atty acids (mg/dL)
Additional secondary at 176 weeks, by [CONTACT_261729] 5-mg QW dose, to demonstrate 
superiority to placebo (forparticipants with 
prediabetes at randomization) for:
body weight
For tirzepatide 5 mg, 10 mg and/or 15 mg QW doses, 
to demonstrate superiority to placebo (forparticipants 
with prediabetes at randomization) for:
body weightmean percent change in body weight from 
randomization
percentage of study participants who achieve ≥5% 
body weight reduction from randomization  
Additional Secondary at 176 weeks, pooled dose
analysis
For tirzepatide QW (all doses combined) , to 
demonstrate superiority to placebo (for participants 
with prediabetes at randomization) for:
Patient -reported outcomes mean c hange in SF -36v2 acute form P hysical 
Functio ning domain score from randomization
mean change in IWQOL -Lite-CT Physical 
Function composite score from randomization
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 15Objectives Endpoints
Additional Secondary
Pharmacokinetics/Pharm acodynamics
To characterize the population PK of tirzepatide 
and explore the relationships between the 
tirzepatide concentration andefficacy, safety and 
tolerability measurespopulatio n PK and PD parameters
Abbreviations: AUC= area under curve: BMI =body mass index ;DBP =diastolic blood pressure; 
HbA1c =hemoglobin A1c; HDL =high-density lipoprotein; IWQOL -Lite-CT =Impact of Weight on Quality of 
Life-Lite-Clinical Trials Version ;LDL = low-density  lipoprotein; PK = pharmacokinetics; QW =once-weekly ; 
SF-36v2 =Short Form survey -36version 2; SBP = systolic blood pressure; T2DM = type 2 diabetes mellitus ; 
VLDL = very low -density  lipoprotein.
CONFIDENTIAL Protocol  I8F-MC-GPHK( b)
LY3298176 16Overall Design :
Study  I8F-MC-GPHK is a Phase 3, mult icenter, rando mized, placebo -controlled, double -blinded 
study  of the safet y and efficacy of 5-mg, 10-mg,and [ADDRESS_318380] o besity (BMI ≥30 kg/m2) or are overwei ght 
(BMI ≥27kg/m2) with weight -related comorbidit ies (excluding T2DM ).  Eligible participants 
will be stratified based on prediabetes status to either 72 (no predi abetes) or 176 weeks
(prediabetes) ,follow
-up for endpoints of weight loss ,and delay  of diabetes onset .
Disclosure Statement : This is a paral lel group -treatment study  with 4arms that is parti cipant 
and invest igator blinded .
Number of Participant s:
Approximately 2400 participants will be randomized in a 1:1:1 :1ratio to 5-mg tirzepat ide (600 
participants), 10
-mg tirzepat ide (600 participants), 15-mg tirzepat ide (600 participants ), and 
placebo ( 600 participants ). An upper limit of 70% enrollment of w omen will be used to ensure a 
sufficient ly large sample of men.
Intervention Groups and Duration :
Study  parti cipants will be randomized in a 1:1:1:1 rati o (tirzepat ide 5 mg QW, tirzepat ide 10 mg 
QW, ti rzepat ide 15 mg QW, and placebo QW),stratified by [CONTACT_1606] , sex, and prediabetes status.
All participants will undergo a 
2-week screening period and a 72-week treatment period
including a [ADDRESS_318381] 72 w eeks will undergo a further 104 -week treatm entperiod (total 
treatm ent duration of176 weeks).  The safet y follow
-up period will be 4 weeks (for those 
completing or discont inuing study  drug during the first 72 weeks) or 17weeks (for participants 
completing or discont inuing study  drug between Weeks 72 through 176).
Data Monitoring Committee: 
Anindependent data monitoring co mmittee (DMC) will review unblinded interim -analysis 
resul ts.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 171.2. Schema
Abbreviations:  QW= once weekly; T= telephone visit
All participants will be randomized to at least [ADDRESS_318382] potential differences in progression to T2DM . The safety follow -up visit will occur after 4 weeks in partic ipants
discontinuing (or completing ) the study withi n the first 72 weeks.  Those discontinuing (or completing) the study after 
72weeks will undergo safety follow -up after 17weeks .

CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 181.3. Schedule of Activities
The Schedule o f Activities described below should be fo llowed for all pa rticipant s enrolled in Study  GPHK. However, for th ose 
participant swhose participat ion in this study  is affected by  [CONTACT_261730] (such as pandemics or natural disasters), please 
refer to Section 10.10 Appendix 1 0for addi tional guidance.
1.3.1. Schedule of Activities covering visits to primary study endpoint
Visit * 123*45678910111213141516171819202199* ED* 801*
Week of Treatment -2-[ADDRESS_318383] TxP
Allowable D eviation 
(days) *±3±3±3+7±3+7±3±3±3±3+7±3±3±3±3±3±3±3±3±7±7 ±3
Fasting Vis it* XXXXXXXXX X X X XX X X
Telephone Visit XX XX XX XX
Infor med consent X
Randomization X
Register study v isit in 
IWRSX X X X X X X X X XX X XX X XX X XX X X X X
Clinical Assessments
Medical history * X
Physical examination X
Height X
Weight * X X X X X X X X X X X X X X X
Waist circumference XXXXXXX X X X XX X X
Electrocardiogram * X X X X X X X X
Vital signs ( 3
sitting BP and 
HR)*X X X X X X X X X X X X X X
Adverse events and 
product complaintsXX X X X X X X X XX X XX X XX X XX X X X X
Concomitant 
medicationsX X X X X X X X X XX X XX X XX X XX X X X X
Participan tEducation and Assessment
Hand out diary, 
instruct in use *X X X X X X X
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 19Visit * 123*45678910111213141516171819202199* ED* 801*
Week of Treatment -2-[ADDRESS_318384] TxP
Allowable D eviation 
(days) *±3±3±3+7±3+7±3±3±3±3+7±3±3±3±3±3±3±3±3±7±7 ±3
Fasting Vis it* XXXXXXXXX X X X XX X X
Telephone Visit XX XX XX XX
Review study 
participant diary, 
including study -
drug compliance* X X X X X X XX X XX X XX X XX X X
Lifesty le Program 
instructio ns*X X X X X X X X X X
Review diet and 
exercise goals *X X X X X X X XX X XX X XX X XX X X
Injection training 
with autoinjector 
demonstration 
device *X
Dispense study 
drugX X X X X X X X X X X*
Observe participant 
administer study 
drug*X
Participant returns 
study drugs and 
injection suppliesX X X X X X X X X X X
Laborato ry Tests
Serum pregnancy test * X
Urine pregnancy test * X X X X X X X X X
Follicle -stimulating 
hormone test *X
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 20Visit * 123*45678910111213141516171819202199* ED* 801*
Week of Treatment -2-[ADDRESS_318385] TxP
Allowable D eviation 
(days) *±3±3±3+7±3+7±3±3±3±3+7±3±3±3±3±3±3±3±3±7±7 ±3
Fasting Vis it* XXXXXXXXX X X X XX X X
Telephone Visit XX XX XX XX
2-hour oral glucose 
tolerance test (includes 
glucose , insulin, c -
peptide at each
timepoint)*X X X
Chemistry panel (include 
Cr for eGFR calculation
and glucose )*X X X X X X X X X X
Lipid panel X X X X X X
Fasting insulin X X X X X X X X
C-peptide X X X X X X X X
Free fatty acids X X X X X X
Urinary  
albumin/creatinine X* X X X X
Cystatin-c X* X X X X
Calcitonin X* X X X X X
Hematology X* X X X X X
HbA1c X X X X X X X X X X
Pancreatic amylase, 
lipaseX X X X X X X
Thyroid-stimulating 
hormone X*
Immunogenicity 
(includes PK sample) *X X X X X X X X
TZP PK * X X X
Pharmacogenetic stored 
sampleX
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 21Visit * 123*45678910111213141516171819202199* ED* 801*
Week of Treatment -2-[ADDRESS_318386] TxP
Allowable D eviation 
(days) *±3±3±3+7±3+7±3±3±3±3+7±3±3±3±3±3±3±3±3±7±7 ±3
Fasting Vis it* XXXXXXXXX X X X XX X X
Telephone Visit XX XX XX XX
Nonpharmacogenetic 
stored sampleX X X X X X X
Mental Health Questionnaires
PHQ -9* X X X X X X X X X X X
C-SSRS 
(Baseline/Screening )
Version)*X
C-SSRS (Since Last 
Visit Version) *X X X X X X X X XX X XX X XX X XX X X X X
Self-Harm Supplement 
Form *X X X X X X X X X XX X XX X XX X XX X X X X
Self-Harm Follow -up 
Form *X X X X X X X X X XX X XX X XX X XX X X X X
Patient Reported Outcomes
  PGI S X X X
SF-36, versio n 2, acute 
formX X X
IWQ OL-Lite CT X X X
EQ-5D-5L X X X
                        
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 221.3.2. Schedule of Activities for additional 2-year treatment period forparticipants with prediabet esat 
randomization
Visit * 101102103104105106107108109110 111112113114115116199* ED* 802*
Week of 
Treatment788591 [ADDRESS_318387] 
TxP
Allowable Deviation 
(days) *±7±7±7 ±7±7 ±7±7±7±7±7±7±7±7±7±7±7 ±7     ±3
Fasting Visit * X X X X X X X X X X X
Telephone Visit X X X X X X X X
Register study v isit in IWRS XXX XX XXXXXXXXXXX X X X
Clinical Assessments
Weight * X X X X X X X X X X X
Waist circumference X X X X X X X X X X X
Electrocardiogram * X X X X
Vital signs ( 3sitting 
BP and HR) *X X X X X X X X X X
Adverse events/Product 
ComplaintsX X X X X X X X X X X X X X X X X X X
Concomitant 
medicationsX X X X X X X X X X X X X X X X X X X
Participan tEducation and Assessment
Hand out diary, instruct 
in use*X X X X X X X
Review study 
participant diary, 
including study drug
compliance *X X X X X X X X X X X X X X X X X
Lifesty le Program 
instructio ns*X X X X X X X X X
Review diet and 
exercise goals *X X X X X X X X X X X X X X X X X
Dispense study drug X X X X X X X
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 23Visit * 101102103104105106107108109110 111112113114115116199* ED* 802*
Week of 
Treatment788591 [ADDRESS_318388] 
TxP
Allowable Deviation 
(days) *±7±7±7 ±7±7 ±7±7±7±7±7±7±7±7±7±7±7 ±7     ±3
Fasting Visit * X X X X X X X X X X X
Telephone Visit X X X X X X X X
Participant returns study 
drugs and injection 
suppliesX X X X X X X X X
Laborato ry Tests
Urine pregnancy test * X X X X X X X X X
[ADDRESS_318389](includes glucose, 
insulin, c -peptide) *X X X X X
Chemistry panel (includes 
Cr for eGFR calculation and 
glucose) *X X X X X X X X X X
Lipid panel X X X X
Free fatty acids X X X X
Urinary  
albumin/creatinine ratioX X X X
Cystatin -c X X X X
  Calcitonin X X X X
Hematology X X X X
HbA1c X X X X X X X X X X
Pancreatic amylase, lipase X X X X
Immunogenicity (includes 
PK sample) *X X X X X X
Nonpharmacogenetic 
stored sampleX X X X
Mental Health Questionnaires
PHQ -9* X X X X X X X X X X X
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 24Visit * 101102103104105106107108109110 111112113114115116199* ED* 802*
Week of 
Treatment788591 [ADDRESS_318390] 
TxP
Allowable Deviation 
(days) *±7±7±7 ±7±7 ±7±7±7±7±7±7±7±7±7±7±7 ±7     ±3
Fasting Visit * X X X X X X X X X X X
Telephone Visit X X X X X X X X
C-SSRS (Since Last Visit 
Version)*X X X X X X X X X X X X X X X X X X X
Self-Harm Supplement 
Form *X X X X X X X X X X X X X X X X X X X
Self-Harm Follow -up 
Form *X X X X X X X X X X X X X X X XX
X X
PROs
PGIS X X X
SF-36, versio n 2acute X X X
IWQOL -Lite -CT X X X
EQ-5D-5L X X X
*Please see table below for corresponding additional information
Abbreviations: BP=blood pressure; Cr= creatinine; C-SSRS =Columbia -Suicide Severity Rating Scale; ED= early 
discontinuation of treatment; eGFR =estimated glomerular filtration rate; HbA1c =hemoglobin A1c; HR = heart rate; 
IWQOL-Lite-CT =Impact of Weight on Quality of Li fe-Lite Clinical trials; IWRS = interactive web -response sy stem ;
PGIS =Patient Global Impression of status for physical activity ; PHQ -9 = Patient Health Questionnaire -9; 
PK=pharmacokinetics; SF -36 = Short-Form -36 Health Survey version 2, acute form; Tx P =treatment period ; 
TZP =tirzepatide
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 25Additional Information Regarding A ctivities Described in Schedule of A ctivities
Activity Notes
Visit
Fasting VisitOn all office visits, study participants should be reminded to report to the site 
before taking study drug (s) in a fasting condition, after a period of 
approximately 8 hours without eating, drinking (except water), or any significant 
physical activity .Since some screening procedures need to be completed in the 
fasting state, Visit [ADDRESS_318391] be completed before processing in the IWRS.
Visit 99
Visit 199Participants wanting to discontinue the study before Week 72 will be asked to 
return for Visit 99at 72 weeks ± [ADDRESS_318392] that the participant has refused to attend. Participants wanting to 
discontinue the study after Week 72 but before Week 176 will be asked to return 
for Visit 199primarily for the body weight measurement and assessment of 
adverse events.  Refusal to attend should be documented.  
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 26ED Participants who are unable or unwilling to continue the study treatment for any 
reason will perform an E Dvisit.  If the participant is discontinuing during an 
unscheduled visit or a scheduled visit, that visit should be performed as the E D
visit.  
Safety Follow -up Visits
Visit [ADDRESS_318393] 72 weeks, 
Visit 801 (safety follow -up visit) should be performed [ADDRESS_318394] visit during the additional 2-year treatment
period for participants with prediabetes at randomization .  
Allowable Deviation (days) Thevisit date isdetermined inrelation tothedate oftherandomization visit
(±theallowed visit window).
Medical History Medical history includes assessment ofpreexisting conditions (for example,
history ofgallbladder disease, cardiovascular disease, andmedullary thyroid 
carcinoma) and substance usage (such as alcohol and tobacco).
WeightWeight measurements should be obtained per the instructions in Section 10.7.  
Body weight must be measured in fasting state.  If the participant is not fasting, 
the participan t should be called in for a new visit within the visit window to have 
the fasting body weight measured.
Electrocardiogram ECG measurements should be obtained per the instructions in Section 10.7.  
ECGs will be performed in triplicate at Weeks [ADDRESS_318395] 30 minutes prior to 
collection of blood samples for l aboratory testing, including PK samples .
Vital signs ( 3sitting BP and HR) Vital -sign measurements should be taken before obtaining an ECG tracing and 
before collection of blood samples for laboratory testing , per the instruction in 
Section 10.7.  
Hand out diary, instruct in use All training should be repeated as needed to ensure participant compliance.
Review study participant diary and study -
drug complianceData from diary ,as well as study drug compliance, should be reviewed.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 27Lifesty le Program instruction s Counselling on diet and exercise, to be performed by a dietician or equivalent 
qualified delegate, to include calculation of individualized energy requirement 
and methods to change dietary composition and amount of physical activity.  
The Lifestyle Program Instruction may be delivered on a separate day from the 
rest of that visit’s study procedures but must occur within the visit window.  
Beginning at Week 8, the Lifestyle Pro gram Instruction may be delivered by 
[CONTACT_648].
Review diet and exercise goals All training should be repeated as needed to ensure participant compliance.  
Study personnel to provide reinforcement and encouragement for lifestyle 
modifications.
Injection training with Autoinjector 
demonstration deviceAll training should be repeated as needed to ensure participant compliance
Dispense study drug Visit [ADDRESS_318396] injection of study drug(s) for women of 
childbearing potential only. Additional pregnancy tests (beyond those required 
per the Schedule of Activities) should be performed at any time during the trial 
if a menstrual period is missed, there is clinical suspi[INVESTIGATOR_51940], or as 
requi red by [CONTACT_51967].
Follicle -stimulating hormone test Follicle -stimulating hormonetestperformed atVisit 1forpostmenopausal
women atleast 40years ofagewith anintact uterus, notonhormone therapy,
and w ho have had spontaneous amenorrhea for more than [ADDRESS_318397] (includes 
glucose, insulin, c -peptide)2-hour OGTT testing should be omitted at visits following a protocol -defined 
diabetes diagnosis.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 28Abbreviations:  ADA = antidrug antibody; BP=blood pressure; CKD -EPI= Chronic Kidney Disease -Epi[INVESTIGATOR_623] ; Cr=creatinine; 
C-SSRS =Columbia -Suicide Severity Rating Scale; ECG =electrocardiogram; ED =early discontinuation of treatment; eGFR =estimated 
glomerular filtration rate; HR =heart rate; IWRS =interactive web -response system; OGTT =oral glucose tolerance test ; PHQ -9 = Patient 
Health Questionnaire -9; PK =pharmacokinetic; TSH =thyroid-stimulating hormone; TZP =tirzepatide .Urinary  albumin/creatinine ratio
Cystatin -c
Calcitonin
Hematology
Thyroid-stimulating hormone (TSH)Screening visit assessment will be used to confirm eligibility .  If calcito nin 
results are not available, a final review of eligibility will occur at Visit 3 before 
randomization can proceed.
Chemistry panel (include Cr for eGFR 
calculation )The CKD -EPI [INVESTIGATOR_261710].
Immunogenicity (includes PK sample)PK samples for immunogenicity must be taken prior to drug administration at 
these visits .Intheevent ofsystemic drug hypersensitivity reactions (immediate
ornonimmediate), additio nalblood samples willbecollected including ADA,
PK,and exploratory biomarker sample s.
TZP PK PK samples will be collected at these visits at time windows of [ADDRESS_318398] dose , as assigned by[CONTACT_261731] . Dependent onthetime windows towhich aparticipant is
assigned, they may be required tocome tositeforPK-specific visits.
PHQ -9
C-SSRS (Baseline/Screening Version)
C-SSRS (Since last Visit Version)
Self-Harm Supplement FormThe C -SSRS , Self -Harm Supplement Form and PHQ-9 should be administered 
after assessment of adverse events. For this study, the C -SSRS is a dapted for 
the assessment of the ideation and behavior categories only.  The Intensity of 
Ideatio n and Lethality of Behavior sections are removed.
Self-Harm Follow -up Form Self-Harm Follow -up Form is only required if triggered by [CONTACT_47584] -Harm 
Supplement Form, per instructions in the form.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 292. Introduction
Obesit y is a chronic disease whose increasing prevalence is a public -health concern associ ated 
with rising incidence of t ype 2 diabetes mellitus (T2DM) , increased risk for premature death and 
increased risk for some cancers ( Alliso n et al . 2008 ; AMA 2013 ;Council on Sci ence and Public 
Health2013 ).  Although loss of 5 % to 10% body weight has been sh own to reduce com plicat ions 
related to obesit y and improve qualit y of life (Mertens and Van Gaal 2000; Knowl er et al . 2002;
Jensen et al. 2014; Li et al . 2014 ;Warkent in et al. 2014), lifest yle therapi[INVESTIGATOR_261711] y of patients wi th obesi ty(Dombrowski  etal. 2014).
2.1. Study Rationale
The gut i ncretin hormones
,glucose -dependent insulinotropic po lypept ide (GIP) and glucagon -
like peptide -1 (GLP -1),are secreted after meal ingestion and mediate the incret in effect . Both 
horm ones have effects on endocrine cells in the pancreas, increasing insulin bio synthesis and 
secretion, stimulating beta-cell neogenesis and proliferat ion,and protecting beta cells fro m 
apoptosis. They  also exert acti ons on alpha cells, modifying glucagon secret ion (Skow et al. 
2016). Based on these properties, several GLP - 1receptor (GLP -1R)agonists have been 
approved for pharmaco logical treatm ent of T2DM (Tomlinson et al. 2016) .
In addit ion to i ts pancreat ic effects, GLP -1R activation decreases gut m otilit y, slows gastric 
emptying,and promotes satiet y (presum ably through a combinat ion of GLP -1R act ivation in the 
central  and peri pheral  nervous system ), thereby [CONTACT_261724](Baggi o 
and Drucker 2007). T he US Foo d and Drug Administration and the European Medicines 
Agency approved the GLP -1R agoni st liraglut ide for the treatment of overweight and obesit y
(SAXENDA®package insert , 2014 ; SAXENDA ®SmPc, 2015 ).
Preclinical data indicate that GIP exert seffects on appetite regulation and food intake , on 
adipose ti ssue and on peripheral energy metabolism. Although studi es evaluating effects of GIP 
on body  weight have yielded equivocal results, GIP receptor (GIPR) activationmay play a role 
in body weight regulat ion and targeting both the GLP -1R and the GIPR simultaneously may
resul t in addi tive or synergist ic effects of the 2 incretins on body weight (Coskun et al. 2018).
Tirzepati de is a [ADDRESS_318399] activit y at both the G IPR and GLP -
1R.  Its structure is based on the GIP sequence and includes a C20 fatty  di-acid m oiety (Coskun 
et al. 2018).  It i s administered once weekly  (QW) by  [CONTACT_6567] (SC) inject ion. As a dual  
GIP/GLP -1R agonist, tirzepat idecould exceed the efficacy  of select ive GLP -1R agoni sts by 
[CONTACT_261732] -1R agoni sts(for example, 
adipose ti ssue as indicated by [CONTACT_261733]) (Baggio and 
Drucker 20 07)and has the potential to reach higher efficacy in target tissues that express both 
GIPR and GLP1R. 
Study  I8F-MC-GPHK (GPHK , SURMOUNT -1) is a Phase 3, mult icenter, randomized, placebo -
controlled, doubl e
-blinded study ,to invest igate the safet y and efficacy  of 5-mg, 10-mg, and [ADDRESS_318400] obesit y(BMI ≥30 kg/m2) orareoverweight (BMI ≥27kg/m2)with at least one 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 30weight-related comorbid condit ion (for example, hypertensio n, dyslipi[INVESTIGATOR_035], or cardiovascular 
disease). All participants will be rando mized to at least [ADDRESS_318401] prediabetes at randomizat ion will be 
studi ed for a total  of 176 weeks of treatm ent to provide sufficient follow -up time to assess the 
effects of tirzepat ide on progression to T2D and on lo ng-term body  weight changes.
2.2. Background
There rem ains an unmet need in the pharmaco logic treatment of obesit y for drugs that are safe, 
efficacious and well tolerated.  With the except ion of orlistat, a drug that blocks absorption of 
dietary  fat, ma ny curr ent obesit y treatm ents work primarily by [CONTACT_261734].  Weight loss induced by [CONTACT_34046] -1Ragonists appears to be mediated through a 
combinat ion of hormonal inputs to satiet y centers (van Bloemendaal et al. 2014) andhas not 
been consistent ly associated wi th changes in mental health or wi th potenti al for addi ction in 
long-term studi es conducted to establish cardio vascular safet y in pat ients with diabetes (Marso et 
al. 2016a, Marso et al. 2016b, Gerstein et al. 2019) .  Tirzepat ide, which isboth a GLP -
1Rand 
GIPRagonist , has been associated with significant dose-dependent weight loss at 5-, 10-and15-
mg doses in Phase 2 studies (Frias et al .
2018).
Dose sel ection for obesit y treatm ent has been informed by  3 clinical tr ials: a Phase 1 study , 
Study I8F-MC-GPGA (GPGA), and twoPhase 2 studies, Study I8F -MC-GPGB (GPGB) and 
I8F-MC-GPGF (GPGF). 
Phase 1 Study  GPGA was a combinat ion of single ascending dose (SAD) and mult iple ascending
dose (MAD) studiesin healthy subjects and a m ultiple dose study in pat ients with T2DM .  A 
total of 142 participant s (89 healthy subjects and 53 patients wi th T2DM) received at least 1 dose 
of treatm ent.  Doses of tirzepat ide ranged from :
0.25 m g to 8 mg in the SAD (with maximum  tolerated dose achi eved at 5 m g) 
multiple doses fro m 0.5mg to 4.5 mg QW and t itrated doses up to 10 mg QW for 4 
weeks in healt hy subjects
multiple doses at 0.5 mg and 5 mg QW and titrated up to 15 m g QW for 4 weeks in 
patients with T2DM in the MAD
Thesafet y and tol erabilit y and pharmacokinet ic/pharm acodynamic (PK/PD )profiles of 
tirzepat ide at doses and escalat ionregimens adm inistered in this Phase 1 study  supported further 
development of tirzepat ide for QW dosing in pat ients with T2DM .
Phase 2 studies GPGB and GPGF studi es provi ded init ial safet y, tolerabilit y and efficacy data in 
the tirzepati de 1-to-15-mg dose range when us ed in treatm ent of  patients wi th T2DM.  In the 
dose range of 5 to 15 mg, tirzepat ide provided significant ly greater reductions in hemoglobin 
A1c (HbA1c )and body  weight com pared wi th dulagl utide 1.[ADDRESS_318402] comm on AEs, 
which were also dose dependent, were mild to moderate nausea, vomit ing, and diarrhea.  Study  
GPGF showed that adjustments in the tirzepat ide dose-escal ationalgori thm resul ted in addi tional 
reducti ons in the frequency  of GI AEs and reduced the frequency  of treatment di scont inuat ions
due to GI AEs . 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 312.3. Benefit/Risk Assessment
More informat ion about the known and expected benefits, risks, serious AEs (SAEs) and 
reasonably  anticipated AEs of tirzepati deare to be found in the Invest igator’s Brochure (IB).
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 323. Objectives and Endpoints
Objectives Endpoints
Primary
at 72 weeks, by [CONTACT_261727] 10 mg QW is superior 
to placebo for:  
percent change in body weight AND
percentage of participants with ≥5% body 
weight reduction 
AND/OR
To demonstrate that tirzepatide 15 mg QW is superior 
to placebo for :
percent change in body weight AND 
percentage of participants with ≥5% body 
weight reduction  mean percent change in body weight from 
randomization 
percentage of study participants who achieve ≥5% 
body weight reduction from randomization  
Key Secondary (controlled for Type I error)
at 20 weeks, pooled dose analysis
For pooled tirzepatide 10 mg and 15 mg QW doses, to 
demonstrate superiority to placebo for:
  
body weight mean change in body weight (kg) from 
randomization
Key Secondary (controlled for Type Ierror)
at 72 weeks, by [CONTACT_261727] 5 mg QW is superior 
to placebo for:
percent change in body weight AND
percentage of participants with ≥5% body 
weight reductionmean percent change in body weight from 
randomization 
percentage of study participants who achieve ≥5% 
body weight reduction from randomization
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 33Objectives Endpoints
For tirzepatide 10mg and/or 15mg QW doses , to 
demonstrate superiority to placebo for:
body weight 
waist circumferencepercentage of participants who achieve :
o≥10% body weight reduction from 
randomization
o≥15% body weight reduction from 
randomization
o≥20% body weight reduction from 
randomization 
mean change in waist circumference (cm) from 
randomization
Key Secondary (controlled for Type I error)
at 72 weeks, pooled dose analysis
To demonstrate that pooled tirzepatide 10 mg and 15
mg QW issuperior to placebo for:
patient -reported outcomes (SF -36v2 acute 
form Physical Functioning domain score)mean change in SF-36v2 acute form Physical 
Functioning domain score from randomization
Key Secondary (controlled for Type I error)
at 72 weeks, pooled dose analysis
For tirzepatide QW (all doses combined), to 
demonstrate superiority to placebo for:
lipid parameters 
SBP
insulinmean change from randomization in 
otriglycerides (mg/dL)
onon-HDL cholesterol (mg/dL)
oHDL cholesterol (mg/dL)
mean change in SBP (mmHg )from 
randomization
mean change in fasting insulin (pmol/L) from 
randomization
Key Secondary (controlled for Type I error)
at 176 weeks, by [CONTACT_261728] 10 mg and/or 15 mg QW doses, to 
demonstrate superiority to placebo (forparticipants 
with prediabetes at randomization) for:
body weight mean percent change in body weight from 
randomization
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 34Objectives Endpoints
Key Secondary (controlled for Type I error)
at 176 or 193 weeks, pooled dose analysis
For tirzepatide QW (all doses combined), to 
demonstrate superiority to placebo (for participants 
with prediabetes at randomization) in :
delayed progression to T2DM at 176 weeks
delayed progression to T2DM at 193 weekstime to onset of T2DM during 176 weeks
treatment period
time to onset of T2DM during entire study 
including safety follow up period
Additional secondary at 72 weeks, by [CONTACT_261735] 5 mgQW dose, to demonstrate 
superiority to placebo at 72 weeks for :
body weight
waist circumference
patient reported outcomes (SF -36v2 Phy sical 
Functioning)
For tirzepatide 5 mg, 10 mg, and/or 15 mg QW doses, 
to demonstrate superiority to placebo for :percentage of participants who achieve
o≥10% body weight reduction from 
randomization
o≥15% body weight reduction from 
randomization
mean change in waist circumference (cm) from 
randomization
mean change in SF -36 v2 acute form Physical 
Functioning domain score from randomization
body weight  mean c hange in body weight (kg) from 
randomization
mean change in BMI (kg/m2) from randomization
glycemic control mean c hange in HbA1c (%, mmol/mol) from 
randomization
mean change in fasting glucose (mg/dL) f rom 
randomization
Patient- reported outcomes Mean change in IWQOL -Lite-CT Physical 
Function composite score from randomization
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 35Objectives Endpoints
Additional secondary at 72 weeks, pooled dose 
analysis
For tirzepatide QW (all doses combined) , to 
demonstrate superiority to placebo at 72weeks for 
DBPmean c hange in DBP (mmHg ) from 
randomization
lipid parameters mean change from randomization in:
oLDL -cholesterol (mg/dL)
ototal cholesterol (mg/dL)
oVLDL -cholesterol (mg/dL)
oFree Fatty acids (mg/dL)
Additional secondary at 176 weeks, by [CONTACT_261728] 5 mgQW dose, to demonstrate 
superiority to placebo (for participants with 
prediabetes at randomization) for:
body weight mean percent change in body weight from 
randomization
For tirzepatide 5 mg, 10 mg, and/or 15 mg QW doses, 
to demonstrate superiority to placebo (for participants 
with prediabetes at randomization) for:
body weight percentage of study participants who achieve ≥5% 
body weight reduction from randomization  
Additional Secondary at 176 weeks, pooled dose 
analysis
For tirzepatide QW (all doses combined) , to 
demonstrate superiority to placebo (for participants 
with prediabetes at randomization) for:
Patient- reported outcomesmean c hange in SF -36v2 acute form P hysical 
Functio ning domain score from randomization
mean change in IWQOL -Lite-CT Physical 
Function composite score from randomization
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 36Objectives Endpoints
Additional Secondary
Pharmacokinetics/Pharm acodynamics
To characterize the population PK of 
tirzepatide and explore the relationships 
between the tirzepatide concentration and
efficacy, safety and tolerability measures populatio n PK and PD parameters
Abbreviations: AUC = area under the curve; BMI =body mass index ; DBP = diastolic blood pressure ; 
HbA1c =hemoglobin A1c; HDL =high-density lipoprotein; IWQOL -Lite-CT =Impact of Weight on Quality of 
Life-Lite-Clinical Trials Version ;LDL = low-density  lipoprotein; PD=pharmacodynamics; 
PK=pharmacokinetic s; QW =once-weekly ; SAP = statistical analysis plan; SBP = systolic blood pressure; 
SF-36v2 =Short Form surve y-36 version 2, T2DM =type 2 diabetes mellitus ; VLDL = very low -density  
lipoprotein .
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 374. Study Design
4.1. Overall Design
Study  GPHK (SURMOUNT -1) is a Phase 3, mult icenter, randomized, double -blinded, placebo -
controlled study  that will invest igate the effects of treatment with tirzepatide 5 mg, 10 m g,and 
15mg QW co mpared withplacebo on weight loss in study  parti cipants without T2DM who are 
either obes e (BMI ≥30 kg/m2) or overwei ght ( ≥27kg/m2 )with at least one wei ght
-related 
comorbid condi tion (f or exam ple, hypertension, dyslipi[INVESTIGATOR_035], or cardiovascular disease).   The 
coprimary  endpoint swill be mean percent change in weight and percentage of parti cipants 
reaching ≥5% total  body weight loss, measured from rando mizat ion to W eek 72 .
Study  parti cipants will be randomized in a 1:1:1 :1ratio (tirzepat ide 5 mg QW, tirzepat ide 10 mg 
QW, ti rzepat ide 15 mg QW, and placebo).  An upper limit of 70% enrollment of wom en will be 
used to ensure a sufficient ly large sample o f men.
All participants will undergo a 2- week screening period and a 72-week treatment period
including a 20-week dose escalat ion.  
Participants who have prediabetes will be studied for a 
total of [ADDRESS_318403] potential 
differences in progression to T2 DM. 
The safet y follow-up period will be 4 weeks (for participants completing or discont inuing study 
drug during the first 72 weeks) or 1 7week s (for participants completing or discontinuing study 
drug between Weeks 72 through 176).
4.1.1. Overview of Study Periods
[IP_ADDRESS]. Visit Structure for all Office Visits
On all designated fasting o ffice visits, study  participants are required to report to the site in a 
fasting condit ion, after approximately 8 hours wi thout eating, drinking (except water), or 
performing any significant physical act ivity.  If a parti cipant is adversely  affected by  [CONTACT_941] f asting 
condi tion, they  are all owed to eat, however, specific study  proc edures need to be completed 
while fast ing. SeeSection 10.[ADDRESS_318404] ivities that occurs at office visits. 
[IP_ADDRESS]. MainStudy Period 
[IP_ADDRESS].1. Scree ning Period
Visit 1
The purpose of screening procedures at Visit 1 is to establish init ial eligibilit y,and to ob tain 
blood sam ples for l aboratory  assessments needed to confirm eligibilit yand classify  glycemic 
status (Section [IP_ADDRESS] ).  Theparticipant must sign the informed consent form (ICF) before the 
study  procedures are performed ,as outlined in the Schedule of Act ivities, Section 1.3.Since 
some screening procedures need to be completed in the fast ing state (approximately 8 hours 
without eati ng, drinking [except water ], or any  significant physical activit y), Visit [ADDRESS_318405] ive o fT2DM (Section [IP_ADDRESS] )andmeet all other applicable 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 38inclusio n criteria and none of the applicable exclusio n criteria (Secti ons5.1and5.2) at Vi sit [ADDRESS_318406] ing state (approximately 8 hours wi thout eating, 
drinking [except water ], or any significant physical activit y).  At Visit 2, the screening laboratory  
resul ts will  be reviewed.  For th ose participants without glycemic evid ence of T2DM 
(Secti on4.1.2.1 ),and meet ing all other eligibilit y requi rements, a [ADDRESS_318407] (OGTT) will be performed .  The 2-hour OGTT consists of assessment of glucose, insulin, 
and c -pepti de at time 0, 30, 60, 90, and 120 minutes (Secti ons4.1.2.2 and 10.7).If calcitonin 
resul
ts are not available, Visit [ADDRESS_318408] ionnaires (Columbia- Suicide Severi ty Rating Scale [ C-SSRS ]and Self -
Harm  Form ) should be com pleted after the assessment for AEs.
[IP_ADDRESS].2. Treatment Period
Randomization (Visit 3)
At Visit 3, eligible participants will perform all required baseline study procedures (including the 
collection of all baseline laboratory measures and questi onnai res) prior to randomizat ion and 
prior to taking the first dose of study  drug.  Participant sshoul d arrive to the clinic in the fasting 
state (after a period of approximately 8 hours without eating, drinking [except water ], or any  
significant physical act ivity). Patient-reported outcomes (PROs) questionnaires should be 
administered as early as possible, as per Suggested Visit Structure ( Secti on 10.8).Preferred 
administration order is: Patient Global Impressio n of s tatus for phy sical activity (PGIS ), Short 
Form  survey -36 versi on 2 ( SF-36v2) acute form , Impact of Weight on Qualit y of Life-Lite-
Clinical Trials Versio n (IWQOL -Lite-CT), and EQ-5D- 5L.The m ental  heal th questi onnai res 
(Patient Heal th Quest ionnaire -9 [PHQ -9], C- SSRS , and Self-Harm  Form) should be com pleted 
after the assessment for AEs.
Parti cipants will receive an init ial consultat ion with a qualified di etician, according to local 
standards, to set lifest yle goals for caloric intake and physical activity (Sect ions5.3.1 and 5.3.2 ).  
Following rando mizat ion, study  site personnel  will demonstrate use of the autoinjector (also 
referred to as single- dose pen) using the provided demonstration device and observe the study  
participant inject the first dose of tirzepatide or placebo.  The date ,time, and locat ionof the fi rst 
dose of study  drug willbe recorded on the electronic case report form (eCRF) .  Beginning at 
rando mizat ion, all part icipants will receive study  drug according to the randomized treatment 
arm for the durati on of  the [ADDRESS_318409] key  study  informat ion, as 
appropriate.  
Treatment Period ( End of Visit 3 to Visit 21):
During the treatment period, office visits will occur monthly through [ADDRESS_318410] ing for all o ffice visits.  Telephone 
visits will occur at 4-week intervals between the office visits starti ng at W eek 28.   
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 39Office visit procedures should be conducted according to the Schedule of Activit ies(Section 
1.3), and will include :
weight, waist circumference ,and vital signs measurem ents 
review of participant diary inform ation (to include reinforcement and co mpliance 
assessments for study drug administration and lifestyle goals)
administration of quest ionnaires 
laboratory  testing 
drug di spensing
collect AEs, product complaints and conco mitant medicat ions  
Mental Heal th Questi onnai res shoul d be co mpleted after the assessment of AEs.  
Dietician consultat ions continue at W eeks 4, 8, 12,and the n every  [ADDRESS_318411] ivities 
(Secti on 1.3) and according to local requirements.  New supplies will be dispensed as needed.
Study  drug dose escalation is double -blinded and will be managed via the interactive web-
response system (IWRS ).  The starting dose is 2.5 mg QW (or m atching placebo) for 4weeks, 
then the dose isincreased by 2.5 m g (or m atching pl acebo) every 4 weeks :2.5 to 5 mg for those 
rando mized to 5 mg, 2.5 to 5 to 7.5 to 10 mgfor those randomized to 10 mg, and continuing to 
12.5 to 15 mgfor those randomized to 15 mg.  The dose is then maintained up to 72 weeks . 
At each of the 8scheduled telephone visit s, procedures will include :
reinforcement and co mpliance assessments for study  drug administration and lifest yle 
goals ,
listing of conco mitantmedications
AE and Product Com plaints (PCs)assessment (see Schedule of Activit ies
Secti on1.3.1 )
administration of quest ionnaires   
Parti cipants shoul d be instructed to contact [CONTACT_261736].  Participants
shoul d also be advised about the appropriate course of action in the event that study  drug i s not 
taken at the required time (late/missing doses).
Study  parti cipants will be permitted to use concomitant medications that they  requi re during the 
study , except certain excluded medicat ions (see Secti on 5.2)thatmay interfere wi th the 
assessment of efficacy  and safet y characteri stics of the study  treatm ents.  
For those participants without glycemic evidence of T2DM (Section [IP_ADDRESS] ), a 2 -hour oral 
OGTT will be performed at Visit 21.  
Visit 99
Visit 99is only applicable to participants who discontinue the study  treatm ent prematurely 
(before W eek72).  Parti cipants will be asked to return for Visit 99at 72 weeks ± 7 days after 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 40rando mizat ion.  Thi s visi t is critical to ensure compl ete data collect ion for the primary weight -
loss endpo int.  
Parti cipants should attend this visit in the f asting state.  Procedures to be completed are
measurement of weight 
listing of conco mitant m edicati ons
assessment of AEs
completion of the mental healt h quest ionnaires (after the AEassessment)
For parti cipants unwilling to attend this visit, their refusal to attend should be documented in the 
participant medical record.
[IP_ADDRESS].3. Additional 2-Year Treatment Period for Participants with Prediabetes at 
Randomization (Visit s
101 through 116)
Participants cl assified as having predi abetesat randomizat ionand who remain on study  drug 
through Week 72, will continue follow
-up for an addit ional 104 weeks (total  study  durat ion 176 
weeks). Subsequent visit s will occur approximately  every  1.5months, alternat ing between 
telephone and office visits. 
Office visit procedures shoul d be conducted according to the Schedule of Activit ies
(Section1.3), and will include :
weight,waist circumference ,and vital signs measurem ents 
review of participant diary inform ation (to include reinforcement and co mpliance 
assessments for drug administration and lifest yle goals)
administration of quest ionnaires 
laboratory  testing
drug di spensing
collect ion ofAEs, product complaints ,and concomitant medications
Patient-reported outcomes quest ionnaires should be administered as early as possible, as per 
Suggested Visit Structure ( Section 10.8). Mental Health Quest ionnaires should be co mpleted 
after the assessment of AEs.  
Dietician consultat ions continue approximately every  
3 months after Visit 21to Visit 116.  At 
Visits 
108 and 116, parti cipants will undergo 2 hour OGTT s,unless diabetes hadbeen diagnosed
prior to the visits (Secti ons4.1.2.2 and 10.7).  Study drug and inject ion supplies will be returned 
per the Schedule of Act ivities (Section 1.3) and according to local requirements.  New supplies 
will be dispensed as needed.
At each of the 8 scheduled telephone visit s, procedures will include :
reinforcement and co mpliance assessments for study  drug administration and lifest yle 
goals
listing of conco mitantmedications
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 41AE and PC assessment (se e Schedule of Act ivities [Secti on 1.3]) 
administration of quest ionnaires
Parti cipants shoul d be instructed to contact [CONTACT_261737].  Parti cipants 
shoul d also be advised about the appropriate course of action in the event that study  drug i s not 
taken at the required time (late/missing doses).
Visit 199
Visit 199is only applicable to participants who discontinue the study treatment prematurely 
(between Week 72 and Week 176).  Participants will be asked to return for Visit 199at 176 
weeks ± [ADDRESS_318412] ion for 
the weight
-loss and progressi on-to-diabetes endpo ints.  
Parti cipants shoul d attend thi s visi t in the fasting state.  Procedures to be completed are :
measurement of weight
measurement of waist circumference
listing of conco mitant m edicati ons
assessment of AEs
completion of the mental healt h quest ionnaires (after the AE assessment)
2-hour OGTT
For parti cipants unwilling to attend this visit, their refusal to attend should be documented in the 
participant m edical  record. 
[IP_ADDRESS].4. Early Discontinuation of
Treatment Visit
Parti cipants unable or unwilling to continue the study  treatm ent for any  reason will  perform an
early  discontinuat ion of treatment (ED) visit.  If the participant is discont inuing during an 
unscheduled visit ,that visit shoul d be perform ed as the E Dvisit.  If the participant is 
discontinuing during a scheduled visit, that visit should be performed as an E Dvisit.  Procedures 
shoul d be com pleted according to the Schedule of Activities (Section 1.3).  Patient -reported 
outcom es quest ionnaires shoul d be administered as early as possible, as per Suggested Visit 
Structure (Section 10.8).  Administration of mental health quest ionnaires should fo llow 
assessment for AEs (see Section 7.2). 
[IP_ADDRESS].5. Safety Follow -up Period
Visit 801 or Visit 802
All participant sare required to complete a safet y follow -up visit (Visi t 801 or Vi sit 802)
, 
according to the Schedule of Act ivities(Secti on 1.3). Participants discontinuing the study  early 
and performing an E Dvisit will also be asked to perform the safety  follow-up visi t.During the 
safet y follow-up peri od, participants will not rec eive study  drug.  Participants are al so requi red to 
return any remaining study  diari es to the study  site at the end of this period.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 42For parti cipants who discontinue or complete the study within the first 72 weeks, Visit 801 
(safet y follow-up visit) shoul d be perform ed [ADDRESS_318413] treatment visit (Visit 21 or 99) 
or 4 weeks after the E
Dvisit for those who decline to return for Visit 99.  Participants with 
predi abetes continuing to Week 78 should not perform Visit 801.   
For tho se participants without glycemic evidence of T2DM (Section [IP_ADDRESS] ), a 2 -hour oral 
OGTT will be performed at Visit 802.  
4.1.2. Study Procedures
Parti cipantswill perform study  procedures listed in the Schedule of Activities (Section 1.3)
.
Parti cipants will be permitted to use concomitant medicat ionsthat they  requi re during the study , 
except certain medicat ions that may interfere with the assessment of efficacy and safet y 
characterist ics of the study  treatm ents (Section 5.2).
Study  governance considerations are described in detail in Section 10.1 (Appendix 1).
[IP_ADDRESS]. Definition of P rediabetes
The durati on of  treatm ent in Study  GPHK (SURMOUNT -1)is determined by [CONTACT_261738], categori zed into those with prediabetes or normoglycemia (parti cipants with 
T2DM are excluded), as defined by [CONTACT_941] 201 9American Diabetes Associat ion Standards of 
Medical Care in Diabetes (American Diabetes Associ ation
2019b ).  The following populat ions 
are defined:
Normoglycemia Prediabetes Diabetes
Fasting glucose
Obtained alone or at time =0 
during an OGTT<100 mg/dL
(<5.6 mmol/L)100-125 mg/dL
(5.6-
6.9mmol/L)≥126 mg/dL
(≥7.0mmol/L)
2H glucose
Obtained at time =120 min 
during an OGTT<140 mg/dL
(<7.8 mmol/L)140-mg -199 mg/dL
(7.8-
11.0mmol/L)≥200 mg/dL
(≥11.1 mmol/L)
HbA1c <5.7%
(<39 mmol/mol)5.7%-6.4%
(39-47 mmol/mol)≥6.5%
(≥48 mmol/mol)
Abbreviations:   H= hour; HbA1c =hemoglobin A1c; OGTT = 2-hour oral glucose tolerance test .
Screening to determine rando mizat ionglycemic status will occur in 2 visits:
Screening Visit [ADDRESS_318414] a fasting glucose (FG) and HbA1c test.  Results of these tests determine 
eligibilit y to proceed to Screening Visit 2.
 FG ≥126 m g/dL (7.0 mm ol/L) OR HbA1c ≥6.5% (48 mmo l/mol) suggests DM.  
These participants are excluded from the study and should be referred to their 
primary  care physician for further work -up to confirm the diagnosis.  
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 43 All participants otherwise eligible and without FG or HbA1c values suggest ive of 
diabetes will proceed to Screening Visit [ADDRESS_318415].  These results, in 
combinat ion with those obtained from  Screening Vi sit 1, will be used to determine study  
eligibilit y and rando mization glycemic status.
2-hour OGTT results:  FG ≥126 mg/dL (≥7.0 mmo l/L) OR 2 -hour OGTT ≥200 
mg/dL ( ≥11.1 mmo l/L) suggests diabetes mellitus.  These participants are excluded
from the study  and shoul d be referred to their primary  care physician for further 
work -up to confirm the diagnosis.  
Glycemic Classification
All participant s without laboratory  tests suggestive of diabetes will be classified as having eit her 
norm oglycemia or prediabetes.  In keepi[INVESTIGATOR_18499] A merican Diabetes Associ ationguidelines
(American Diabetes Associ ation
2019b) , at least 2 abnorm al tests are requi red to d iagnose 
predi abetes.  For example :
Both 0 AND 2-hour values during the 2-hour OGTT values are in the prediabet es
range.
FGat Screening Visit 1 AND Visit 2 are in the prediabet esrange.
FG at Screening Visit 1 AND 2-hour values during 2-hour OGTT are in th e 
predi abetesrange
.
HbA1c AND 1 of either the FGor 2-hour OGTT values are in the prediabet esrange.
[IP_ADDRESS]. Oral Glucose Tolerance Test
Parti cipants should attend visit srequi ring a 2-hour OGTT in the fast ing state.  Samples will be 
collected at 0, 30, 60, 90, and 120 minutes during the 2-hour OGTT , unless the OGTT is 
repeated to confirm the diagnosi s of diabetes .  For glycemic classification, the values at time = 0 
min (F G) and 120 minutes (2-hour OGTT) will be used. If a 2 -hour OGTT isrepeated to confirm
the diagnosis o f diabetes (see Section [IP_ADDRESS] ), only samples at [ADDRESS_318416] ivities (Section 1.3)and as 
described in Section 10.7, until such time as a pro tocol-defined di agnosis of diabetes is 
confirmed ( see Sect ion [IP_ADDRESS] ).  Two -hour OGTT testing shoul dbe omitted at visit s following a 
protocol -defined diabetes diagnosis.
[IP_ADDRESS]. Definition and M anagement of Incident Diabetes
Definition of incident diabetes
Incident diabetes is defined when any 1of the f ollowing occur after randomizat ion(American 
Diabetes Association 2019b):
unequivocal hyperglycemia (rando m glucose ≥200 mg/dL) with signs or symptoms of 
hyperglycemia
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 44any 2 of the f ollowing criteria areobserved at the sam e visi t, or 1abnormal v alue is 
observed and subsequent ly confirmed :
oHbA1c ≥6.5% (48 mmo l/mol)
oFGor 0-hour serum glucose from 2-hour OGTT ≥126 mg/dL (7.0 mmo l/L)
o2-hour glucose ≥200 mg/dL (11.1 mmo l/L) by  a 2-hour OGTT
initiation of any medicat ion for the treatm ent of diabetes
Confirmation of diabetes diagnosis 
In the event 1 abnormal value is observed (HbA1c ≥6.5% [48 mmo l/mol]) OR f asting glucose 
(or 0 -hour serum glucose fro m 2-hour OGTT) ≥126 mg/dL (7.0 mmo l/L) OR 2 -hour gl ucose 
from 2-hour OGTT ≥200 mg/dL (11.1 mmo l/L) *after rando mizat ion, the abnormal test should 
be repeated within 4 weeks to confirm diagnosis of diabetes and to ensure that diabetes 
management is init iated wi thout delay .
*Ifthe abnorm al value observed is 2 -hour gl ucose fro m the OGTT ≥200 mg/dL (11.1 mmo l/L),
the 2-hour OGTT should be repeated within 4 weeks (only samples at 0 and 120 minutes for 
glucose m easurement willbe collected) .
The di agnosis of diabetes is confirmed if any of the following occur :
•HbA1c ≥6.5% (48 mmo l/mol)is observed at 2measurements any  time during the study .
•2-hour gl ucose ≥200 m g/dL (11.1 mmo l/L) during an OGTT is observed at 2
measurements any  time during the study .
•FG value ≥126 m g/dL (7.0 mmo l/L) i s observed at a consecut ive FG measurement (either 
at a scheduled or an unscheduled visit) fo llowing an iso lated FG (or 0 -hour serum 
glucose from  2-hour OGTT) value ≥126 mg/dL (7.0 mmo l/L).
oIf diabetes diagnosis has not been confirmed at the consecutive FG measurement, 
another FG (or 0 -hour serum glucose result fro m 2-hour OGTT) result ≥126 
mg/dL (7.0 mmo l/L) observed during the study  will be considered as a new 
finding requiring confirmat ion.
Note : Once diabetes has been confirmed, repeating any future abnormal test w ithin 4 w eeks is 
no longer required.
Recording of incident diabetes events
•Diabetes di agnosis and the onset date as assessed by [CONTACT_261739] . 
•If the diagnosis of diabetes is based on laboratory  resul ts, the date of the first abnormal 
HbA1c o r glucose value wit hin the diabetes range should be indicated as the date of 
diagnosis , unless, in the invest igator’s opi[INVESTIGATOR_3078] n, a different date is more appropriate .If the 
diagnosis is based on init iation of any medicat ion for the treatment of diabetes, th e 
investigator should indicate the most probable date of diagnosis in the eCRFs.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 45•All reported or suspected cases of incident diabetes will be adjudicated by [CONTACT_82384] (adjudication committee) . 
•Decisio ns of the adjudicati oncommittee regarding diabetes diagnosis and the onset date 
will be recorded in the dedicated a djudication eCRF.
Management of incident diabetes
Parti cipants who devel op di abetes during the study will be
provi ded and trained to use a gluco meter 
educated on the signs and symptoms of hypoglycemia and i ts treatm ent, and 
provi ded a di ary to record hy poglycemic epi[INVESTIGATOR_261712] [IP_ADDRESS] .  
Parti cipantswill be referred to their usual care provider and provided with a letter showing the 
study  resul ts indicative of diabetes.  The decision to further evaluate ,to ini tiate 
antihyperglycemic therapy ,and the cho ice of ant ihyperglycemic medicat ion will be at the 
discreti on of  the parti cipant’s usual care provider , with the excepti on of  use of  dipeptidyl-
pepti dase-4 (DPP-4) inhibitors and open- label GLP - 1Ragonists , whi ch are prohib ited in the
study .  
Moni toring for hy poglycemia includes capture of events as defined in Section 10.3
(Appendix 3 ).
4.2. Scientific Rationale for Study Design
Tirzepati de is a [ADDRESS_318417] activit y at both the GIPR and GLP -
1R.  Its structure is based on the GIP sequence and includes a C20 fatty  di-acid m oiety (Coskun 
et al. 2018).  It i s administered QW by [CONTACT_57982]. 
As a dual  GIP/GLP -1R agoni st, tirzepat idecould exceed the efficacy  of select ive GLP -1R 
agonists by [CONTACT_261740] -1R agonists (for 
example, adipose tissue as indicated by [CONTACT_261741]) (Baggio 
and Drucker 2007) and has the potential to reach higher efficacy in target tissues ,such as insulin -
producing pancreatic beta cells that express both GIPR and GLP -1R, before reaching its 
therapeuti climitat ion. Results from a P hase 2 study (GPGB) demo nstrated that tirzepat ide use in 
participant s with T2DM was associated with a substantial, dose -dependent weight loss, greater 
than the weight change observed wit h dul aglut ide, a specific GLP -1Ragonist. General safet y 
characterist ics of all  studi ed doses of ti rzepati de were similar to that of the GLP -
1Ragonist class, 
consist ing mainly of nausea, vo miting, and diarrhea . In general, these events were transient and 
mild or moderate in severit y, with few se vere epi[INVESTIGATOR_1841].  Although GIAEs were m ore commo n at 
the 15-mg armof tirzepat ide, th isdose demonstrated the highest efficacy in terms of weight loss. 
This suggest sthat tirzepat ide has the potential to become a medicat ion for chronic weight 
management. An optimized dose escalat ionregimen ,proposed in the Study GPHK
(SURMOUNT -
1)to improve tolerabilit y (and supported by  a dose-escalat ion algorithm fro m 
study  GPGF), shoul d enable a use o f higher doses to maximize effects on body  weight . Study 
GPHK (SURMOUNT -1)is designed to determine the comparative benefits and risks of 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 46tirzepat ide 5mg, [ADDRESS_318418] igator bias in 
assessments for efficacy , safet y, and study  drug tolerabilit y.
A placebo comparator was selected for this trial in accordance with regulatory  guidance (FDA 
2007; EMA 2016).  In addit ion, all participants, regardless of treatment assignment, will r eceive 
lifest yle modificat ion counselling consistent with current guidelines for weight management 
(Jensen et al. 2013).  Specifically , parti cipants will consult with a dietician , or equivalent 
qualified delegate ,throughout the study to achieve at least a 500 kcal /day energy  defici t through 
a combinat ion of caloric restriction and increased physical act ivity (Secti on5.3.1 ).  The pl anned 
durati on of  treatm ent for the primary endpoint at [ADDRESS_318419] a 52-week 
treatm ent peri od at the dose achieved fo llowing dose escalat ionto either 5, 10,or 15 m g. This 
durati on is consi dered appropriate to assess the full effects and benefit/risk of each m aintenance 
dose of tirzepat ide co mpared with placebo on body weight and is consistent with regulatory 
guidelines (FDA 2007; EMA 2016). 
The effects of drug cessation will be assessed in the 4 -week and in the 12
-week safet y follow-
up/observat ional per iods
Another objective of the study  is to eval uate theeffect of tirzepatide on the risk of new -onset 
diabetes. Obesit y is associated with an increased ri sk of developi[INVESTIGATOR_007] T2DM and diabetes 
prevent ion is of a great importance in obese subjects to protect them from complications of the 
disease. Several studies have shown that interventio ns leading to weight loss may help prevent 
diabetes (Adams et al. 
2017, le Roux et al. 2017).
Toobtain additional informat ion regarding the rate of conversio n to di abetes on tirzepati de, 
participants wi th predi abetes di agnosed at the beginning of the study  (being at increased risk of 
diabetes ), will be treated and observed for an additional 2years . Based on available literature, 
the [ADDRESS_318420] of changes to concomitant medications, 
participants will be permitted to use conco mitant medicat ions that do not interfere with the 
assessment of efficacy  or saf ety characteristics of the study  treatments.
4.3. Justification for Dose
Tirzepatide doses of 5 mg, 10 m g, and 15 m g QW will be evaluated in this study .These doses 
and associated escalation schemes were selected based on assessment of safet y, efficacy  (weight 
loss), and GI tol erabili ty data ,followed by  [CONTACT_80063] -response modeling of data in pat ients in 
Phase [ADDRESS_318421] l evel doses in 6 -
mont
h monkey and rat toxico logy studi es.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 474.4. End of Study Definition
Section 7.2describes the criteria used to determine if a participant has co mpleted the study .
The end o f the study  is defined as the date of the last vi sit of the l ast parti cipant in the study  or 
the last scheduled procedure shown in the Schedule of Act ivities(Sect ion 1.3.1 or1.3.2 based on 
rando mizat ion glycemic status ), for the last participant in the trial globally .
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 485. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, isnot permitted.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Type of Participant and Disease Characteristics
1.Have a BMI
≥30 kg/m2or
≥27 kg/m2and previously  diagnosed with at least one of the fo llowing wei ght 
related comorbidities:
ohypertensio n : treated or with systolic blood pressure (SBP) ≥130 mmHg 
or diastolic blood pressure ≥80 mmHg
odyslipi[INVESTIGATOR_035] : treated or with low-densit y lipoprotein 
(LDL )≥160 mg/dL (4.1 mmo l/L) or tri glycerides ≥150 m g/dL (1.7
mmo l/L), or high-densit y lipoprotein ( HDL )<40mg/dL (1.0 mmo l/L) 
for men or HDL<50 mg/dL (1.3 mmo l/L) for women
oobstructive sleep apnea
ocardiovascular di sease (for example ,ischemic cardio vascular disease, 
[LOCATION_001] Heart Associat ion (NYHA )Funct ional Class I-III hear t 
failure)
2.Have a history  of at least one self -reported unsuccessful dietary  effort to l ose 
body  weight
3.In the invest igator’s opi[INVESTIGATOR_3078] n, are well -motivated, capable, and willing to 
learn how to self- inject study  drug , as required for this protocol (visually impaired 
persons who are not able to perform the inject ions must have the assistance of a 
sighted individual trained to inject study  drug; persons with physical limitat ions who 
are not able to perform the inject ionsmust have the assistance of an individual trained 
to inject study  drug) 
inject study  drug (or receive an inject ion from a trained individual if visually 
impaired or with physical limitat ions)
follow study  procedures for the durati on of  the study , includ ing, but not limited to: 
follow lifest yle advice ( for example ,dietary  restri ctions and exercise plan), maintain 
a study  diary ,and complete required quest ionnaires
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 49Participant Characteristics
4.Are 18 y ears or ol der
a.male parti cipants:
Male parti cipants with partners of childbearing potent ial shoul d be willing 
to use reliable contraceptive methods throughout the study  and f or [ADDRESS_318422] ion.
b.female participants:
Female participants not of childbearing potential may participate and 
include those who are:
oinfertile due to surgi cal sterilizat ion (hysterectomy ,bilateral 
oophorectomy  or tubal  ligat ion), congenital ano maly such as
Mullerian agenesis 
opostmenopausal , defined as eit her
a woman at least [ADDRESS_318423] 1 y ear wi thout an al ternat ive medical cause, AND a 
follicle -stimulat ing horm one ≥40mIU/mL ; women in this 
category  musttest negative in pregnancy  test pri or to study  
entry
or
awom an [ADDRESS_318424] 12 m onths of spontaneous amenorrhea 
or
awom an at l east 55 y ears of age with a diagnosis of 
menopause prior to starting hormone replacement therapy
Female participants of child -bearing potential (not surgically sterilized and 
between m enarche and 1 -year postm enopausal ) must:
otest negative for pr egnancy at Visit [ADDRESS_318425] (ERB) governing the study 
site 
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing criteria apply:
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 50Medical Conditions
Diabetes -related
6.Have type 1 di abetes m ellitus(T1DM) or T2DM ,history  of ketoaci dosis, or hyperosmo lar 
state/com a
7.Have laboratory  evidence di agnostic of di abetes mellitus during screening , including 1 or 
more of: HbA1c ≥6.5% (≥48 mmo l/mol), FG ≥126 m g/dL (≥7.0 mmo l/L), random  glucose 
or 2-hour glucose measurement from a 2-hour OGTT ≥200 mg/dL ( ≥11.1 mmo l/L)
Obesity -related
8.Have a self -reported change in body  weight >[ADDRESS_318426] a prior o r planned surgical treatment for obesit y (excluding liposuct ion or 
abdo minoplast y if performed>1 year pri or to screening )
10.Have or plan to have endoscopi c and/or device -based therapy  for obesi ty or have had device 
removal within the l ast 6 months (for example ,mucosal  ablat ion, gastric artery  
embo lization, intragastri c balloon and duodenal -jejunal by[CONTACT_17991])
Other medical
11.Have renal impairment measured as est imated glomerular filtration rate (eGFR) 
<30mL/min/1.[ADDRESS_318427] a known clinically significant gastric em ptying abnormalit y (for example ,severe 
diabetic gastroparesis or gastric outlet obstruction) or chronically take drugs that direct ly 
affect 
GImotility
13. H ave h ad a history  of chronic or acute pancreat itis
14.Have thyroi d-stimulat ing hormone (TSH) outside of the range of 0.4 to 6.0 mIU/L at 
screening visit
Note
:Patients receiving treatment for hypothyro idism may be included, provided their 
thyroid horm one repl acement dose has been stable for at least 3 months.
Note: TSH values above the norm al range can, in some patients, suggest subclinical 
hypothy roidism .  If, in the invest igator’s opi[INVESTIGATOR_3078] n,the participant has subclinical 
hypothy roidism  and may require initiation of thy roid horm one repl acement during the 
course of the s tudy, the pati ent shoul d be excluded from  the study . 
15.Have obesit y induced by  [CONTACT_261742] (for example ,Cushing Syndro me) 
or diagnosed m onogenetic or syndromic forms o f obesit y (for example ,Melanocortin 4 
Receptor deficiency or Prader Willi Syndrome)
16.Have a history  of significant active or unstable M ajor Depressive Disorder (MDD) or other 
severe psychiatric disorder (for example, schizophrenia, bipo lardisorder , or other serious 
mood or anxiet y disorder ) within the last 2 years
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 51Note: Patients with MDD or generalized anxiet y disorder whose disease state is considered 
stable and expected to remain stable throughout th e course of the study , in the opi[INVESTIGATOR_1070], may be considered for inclusion if they are not on excluded medicat ions
17.Have any lifet ime history  of a sui cide attem pt
18.Have a Patient Health Questionnaire -9 (PHQ -9) score of 15 ormore at Vi sit 1or 3, prior to 
rando mizat ion
19.On the C -SSRSat Visits 1,2,or 3, prior to randomizat ion: 
a
“yes”answer to ei ther Questi on 4 (Act ive Suicidal Ideation wit h Som e Intent to 
Act, Without Specific Plan) 
or
a “yes”answer to Question 5 (Act ive Suicidal Ideation with Specific Plan and 
Intent) on the "Suicidal Ideation" portion of the C- SSRS 
or 
a “yes”answer to any  of the suici de-related behaviors ( Actual  Attem pt, Interrupted 
Attempt, Abo rted Attempt , Preparatory A ct or Behavior ) on the "Sui cidal Behavior" 
porti on of  the C -SSRS
and
the ideati on or behavior occurred within the past month
20.Have uncontrolled hypertensio n (SBP above or equal to 160 mmHg and/or diastolic blood 
pressure above or equal to 100 mmHg)
21.Have any of the fo llowing cardi ovascular condi tions wi thin 3months prior to 
rando mizat ion: acute my ocardial  infarcti on(MI) , cerebrovascular accident (stroke), 
unstable angina, or hospi[INVESTIGATOR_261713] (CHF)
22.Have NYHA Funct ionalClassificat ion IV CHF
23.Have acute or chronic hepat itis, signs and symptoms of any other liver disease other than 
nonalcoho lic fatty liver di sease, or any o f the following , as determined by [CONTACT_261743] :
alanine aminotransferase (ALT) level >3.0Xthe upper limit of normal 
(ULN) for the reference range
or
alkaline phosphatase (ALP) level >1.5X the ULN for the reference range
or
total bilirubin (TBL) level >1.2X the ULN for the reference range
(except for cases of known Gilbert’s Syndro me)
Note :Participants with nonalcoho lic fatty liver disease are eligible to parti cipate in this trial
if their ALT level is ≤3.0X the ULN for the reference range  
24.Have a calcitonin level (at Visit 1) of :
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 52o≥20 ng/L at Visit 1, if eGFR ≥60 mL/min/1.73 m2
o≥35 ng/L at Visit 1, if eGFR <60 mL/min/1.[ADDRESS_318428] a family or personal history  of medullary  thyroi d carcino ma (MTC) or Mult iple 
Endocrine Neoplasia (MEN) Syndro me type [ADDRESS_318429] ive or untreated malignancy or are in remiss ion from a clinically
significant malignancy  (other than basal -or squamous -cell skin cancer, in situ carcino mas of 
the cervix, or in situ prostate cancer) for less than [ADDRESS_318430] ion (for exa mple ,hypersensit ivityor 
intolerance ) that i s a contraindicat ion to GLP -1Ragonists
28.Have a history  of any other condit ion (such as known drug or alcoho l abuse, di agnosed 
eating disorder ,or other psy chiatri c disorder) that, in the opi[INVESTIGATOR_3078] n of the invest igator, may 
precl ude the participant from following and completing the protocol
29.Have history  of use of marijuana within [ADDRESS_318431] had a transplanted organ (corneal transplants [keratoplasty] allowed) or awaiting an 
organ transplant
31.Have any hematological condit ion that may interfere wi th HbA1c measurement (for 
example, hemo lytic anemias, sickle cell disease)
Prior/Concomitant Therapy
32.Are receiving or have received wit hin 3monthsprior to screening chroni c (>2 weeks or 
14days) systemic glucocorticoid therapy  (excluding topi[INVESTIGATOR_2855], intraocul ar, intranasal, intra -
articular, or inhaled preparations) or have evidence of a significant, active autoimmune 
abnorm ality (for example, l upus or rheumatoi d arthri tis) that has required (within the last 
3months) or i s likely  to requi re, in the opi[INVESTIGATOR_3078] n of the invest igator, concurrent treatment with 
systemic glucocortico ids (excluding topi[INVESTIGATOR_2855], intraocular, intranasal, intra -articular or inhaled 
preparati ons) in the next [ADDRESS_318432] current or history  of (within 3 m onths pri or to randomiz ation) treatm ent wi th 
medicat ions that m ay cause significant weight gain, including but not limited to: tricyclic 
antidepressants, atypi[INVESTIGATOR_261714] c and mood stabilizers for example:
imipramine
amitript yline
mirtazapi[INVESTIGATOR_050]
paroxetine
phenelzine
c
hlorpromazine
thioridazine
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 53clozapi[INVESTIGATOR_050]
olanzapi[INVESTIGATOR_050]
valpro ic acid and its derivat ives
lithium
Note: Select ive serotonin reuptake inhibitors other than paroxet ine are permitted.
34.Have taken within 3 months prior to randomizat ion, medications (prescribed or over -the-
counter) or alternat ive remedies intended to promote weight loss .  Exam ples include, but are 
not limited to
Saxenda ® (liraglut ide 3.0 mg )
Xenical® /Alli® (orlistat)
Meri dia® (sibutramine)
Acutrim® (phenylpropanolamine)
Sanorex® (mazindo l)
Adipex® (phentermine)
BELVIQ® (lorcaserin)
Qsymia ® (phentermine/topi[INVESTIGATOR_82336])
Contra ve® ( naltrexone/bupropi [INVESTIGATOR_2394])
Note: Use of met formin or any  other gl ucose -lowering medication , whether prescribed 
for polycyst ic ovary syndrome or diabetes prevent ion is not permitted.
35.Have started implantable or injectable contraceptives (such as Depo -Provera®) wi thin 18 
months prior to screening
Prior/Concurrent Clinical Study Experience
36. Are current ly enrolled in any other clinical study  involving an invest igational prod uct (IP)or 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study
37.Withinthe last [ADDRESS_318433] igator site personnel directly affiliated wit h this study  and/or thei r immediate 
family . Immediate family is defined as a spouse, legal partner, parent , child, or sibling, 
whether bio logical or legally adopted .
39. A re Eli Lilly and Co mpany ( Lilly )empl oyees
5.3. Lifestyle Considerations
Per the Schedule of Activities (Section 1.3), parti cipants will consult with a dietician,or 
equivalent qualified delegate , according to local standards, to receive lifest ylemanagement 
counseling at W eeks 0, 4, 8 and 12 during dose es calation and then at W eek 24 and every  12 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 54weeks thereafter through [ADDRESS_318434] yle management 
counseling at 3
-month intervals as defined in the Schedule o f Activities (Section 1.3).
Diet and exercise goal s established during the lifestyle consultat ion and t he importance of 
adherence to the lifest yle co mponent of the trial will be reinforced at each trial contact [CONTACT_261744].
5.3.1. Meals and Dietary Restrictions
At Visit 3 and subsequent visit s,study  participants will receive diet counselling by a 
dietician/nutritionist,or equivalent qualified delegate ,according to local standard .Dietary  
counseling will consist of advice on healthy food cho icesandfocus on calorie restricti on using a 
hypocalori c diet wi th macronutri ent com positionof:
maximum 30% of  energy  from fat 
approximately  20% of  energy  from protein
approximately  50% of  energy  from carbohydrates
an energy  defici t of approximately 500 kcal/day compared to the participant ’s est imated 
total energy  expendi ture (TEE)
To encourage adherence, it is recommended that a 3-day dietand exercise diary  be com pleted 
prior to each counseling visit. During each visit ,the participant’s diet is reviewed and advice to 
maximize adherence is provided if needed.
The hypocaloric diet i s cont inued after rando mization and throughout the treatment period. If a 
BMI ≤22kg/m 2is reached, the recommended energy  intake should be recalculated with no kcal 
deficit for the remainder of the trial.
Total  energy expenditure (TEE) is calculated by [CONTACT_261745] 
(BMR ) (see tabl e bel ow) with a Physical Act ivity Level value of 1.3 (FAO/WHO/UNU 2004 ), 
which reflects an inact ive lifest yle.  This calculat ion provi des a conservative estimate of caloric 
requi rements :
                        TEE (kcal/day) =BMR X1.3
Equations for estimating BMR in kcal/day*
Sex Age BMR (kcal/day)
Men 18-30years 15.057 Xactual weight in kg [PHONE_5431]years 11.472 Xactual weight in kg + 873.1
>60 y ears 11.711 Xactual weight in kg + 587.7
Women 18-30 years 14.818 Xactual weight in kg [PHONE_5432] years 8.126 Xactual weight in kg + 845.6
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 55>60 y ears 9.082 Xactual weight in kg + 658.5
Abbreviation s:  BMR = basal metabolic rate ; WHO =World Health Organization.
*Revised WHO equations (adapted from: FAO/WHO/UNU 2004 ).
5.3.2. Physical Activity
At Visit [ADDRESS_318435] 150 minutes per week .
5.4. Screen Failures
Screen failures are defined as participant s who co nsent to participate in the clinical study but are 
not subsequently randomly  assigned to the study  intervent ion.A minimal set of screen -failure 
inform ation shoul d be collected to ensure transparent reporting of screen -failure partici pants to 
meet the Consolidated Standards of Reporting Trials (CONSORT ) publishing requirements and 
to respond to queries fro m regulatory  authori ties. Minimal informat ion includes demography, 
screen failure details, eligibilit y criteria, and any  SAE.
Individua ls who do not meet the criteria for participation in this study  (screen failure) may not be 
rescreened.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 566. Study Intervention
Study  intervent ion is defined as any invest igational intervent ion(s), m arketed product(s), 
placebo, or m edical device(s) intended to be administered to a study  parti cipant according to the 
study  protocol .
6.1. Study Interventions Administered
ARM Name [CONTACT_261788] 5 m g Tirzepati de 10 m g Tirzepati de 15 m g Placebo
Dose 5 mg QW 10 m g QW 15 m g QW N/A
Route of 
AdministrationSC SC SC SC
Sourcing Provi ded centrally  by [CONTACT_261746] (single -dose pen s), 
packaged in cartons to be dispensed.  Clinical study materials will be 
labeled according to c ountry  regul atory  requi rements .
Abbreviations:  IWRS = interactive web response service ;N/A = not available ;QW = once -weekly ;
SC=subcutaneous .
There are no restrict ions on the time of day  each weekly dose of study  drug is given, but it is 
advisable to administer the SCinjections on the same day and same time each week.  The actual 
date,time and inject ion site locat ionof all dose administrations will be recorded in the diary by 
[CONTACT_2299].   If a dose of study  drug is missed, the participant should take it as soon as 
possible unless it is wit hin 72hours of the next dose, in which case that dose should be skipped ,
and the next dose should be taken at the appropriate time.  The day o f weekly administration can 
be cha nged if necessary, as long as the l ast dose was administered [ADDRESS_318436] study  drug subcutaneously in the abdomen or thigh using the injection 
supplies provided; a caregiver may  admini ster the inject ion in the part icipant’s upper arm . The 
inject ion site location o f all dose administrations will be recorded by  [CONTACT_17071].  A new
autoinjector will be used for each inject ion.If study drug is to always be injected in the same 
body  region, participants shoul d be advised to rotate inject ion site seach week.
6.1.1. Medical Devices
The combinat ion products provided for use in the study  are tirzepat ideinvest igational 
autoinjector (or matching placebo) . Any medical -device incidents, including those result ing 
frommalfunct ions of the device, must be detected, documented, and reported by  [CONTACT_261747]  (see Secti on10.6).
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 576.2. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion receiv ed and any  discrepancies are 
reported and resolved before use of the study  intervent ion.
Only participants enro lled in the study  may receive study  intervent ion and only 
authori zed si te staff may  supply  study  intervent ion. 
All study  intervent ion must be st ored in a secure, environmentally controlled, and 
monitored (m anual  or automated) area in accordance with the labeled storage conditions 
with access limited to the invest igator and authorized site staff.   
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on(includes study  drug and autoinjector or single -dose 
pen)accountabilit y, reconcilia tion, and record m aintenance (for example , recei pt, 
reconciliat ion, and final disposit ion of records).
Study  site staff must regul arly assess whether the participant is correctly administering 
the assigned study drug and storing study  drug according to the provided instructions .
6.3. Measures to Minimize Bias:  Randomization and Blinding
This is a double -blind study .
Participants who meet all criteria for en rollment will be rando mized to one of the study  treatm ent 
groups at Visit 3.  Assignment to treatment groups will be determined by a co mputer -generated ,
rando m sequence using an IWRS.  Participant s will be rando mized in a 1:1: 1:1ratio to receive
tirzepat ide 5 mg, tirzepat ide 10 m g, tirzepati de 15 mg, or placebo .  
The rando mizat ion will be stratified b y prediabetes status ,coun try,and sex (female, male) . 
Invest igators, site s taff, clinical monitor s and participants will remain blinded to the treatm ent 
assignments unt il the study is complete .To preserve the blinding of the study, alimited number 
of individuals from the Sponsor will be unblinded to treatment assignments as needed for the 
interim a nalysis and for the primary  endpoint (Week 72) database lock (see Section 9.5)
.
Emergency  unblinding m ay be perform ed through the IWRS .  This option may  be used ONLY if 
the participant’s wellbeing requires knowledge of the participant’s treatm ent assi gnment.  All  
emergency unblinding event sare recorded and reported by  [CONTACT_8784] .
If an invest igator , site personnel performing assessments, or participant is unblinded, the 
participant must be di scont inued fro m the study .  In cases where there are ethical reasons to have 
theparticipant remain in the study , the investi gator m ust obtain specific approval from a Lilly  
clinical research physician (CRP) for the participant to continue in the study .  
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a participant ’s treatment assignment is warranted for medical management of the event.  The 
participant safet y must always be the first consideration in making such a determinat ion.  If a 
participant ’s treatment assignment is unblinded, Lilly must be notified immediately.  If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investi gator to 
prom ptly docum ent the decisio n and rationale and notify Lilly as soon as possible.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 586.4. Study Intervention Compliance
Parti cipant com pliance wi th study  intervent ion will be assessed at each visit. Com pliance will be 
assessed by [CONTACT_261748]/or em pty cartons returned .
Study  drug compliance will be determined by  [CONTACT_82374]: 
Study  drug administration data will be recorded by [CONTACT_261749].
The parti cipant s will be instructed to return any unused study drug and/or empt y 
cartons at the next visit to the study  site for the purpose of performing drug 
accountabilit y.
Treatment compliance for each visit interval is defined as taking at l east 75% of the required 
doses of study  drug.  Similarly , aparticipant will be considered significant ly nonco mpliant if he 
or she is judged by [CONTACT_261750] m ore than the 
prescribed amount of medica tion(more than 125%) .  
In addit ion to the assessment of a participan t’s compliance wit h study  drug administration, other 
aspects of compliance wit h the study  treatments will be assessed at each visit based on the 
participant ’s adherence to the visit schedule, complet ion of study  diaries, and any other 
param eters the invest igator considers necessary.
Participants considered to be poorly co mpliant with their medicat ion and/or the study  procedures 
will receive addit ional trainin g and instructi on, as requi red, and will be reminded of the 
importance of co mplying wit h the protocol.
6.5. Concomitant Therapy
Parti cipants will be permitted to use concomitant medicat ions that they  requi re during the study , 
except certain medicat ions (for exa mple; other medications for wei ght m anagement) that may 
interfere wi th the assessment of efficacy and safet y characterist ics of the study  treatm ents.
Parti cipants who devel op di abetes during the study may  initiate m edicat ion for glucose control , 
with the e xcepti on of  DPP-4 inhibitors or GLP -1Ragonists (Section [IP_ADDRESS] ).  Initiation of  
metformin for the treatment of diabetes is permitted, but met formin should not be init iated 
during the study  for the treatm ent of other m etabolic condit ions (for example ,polycyst ic ovary  
syndro me, diabetes prevent ion).
Invest igative-site 
staff will inform participants that they  must consul t with the invest igator or a 
designated site staff member upon being prescribed any new medicat ions during the study .  Thi s 
may not be possible when init iated for treatment of medical emergencies, in whic h case ,the 
participant will inform the invest igator or a designated site staff member as soon as possible.  
Nonst udy medicat ions taken by  [CONTACT_261751] i nvest igator believes may have been 
caused by  a study  procedure.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 596.6. Dose Modification
6.6.1. Tirzepatide
Tirzepati de is given once weekly  by [CONTACT_134087].  There are no restrict ions on the time of day  
each weekly dose of tirzepat ide is given, but it is advisable to a dminister the SCinject ions on the 
same day of the week andsimilar time each week.  If a dose of ti rzepat ide is missed, the 
participant shoul d take i t as soon as possible unless it is within 72hours of the next dose, in 
which case, that dose should be sk ipped ,and the next dose should be taken at the appropriate 
time.  
Study  drug dose modificat ion is not permitted, except for:
management of intolerable GIsymptom sduring the ent ire course of the study (see 
Secti on6.6.2 )and, 
management of participants with perceived excessive weight loss during the additional 
2-year treatm entperiod for parti cipants wi th prediabetes at randomizat ion only (see 
Secti on 6.6.3 )
.
Only 1 dose reduction per participant will be permitted during the ent ire course of the study . All 
dose adjustments will be managed through IWRS.   
6.6.2. Management of Participants with Gastrointe stinal Symptoms
Parti cipants who experi ence intol erable GI symptoms (for example ,nausea, vomit ing, or 
diarrhea) at any  time during the study ,shoul d first be counselled on dietary  behavi ors that m ay 
help mit igate nausea and vo miting, (for example, eating smaller m eals, splitt ing 3 daily meals 
into 4 or m ore smaller ones, and stoppi[INVESTIGATOR_134050] ).  If symptoms persist, the 
participant shoul d be prescribed, at the investigator’s discret ion, symptom atic medicat ion (for 
example, antiemetic or antidiarrheal medication ).A temporary  interrupti on of  study  drug for [ADDRESS_318437] 3 weekly doses.  Study  treatm ent 
shoul d be resumed at the assigned dose immediately , either alone or in co mbination wit h 
symptom atic medicat ion,which can also be utilized to manage symptoms (Secti on 10.9).  
Management of study drug afterinterruptions >1 dose is discussed in Section 7.1.1 .
If intolerable GI symptoms ( for example ,nausea, vomit ing, or diarrhea) persist despi[INVESTIGATOR_134051], the invest igator should contact [CONTACT_261752]-
lowest m aintenance dose in a blinded fashio n (for example , 15mg reduced to 10 mg, 10mg 
reduced to 5mg, or 5 mg reduced to placebo) (Section 10.9).
If intolerable GI symptoms persist despi[INVESTIGATOR_134052], temporary  drug interrupti on, 
and r esumpt ion at a lower dose of study  drug, the participant shoul d be discont inued fro m study  
drug.  All participant swho di scont inue study  drug shoul d continue to attend scheduled study 
visits. 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 606.6.3. Management of Participants with Perceived Excessive Weight Loss During the 
Additional 2-year Treatment Period for Participants with Prediabetes at 
Randomization
As indicated in Section 5.3.1 , if BMI ≤22 kg/m2is reached any time during the study , the 
recommended energy  intake shoul d be recalculated. From Visit [ADDRESS_318438] reached BMI ≤22 kg/m2, if weight l oss continues despi[INVESTIGATOR_261715]/or there 
are concerns related to degree of weight loss that may lead to discont inuat ion from study  drug, 
the invest igator should contact [CONTACT_261753] a study  drug dose reduction in a 
blinded fashio n(seeSecti on 6.6.2 for details regarding study  drug dose reduc tion)
.
6.7. Intervention after the End of the Study
6.7.1. Treatment after Study Completion
Tirzepati de will not be made available to parti cipants after conclusion o f the study .
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 617. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
7.1. Discontinuation of Study Intervention
Possible reasons leading to permanent disco ntinuatio n of IP:
participant decision
othe participant requests to discont inue IP.
clinical considerations
oinitiation of open -label GLP -1Ragonist or DPP -4 inhibitor , if participants will 
not or cannot discont inue them
ointolerable GI symptom s despi[INVESTIGATOR_134053] 6.6.2
oBMI ≤18.5 kg/m 2is reached at any  
time during the treatment period 
Note: The investigator should contact [CONTACT_261754]. 
odiagnosis of T1DM
odiagnosis of MTC after randomizat ion
osignificant el evation of calcitonin (Sect ion [IP_ADDRESS] )
odiagnosis of acute or chronic pancreat itis 
odiagnosis of an active or untreated malignancy (other than basal or squamous 
cell skin cancer, in situ carcino mas of the cervix, or in situ prostate cancer) 
after randomizat ion
odevelopment of any significant study  drug -related hypersensit ivity react ion
oonset of pregnancy in a female participant 
ooccurrence of any other treatm ent-emergent AE ( TEAE ), SAE, or clinically 
significant finding for which the invest igator believes that permanent study
drug discontinuation is the appropriate measure to be taken
oinadvertent enrollment if continued treatment with study  drug woul d not be 
medically appropriate (Section 7.2.3 )
oPHQ -
9 score ≥15  
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 62Parti cipants shoul d be referred to a Mental Healt h Professio nal (MHP) 
to assist in deciding whether the subject should be discontinued fro m 
study  drug .  If a parti cipant’s psychiatri c disorder can be adequately  
treated with psycho -and/or pharmacotherapy , then the subject, at the 
discreti on of  the Investi gator (in agreement with the MHP), may  be 
continued in the trial on rando mized therapy.  
oin addition, study  drug m ay be d iscont inued if participants:
answered “yes”to either Quest ion 4 (Active Suicidal Ideation wit h 
Some Intent to Act, Without Specific Plan) on the "Suicidal Ideat ion" 
porti on of  the C -SSRS
or
answered “yes”to Questi on 5 (Active Sui cidal  Ideati on wi th Specific 
Plan and Intent) on the "Suicidal Ideation" portion of the C -SSRS 
or 
answered “yes”to any  of the suicide -related behaviors ( Actual  
attem pt, Interrupted attempt, Aborted attempt, Preparatory  act or 
behavi or) on the “Suicidal Behavior” porti on of  the C -SSRS .
Note: A psychiatrist or appropriately trained professio nal may assist in the decisio n to 
discontinue the participant.
discontinuation due to a hepatic event or liver test abnormality
oParti cipants who are discont inued fro m IP due to a hepat ic event or liver test 
abnorm ality should have addi tional hepatic safet y data collected via eCRF .
oDiscontinuati on of  the IPfor abnormal liver tests should be considered by [CONTACT_32845] a participan tmeets one of the following condit ions after 
consultation wit h the Lilly designated medical monitor:
ALT or aspartate aminotransferase (AST) >8X ULN
ALT>2X baseline value OR ≥300U/L, whichever occurs first, if 
baseline ALT ≥2X ULN
ALT or AST >5X ULN for more th an 2 weeks
ALT or AST >3X ULN and total bilirubin level (TBL) >2X ULN or 
internat ional norm alized rati o (INR) >1.5 
ALT or AST >3X ULN with the appearance of fat igue, nausea, 
vomiting, right upper- quadrant pain or tenderness, fever, rash, and/or 
eosinophil ia (>5%)
alkaline phosphatase (ALP) >3X ULN
ALP >2.5X ULN and TBL >2X ULN
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 63ALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, 
right-quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
Parti cipants who stop study  drug perm anent lyshoul d continue to attend all scheduled study  visits
to collect all planned efficacy and safet y measurements. Participants who are unwilling to attend 
all scheduled visits and stop the study  prior to 72 weeks, should return for a final weight 
measurement (Visit 99).  If parti cipants are unwilling to attend Visit 99, thei r refusal to attend 
shoul d be docum ented in the patient medical record.   Participants wi th predi abetes who stop 
study  drug after 72 weeks should return for a final assessment of weight and glycemic status 
(Visit 199).  Refusal to attend should be documented in the patient medical record.
Parti cipants discont inuing from the IPprematurely for any reason should co mplete AEand other 
follow
-up procedures per Section 1.3(Schedule of Act ivities), Section 8.3(Adverse Events and 
Serious Adverse Events), and Section 8.2(Safet y Assessments) of the protocol.
7.1.1. Temporary Study Drug Discontinuation
In certain situat ions,after randomizat ion, the investigator may need to temporarily interrupt 
study drug.  Every  effort shoul d be made by  [CONTACT_261755] m aintain participant son study  
drug and to restart study  drug after any  temporary  interruption, as soon as it is safe to do so.   
Distribut ion of study  medicat ion at the correct dose will be per IWRS instructions.
  
If study drug 
interrupti on is…then…
[ADDRESS_318439] 
administered dose, as per escalat ion 
schedule .
3 consecutive doses 
or more participant restarts study  drug (at 5mg, 
managed by [CONTACT_10966]) and repeats dose 
escalat ion scheme .
due to an AE the event is to be documented and fo llowed 
according to the procedures in Sect ion 8.3
of this protocol .
due to intolerable 
persistent GI AEparticipants shoul d be treated as suggested 
in Section 6.6.2 .
Abbreviations:  AE = adverse event; GI = gastrointestinal; IWRS = interactive web res ponse service.
Invest igators should inform Lilly that study  drug has been temporarily interrupted.  The data 
related to tem porary  interrupti on of  study  treatm ent will be documented in source documents and 
entered on the eCRF.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 647.2. Participant Discontinuation/Wi thdrawal from the Study
To minimize the amount of missing data and to enable assessment of study  objectives as planned 
in the study  protocol , every  attem pt will be m ade to keep participants in the study irrespect ive of 
the following:
adherence to or discont inuat ion from study  drug
adherence to visit schedule
missing assessments
study  drug discont inuat ion due to AE 
development of comorbidit ies
development of clinical outcomes
The ci rcumstances listed above are notvalid reasons for discont inuat ion from the study . 
Parti cipants will be withdrawn from  the study in the fo llowing ci rcumstances:
enrollment in any other clinical study involving an IPor enrollment in any other ty pe 
of medical research judged not to be scientifically or medically compat ible with this 
study
participat ion in the study needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, r egulations, and good clinical pract ice (GCP)
participant requests to be withdrawn fro m the study and cl early indicates that there 
will be no further contact [CONTACT_261756] h the site
Female participants will be withdrawn fro m the study  if the parti cipant b ecomes 
pregnant.
Parti cipants who agree to provide information relevant to any  trial endpoint at the end of the 
study  are not considered to have di scontinued from the study .
Parti cipants discont inuing from the study  prem aturely for any  reason shoul d com plete AEand 
other safet y follow-up per Section 1.3(Schedule of Act ivities), Secti on 8.3(Adverse Events and 
Serious Adverse Events), and Section 8.2(Safet y Assessments) of this protocol.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 657.2.1. Participant Disposition and Timing of Safety Follow -up for the Primary Endpoint (72 Weeks)
Abbreviations:  E D
=early  discontinuation of treatment ; Pt= participant; w ks = weeks .

CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 667.2.2. Participant Disposition and T iming of Safety Follow -up for those with Prediabetes at Randomization
Continuing in Additional 2-year Treatment Period
Abbreviations:  E D= early discontinuation of treatment ; wks
=weeks .
Note: Participants with pre diabetes at randomization who discontinue study drug on or before Week 72 are not eligible to continue in additio nal 
2-year treatment period after Visit 21 (Week 72) and should proceed to V801 .

CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 677.2.3. D iscontinuation of Inadvertently Enrolled Participants
If the Sponsor or invest igator ident ify aparticipant who did not meet enrollment criteria and was 
inadvertent ly enro lled, the invest igator and the Sponsor CRP must agree whether conti nuing the 
study  treatm ent is medically appropriate.  Continuation of inadvertently enro lled participants in 
the study ,with or wi thout study drug treatment ,requires documented approval fro m the Sponsor 
CRP . Safet y follow up i s as outlined in Section 1.3(Schedule o f Activities), Section 8.3
(Adverse Events and Serious Adverse Events), and Section 8.2(Safet y Assessments) of the 
protocol .
7.3. Lost to Follow -up
Aparticipant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be conta cted by  [CONTACT_4145].  Si te personnel are expected to 
make diligent attempts to contact [CONTACT_10971] a scheduled visit or were 
otherwi se unable to be fo llowed up by [CONTACT_779].
Site personnel, or an independent third party , will  attempt to collect the vital status of the 
participant within legal and ethical boundaries for all participants rando mized, including those 
who did not get IP.  Public sources may be searched for vital status informat ion.  If vital status is 
determined, this w ill be docum ented ,and the partici pant will not be considered lost to fo llow-up.
Eli Lilly and Company  personnel  will not be involved in any attempts to collect vital status 
inform ation.
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Secti on10.1.9 .
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 688. Study Assessments and Procedures
Secti on10.2 (Appendix 2) liststhe laboratory  tests that will be performed for this 
study .  
Repeat or unscheduled samples may be taken for safet y reasons or for 
technical issues wit h the samples .
Unless otherwise stated in the subsect ions below, all samples co llected for specified 
laboratory  tests will be destroyed within [ADDRESS_318440] ivities (Section 
1.3).  Methods for measuring body weight are described in Section 10.7 (Appendix 7).
8.1.2. Secondary Efficacy Assessments
The fo llowing secondary  efficacy assessments 
will also be collected according to the Schedule of 
Activities:
waist circumference (measuring method is described in Secti on 10.7 [Appendix 7 ]).
fasting insulin (measured through central lab)
onset of T2DM (definit ion is described Section [IP_ADDRESS] )
HbA1c (%, mmo l/mol)(measured through ce ntral lab)
fasting glucose (measured through central lab)
BMI (derived using body  weight in kil ograms divided by  [CONTACT_261757]) 
blood pressure
lipi[INVESTIGATOR_805]
8.1.3. Patient -Reported Outcomes Assessments
The self -reported questi onnai res will be translated into the nat ive language of the region, 
linguist ically validated and administered according to the Schedule of Activit ies (Secti on 1.3)
.  
At these visits, the questionnaires should be co mpleted before the participant has discussed their 
medical condit ion or progress in the study  with the invest igator and/or site staff ,if the participant
is not adversely affected by [CONTACT_261758].
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 698.1.4. Short Form 36 version 2, acute, 1 week recall version
The SF -36v2 acute, 1 -week recall versio nis a 36 -item,generic, patient -administered measure 
designed to assess the following 8 dom ains:
Physical Funct ioning 
Role
-Physical  
Bodily Pain
General Healt h
Vitality
Social Functioning 
Role-Emotional 
Mental Heal th 
The Physical -Funct ioning domain assesses limitat ions due to health “now” while the remaining 
domains assess funct ioning “in the past week.” Each do main is scored individually  and 
inform ation from these 8 dom ains are further aggregated into 2 health -component summary 
scores:  Physical-Component Summary and Mental -Component Summary.  Items are answered 
on Likert scal es of  varying l engths (3 -, 5-, or 6- point scales).  Scoring of each domain and both 
summary scores are norm -based and presented in the form of T -scores, with a mean of [ADDRESS_318441] deviat ion (SD) of 10; hi gher scores indicate better levels of funct ion and/or better health 
(Marui sh2011).   
8.1.5. Impact of Weight on Quality of Life -Lite Clinical Trials Version
The IWQOL -Lite-CT is a 20 -item, obesi ty-specific PRO instrument developed for use in obesit y 
clinical trials.  It assesses 2 primary do mains of obesit y-related healt h-related quali ty of life
(HRQoL): physical (7 items), and psychosocial (13 items).  A 5- item subset of the physical 
domain,the physical -function com posite is also supported.  Items in the physical -funct ion 
composite describe physical impacts related to general and spec ific physical activit ies.  All items 
are rated on either a 5 -point frequency (“never” to “always”) scale or a 5 -point truth (“not at all 
true” to “completely true”) scale (Ko lotkin et al . 2017, 2018). 
8.1.6. EQ-5D-5L
Generic healt h-related quali ty of lifewill be assessed using the EQ -5D- 5L (EQ -5D; EuroQoL 
Group 2015).  The EQ -5D- 5L is a standardized 5-item instrument for use as a measure of healt h 
outcom e.  It provi des a simple descript
ive profile and a single index value for health status that 
can be use d in the clinical and econo mic evaluat ion of healt hcare as well as populat ion health 
surveys.  The EQ-5D- 5L com prises 5 dimensio ns of health (mobilit y, self-care, usual act ivities, 
pain/disco mfort, and anxiet y/depressi on).  The 5L versio n, introduced in 2 005, scores each 
dimensio n at 5 l evels (no probl ems, slight problems, moderate problems, severe problems, 
unable to perform/extreme problems), for a total of 3125 possible health states.  In addit ion to the 
healt h profile, a single health-state index value can be derived based on a formula that attaches 
weights to each of the levels in each dimensio n. This index value ranges between ˂0 (where 0is 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 70a healt h-state equivalent to death; negative values are valued as worse than dead) to 1 (perfect 
healt h)(Dolan 1997). In addit ion, the EQ Visual Analog Scale records the respondent ’s 
self-rated heal th status on a verti cal graduated (0 to 100) scale.  In conjunct ion with the healt h-
state data ,it provi des a com posite pi[INVESTIGATOR_10905]’s healt h status.  
The EQ -5D- 5L is used worldwide and is available in more than 170 different languages.  Details 
on the instrument, and scoring, organizing, and presenting the data collected can be found in the 
EQ-5D- 5L User Guide (EuroQoL Group 2015).
8.1.7. Patient Global Impre ssion of Status for Physical Activity
Study  parti cipants will be asked to complete a PGIS item specifically developed for this study .  
This is a patient -rated assessment of current health limitat ion and i s rated on a 5 -point scale 
ranging from “1 -not at a ll limited” to “5 -extremely  limited.”
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the Sch edule of Act ivities 
(Secti on1.3).
8.2.1. Physical Examinations
A co mplete physical examinat ion will include, at a minimum, assessments of the 
cardi ovascular, respi [INVESTIGATOR_696] , GIand n eurol ogicalsystems , as well as a thy roid exam .
Height,weight ,and w aist circumference will also be measured and recorded , per 
Secti on10.7.
Invest igators should pay special attention to clinical signs related to previous serious 
illness es.
8.2.2. Vital Signs
For each participant , vital signs shoul d be measured according to the Schedule of Act ivities 
(Secti on 1.3)and Section 10.7.
Any clinically  significant findings from vital-signs measurement that result in a diagnosis and 
that occur after the participant receives the firs t dose of study  treatm ent shoul d be reported to 
Lilly or i ts desi gnee as an AE via the eCRF.
8.2.3. Electrocardiograms
For each participan t, 12-Lead electrocardi ogram s (ECGs) shoul d be collected according to the 
Schedule of Act ivities (Section 1.3)and Section 10.7.  
Electrocardiograms will init ially be interpreted by  a qualified ph ysician (the investigator or 
qualified designee) at the site as soon after the time of ECG collection as possible, and ideally  
while the participant is still present, for immediate subject management, should any clinically 
relevant findings be identified . Any clinically significant findings fro m ECGs that result in a 
diagnosis and that occur after the participan t receives the first dose of the invest igational 
treatm ent shoul d be reported to Lilly or its designee as an AE via the eCRF.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 71All digital ECGs will be obtained using centrally provided ECG machines and will be 
electroni cally transmitted to a designated central ECG laboratory .ECGs will be performed in 
triplicate at Weeks 0 and 36.  The central ECG laboratory  will perform a basic quali ty control  
check (for example , dem ographics and study  details) and then store the ECGs in a database. At a 
future time, the stored ECG data may be overread by a cardio logist at the central  ECG l aboratory  
for further evaluat ion of machine -read measurements or to meet regulatory requirements. The 
machine -read ECG intervals and heart rate (HR) may be used for data analysis and report- writing 
purposes, unless a cardi ologistoverreading of the ECGs is conducted prior to complet ion of the 
final study  report (in which case, the overread data would be used).
8.2.4. Clinical Safety Laboratory Assessments
For each participant, laboratory tests detailed in ( Secti on10.2) should be conducted 
according to the Schedule of Act ivities (Secti on 1.3). 
With the exception o f laboratory  test resul ts that may  unblind the study , Lilly or i ts 
designee will provide the invest igator with the results of laboratory tests analyzed by 
a central  vendor, if a central vendor is used for the clinical trial.  
Any clinically  significant findings from laboratory tests that result in a diagno sis and 
that occur after the participant receives the first dose of IPshoul d be reported to Lilly 
or its desi gnee as an AE via eCRF.
[IP_ADDRESS]. Immunogenicity Assessment
Where local regulat ions and ERBs allow, blood samples for immunogenicit y testing will be 
collect ed to determine ant ibody  producti on against tirzepat ideas specified in the Schedule of 
Activities (Section 1.3).
At the visit s and t imes specified in the Schedule of Act ivities (Secti on 1.3),venous blood 
samples will be co llected to determine ant ibody  producti on against ti rzepati de.  To interpret the 
resul ts of immunogenicit y, a PK sample will  be collected at the same time points as the 
immunogenicit y sample .  All samples for immunogenicit y should be taken predose when 
applicable and possible.  In the event of systemic drug-hypersensit ivity react ions (immediate or 
nonimmediate), additional samples will be co llected (including antidrug ant ibodies [ADAs] , PK,
andexploratory  biomarker sam ples) as close to the onset of the event as possible, at the 
resol ution of the event, and [ADDRESS_318442] ion and 
handling of blood samples will be provided by  [CONTACT_1034] .  The actual date and time (24- hour 
clock time) of each sampling will be recorded.  Immunogenicit y will be assessed by a validated 
assay designed to detect ADAs in the presence of tirzepat ideat a l aboratory  approved by [CONTACT_429] . Antibodies may be further characterized and/or evaluated for their abi lity to neutralize 
the activit y oftirzepat ide. Sample co llected at Visit 801 or Vi sit 802 will assess immunogenicit y 
at washout of tirzepat ide ([ADDRESS_318443] end of treatment).
Samples wi th tirzepat ide ADA detected will be titered and evaluated for t heir abilit y toneutralize 
the activit y of assigned treatm ent (ti rzepati de-neutralizing ant ibodies). Samples with tirzepat ide 
ADA detected will also be tested for cross -reactive binding to native GIP and GLP -1, and if such 
is detected, then for neutralizi ng ant ibodies against  native GIP and GLP -1, respectively .
Treatment -emergent ADAs are defined in Section9.4.6 .  
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 72Samples will  be retained for a m aximum  of [ADDRESS_318444].
[IP_ADDRESS]. Hepatic Safety Monitoring
If a study participant experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated 
TBL ≥2X ULN, liver testing (Section 10.5) shoul d be repeated wi thin [ADDRESS_318445], TBL, and ALP 
shoul d cont inue unt il levels normalize or return to approximate baseline levels. 
Addit ional safet y data should be co llected via the eCRF if 1 or m ore of the fo llowing condi tions 
occur :
elevation of serum  ALT to ≥5X ULN on 2 or more consecutive blood tests
elevated serum  TBL to ≥2X ULN (except for cases of known Gilbert’s syndro me)
elevation of serum  ALP to ≥2X ULN on 2 or more consecutive blood tests
participant discont inued from treatment due to a hepatic event or abnormalit y of liver 
tests
hepat ic event considered to be a nSAE
8.2.6. Depression, Suicidal Ideation ,and Behavior Risk Monitoring
Overweight and obese patients are at incr eased risk for depression ( Luppi[INVESTIGATOR_105406]. 2010 ).  
Depressio n can increase the risk for sui cidal  ideation and behavior.  Therefore, study  parti cipants 
will be screened at trial entry  and m onitored during the study  for depressi on,andsuicidal 
ideat ion and b ehavi or.  
Parti cipants should be monitored appropriately and observed closely for suicidal ideation and 
behavior or any  other unusual changes in behavior, especially at the beginning and end of the 
course of treatment, or at the time of dose changes, eith er increases or decreases. Considerat ion 
shoul d be given to discont inuing study medicat ion in subjects who experience signs of suicidal 
ideat ion or behavior, fo llowing a ri sk assessment (Section 7.1).
Baseline and treatm ent em ergent assessment of depressio n, suicidal i deati on and behavior will be 
monitored during the study using the C-SSRS and PHQ-9 (Section [IP_ADDRESS] ).
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 738.3. Adverse Events and Serious Adverse Events
Please refer to Section 10.3 Appendix 3 Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting.
Invest igators are responsible for monitoring the safety of partici pants who have en tered this 
study  and f or alerting Lilly  or its designee to any  event that seem s unusual, even if this event 
may be considered an unant icipated benefit to the participant .
The invest igator is responsible for the appropriate medical care of participants during the study .
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered relate d to the IPor the study , 
or that caused the participant to discont inue the IP before complet ing the study.  The participant 
shoul d be f ollowed until the event resolves, stabilizes with appropriate diagnostic evaluat ion, or 
is reasonably explained.  The frequency o f follow-up evaluat ions of the AE is left to the 
discreti on of  the invest igator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the ICF i s signed, study  site personnel will record via eCRF the occurrence and nature of 
each participant ’s preexist ing condit ions, including clinically  significant si gns and symptom s of 
the disease under treatment in the study .  In addi tion, si te personnel will record any  change in the 
condi tion(s) and any  new condi tions as AEs. Investi gators shoul d record thei r assessment of the 
potenti al relatedness of each AE to protocol procedure and IPvia eCRF .
The invest igator will interpret and document whether or not an AE has a reasonabl e possibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment, or pathologies.
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the IP, 
study  device ,and/or study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the cour se of the study.
If aparticipant ’s IPis discont inued as a result of an AE, study-site personnel must report this to 
Lilly or i ts desi gnee via eCRF, clarifying if possible, the circumstances leading to any  dosage 
modificati ons or di scont inuat ions of treatm ent.
Serious Adverse Events
All AEs occurring after signing the ICF are recorded in the eCRF and assessed for serious 
criteria.  An SAE is any AE from this study that results in one of the following outcomes:
death
initialor prol onged inpatient hospi[INVESTIGATOR_3094] 
a life- threatening experience (that is, immediate risk of dying)
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 74persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or hospi[INVESTIGATOR_3092] m ay jeopardize the participant or may require 
intervent ion to prevent 1of the other outcomes listed in the definit ion above.  
Examples of such medical events include allergic bronchospasm requiring intensive 
treatm ent in an eme rgency  room  or at hom e, blood dyscrasias or convulsions that do 
not resul t in inpat ient hospi [INVESTIGATOR_3094], or the develo pment of drug dependency or drug 
abuse.
when a condit ion related to the drug delivery system necessitates medical or surgical 
intervent ionto preclude either perm anent impai rment of  a body  functi on or 
perm anent dam age to a body  structure, the seri ous outcom e of “requi red intervent ion” 
will be assigned.
All AEs occurring after signing the ICF are recorded in the 
eCRF and assessed for serious 
criteria.  The SAE reporting to the Sponsor begins after the participant has signed the ICF and 
has received IP.  However, if an SAE occurs after signing the ICF, but prior to receiving IP,the 
SAE should be reported to the S ponsor per SAE -reporting requi rements and timelines (see 
Secti on8.3.1 ) if it is considered reasonably possibly related to study procedure .
Study -site personnel  must al ert Lilly or its designee of any SAE within [ADDRESS_318446] addit ional data collected using 
the eCRF.
Pregnancy (during maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulatory  requi rements any  pregnancy  should be reported following the SAE 
process to collect data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (the participant disposi tion case report form [CRF ]has 
been co mpleted).  However, if the investigator learns o f any SAE, including a death, at any  time 
after a subj ect has been disch arged from  the study , and he or she considers the event reasonably 
possibly  related to the study  treatm ent or study  parti cipat ion, the invest igator must prompt ly 
notify Lilly.
Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adve rse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to IPor procedure.  [LOCATION_002] 21 CFR 
312.32 , European Unio n Clinical Trial Directive 2001/20/EC ,and the associated detailed 
guidance or nati onal regulatory  requi rements in parti cipating countri es requi re the reporting of 
S[LOCATION_003]Rs.  Lilly has procedures that will be fo llowed for the i dentificat ion,recording ,and 
expedited reporting of S[LOCATION_003]Rs that are consistent with global regulat ions and the associ ated 
detailed guidance.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 758.3.1. Time Period and Frequency for Collecting AE and SAE Information
All AEdata will be collected from the signing of the ICF untilthe time po ints specified in the 
Schedule of Act ivities (Secti on1.3).
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences .
[IP_ADDRESS]. Adverse Event Monitoring with a Systematic Questionnaire
Before administering the C-SSRS or the PHQ -9,study site personnel will quest ion the 
participant about any  change in the preexist ing condi tion(s) and the oc currence and nature of any 
AEs.
Nonserious AEs obtained through the questionnaire are recorded and analyzed separately.  Only 
serious AEs elic ited through the C-SSRS or PHQ -9are to be recorded as AEs via the eCRF and 
reported to Lil ly or its designee wi thin 24 hours as SAEs .For this study, the C -SSRS is a dapted
for the assessment of the ideat ion and behavior categories only .  The Intensi ty of Ideati on and 
Lethalit y of Behavi or secti ons are removed .
The C-SSRS is ascale that captures the occurrence, severit y,and frequency  of suicidal ideation 
and/or behavior during the assessment period.  T he scale includes suggested questions to solicit 
the type of  information needed to determine if suicidal ideat ion and/or behav ior occurred .  The 
tool was developed by [CONTACT_261759] h trial group for the purpose of 
being a counterpart to the Columbia Classificat ion Algori thm of Suicide Assessment 
categori zation of suicidal events.   
The PHQ -[ADDRESS_318447] ical Manual -
IV depression criteria as “0” (not at all) to “3” (nearly  every day ),was devel oped f or use in 
primary  care settings (Kroenke et al. 2001) .  
8.3.2. Follow -up of AEs and SAEs
After the init ial AE or SAE report, the invest igator is required to proactively fo llow each 
participant at subsequent visits/contacts. All SAEs will be fo llowed until reso lution, stabilizat ion, 
the event i s otherwise explained, or the parti cipant is lost to foll ow-up (as defined in Secti on1.3). 
8.3.3. Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by [CONTACT_261760] a SAE is essent ial so that 
legal obligations and ethical responsibilit ies towards the safet y of parti cipants and the 
safet y of a study  intervent ion under clinical invest igation are m et.
The S ponsor has a legal responsibilit y to notify  both the l ocal regulatory  authori ty 
and other regulatory  agencies about the safet y of a study  interventi on under clinical 
investigat ion. The S ponsor will co mply with country -specific regulatory  
requirements rel ating to safety reporting to the regulatory authorit y, Institutional 
Review Boards (IRB)/Independent Ethics Co mmit tees (IEC) , and invest igators.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 76Invest igator safet y reports must be prepared for S[LOCATION_003]R saccording to local 
regul atory  requi rement s and sponsor policy and forwarded to invest igators as 
necessary .
An invest igator who receives an invest igator safety report describing a nSAE or other 
specific safet y informa tion (f or exam ple,summar y or list ing of SAEs) fro m the 
Sponsor will review and t hen file it along with the IBand will notify the IRB/IEC, if 
appropriate according to local requirements.
8.3.4. Pregnancy
Details o f all pregnancies in female participants and female partners of male 
participants will be co llected after the start of study inter vention and the participant 
will be fo llowed to determine the outcome of the pregnancy for mother and neonate.  
If a pregnancy  is reported, the investigator should inform the S ponsor wi thin 24 hours 
of learning of the pregnancy and should follow the proce dures outlined in Section 
10.4 (Appendix 4).
Abnorm al pregnancy outcom es (for example ,spontaneous abortion, fetal death, 
stillbirth, congenital ano malies, and ectopi c pregnancy) are considered SAEs.
8.3.5. Medical Device Incident s (Including Malfunctions)
Medical devices are being used in this study  for the purposes of administering tirzepat ide. In 
order to fulfill regulatory  reporting obligat ions worldwide, the invest
igator is responsible for the 
detection and documentation of e vents m eeting the definit ions of incident or malfunct ion that 
occur duri ng the study  with such devices.
The definit ion of a medical device i ncident can be found in Secti on 10.6 (Appendix 6).
Note :Incidents fulfilling the definit ion of an AE/SAE will also fo llow the processes outlined in 
Secti on 8.3.2 .
[IP_ADDRESS]. Time Period for Detecting Medical Device Incidents
Medical device incidents ,or malfuncti ons of  the device that result in an incident ,will 
be detected, documented, and reported to the Sponsor during all periods of  the study  
in wh ich the medical device is used.
If the invest igator learns of any incident at any time after a participant has been 
discharged from  the study , and such incident is considered reasonably related to a 
medical device used during the study , the invest igator will pro mptly notify  the 
Sponsor through the complaints process .
The m ethod of docum enting medical device incidents is provided in Section 10.6 (Appendix 6 )
.
[IP_ADDRESS]. Follow -up of Medical Device Incidents
All medical device incidents invo lving an AE will be fo llowed and reported in the 
same m anner as other AEs (see Secti on8.3.2 ).This applies to all participants, 
including those who discont inue study  interventi on.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 77The invest igator is responsible for ensuring that follow -up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the incident.
New or updated informat ion will be recorded on the originally co mpleted form wit h 
all changes signed and dated by  [CONTACT_3170].
[IP_ADDRESS]. Prompt Reporting of Medical Device Incidents and Malfu nctions to Sponsor
Medical device incidents or malfunct ions will be reported to the Sponsor within a 
business day or as determined for the study , after the invest igator determines that the 
event or issue meets the protocol definit ion of a medical device in cident or 
malfunct ion.
Medical device incidents or malfunct ions that result in an SAE will be reported to the 
Sponsor within 24 hours , in the same manner as other (S)AEs.  
Malfunct ionswill be reported via theProduct Com plaint Form  and sent to the 
Sponso r per training and per instructions provided on the Product Complaint F orm.
The same individual at the si te 
will be the contact [CONTACT_261761].
[IP_ADDRESS]. Regulatory Reporting Requirements for Medical Device Incidents
The invest igator will pro mptly report to the Sponsor all incidents occurring wit h any 
medical device provided for use in the study  in order for the Sponsor to fulfill the 
legal responsibilit y to notify appropri ate regulatory authorit ies and other entit ies 
about certain safety  informat ion relating to medical devices being used in clinical 
studi es.
The invest igator, or responsible person ac cording to l ocal requirements (for example;
the head of the medical inst itution), will co mply with the applicable local r egulatory  
requi rements rel ating to the reporting of incidents to the IRB/IEC.
8.3.6. Complaint Handling
Lilly co llects product complaints on all IPs(drugs/medical devices , inclusive of packaging, 
labeling, instructions for use,or other com ponent) used in clinical studies ,inclusive o f 
comparators, in order to ensure the safet y of study  parti cipants, m onitor product qualit y, and 
facilitate process and product improvements.
Parti cipants will be instructed to contact [CONTACT_17074] a 
complaint or probl em wi th the invest igational drug or medical device ,so that the situation can be 
assessed.
Invest igators will provide complete and timely reports to the Sponsor as instructed for the study, 
and per the Product Complaint Form .
8.4. Treatment of Overdose
Study  drug overdose (m ore than the specified number of injections) will be reported as an AE.  
In the event of overdose, refer to the IB for tirzepatide .
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 788.5. Pharmacokinetics
Pharmacokinet ic samples will be co llected from allrandomized pa rticipants.
Plasma tirzepat ideconcentrati ons will only be determined from blood samples obtained fro m 
participants receiving tirzepat idetreatment .Blood sam ples f or PK assessment will be co llected 
at W eeks 8, 16, and 36following tirzepat idetreatment per the Schedule of Activit iesor at E D
(Secti on 1.3).  At each visit prior to a PK assessment, e ach participant will be assigned via IWRS 
to one of the sampling PK t ime windows of [ADDRESS_318448] oratory  analyses such as metabolism work, 
protein binding, and/or bioanalyt ical method cross -validat ion.
8.6. Pharmacodynamics
Samples to assess the PDproperties of tirzepat ideare incl uded in the efficacy measures and not 
applicable in this sect ion.
8.7. Genetics
8.7.1. Whole Blood Sample (s)for Pharmacogenetic Research
A who le blood sample will  be collected for pharmacogenet ic analysis as specified in the 
Schedule of Act ivities (Section 1.3)where local regulat ions allow.  
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the f uture.  Sam ples will be used to investigate variable response to tirzepat ideand to 
investigate genet ic variants though t to pl ay a rol e in obesit y.  Assessment of variable response 
may include evaluation o f AEs or differences in efficacy.
All samples will be coded wi th theparticipant number.  These samples and any data generated 
can be linked back to the patient only by [CONTACT_10991].  
Samples will  be retained at a facilit y selected by  [CONTACT_82395] a m aximum  of 15years 
after the l ast participant visit for the study , or f or a shorter peri od if l ocal regulat ions and/or 
ERBs/ IRBs impose shorter time limit s.  Thi s retention peri od enables use of new techno logies, 
response to regulatory  quest ions, and invest igation of variable r esponse that may not be observed 
until later in the development of tirzepat ideor after tirzepat idebeco me(s) commercially 
available.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 79Molecular techno logies are expected to improve during the [ADDRESS_318449] ion, variabilit y of participant response (including safet y), and 
clinical outcome.  Sample co llection is incorporated into clinical studies to enable examinat ion of 
these quest ions through measurement of bio molecul es including deoxy ribonucleic acid (DNA), 
proteins, lipi[INVESTIGATOR_805], and other cel lular elements.
Serum ,andplasma samples for bio marker research will be co llected at the times specified in the 
Schedule of Act ivities (Section 1.3)where local regulat ions allow.
Samples will  be used for research on the drug target, disease process, variable response to 
tirzepat ide, pathways associated with obesit y,mechanism o f action of  tirzepat ide,and/or 
research method or in validat ing diagnost ic tools or assay(s) related to obesit y.  
All samples will be coded with the participant number. These samples and any data generated 
can be linked back to the participant only by [CONTACT_261762].  
Samples will  be retained at a facilit y selected by [CONTACT_82395] a m aximum  [ADDRESS_318450] participant visit for the study , or f or a shorter peri od if l ocal regulat ions and 
ERBs /IRBs impose shorter time limits.  This retentio n peri od enables use of new techno logies, 
response to regul atory  quest ions, and invest igation of variable response that may not be observed 
until later in the development of tirzepat ideor after tirzepat idebeco me(s) commercially 
available.
8.9. Health Economics
Health Economics and Medical Resource Utilizat ion Parameters are not evaluated in this study.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 809. Statistical Considerations
9.1. Statistical Hypotheses
The alternat ive hypothese s for the primary  objective are the following: 
H10,1:QW tirzepat ide 10 mg is superior to placebo for percent change in body weight 
from randomization AND percentage of parti cipants who achieve ≥5% body weight 
reducti on at 72 weeks.
H15,1:QW tirzepat ide 15 mg is superior to placebo for percent change in body weight 
from randomization AND percentage of parti cipants who achieve ≥5% body weight 
reducti on at [ADDRESS_318451] ive controlling for type 1 error rate are 
the following: 
H15,2and H 10,2:  superi ority of tirzepat ide 10 mg and/or 15 mg versus placebo for 
percentage of particip ants who achie ve ≥10% body  weight reduction from rando mizat ion 
at 72 weeks 
H15,3and H 10,3:  superi ority of tirzepat ide 10 mg and/or 15 mg versus placebo for 
percentage of participants who achieve ≥15% body  weight reducti on from rando mizat ion 
at 72 weeks
H15,4and H 10,4:  superi ority of tirzepat ide 10 mg and/or 15 mg versus placebo for 
percentage of participants who achieve ≥20% body  weight reducti on from rando mizat ion 
at 72 weeks
H15,5and H 10,5:  superi ority of tirzepat ide 10 mg and/or [ADDRESS_318452] circumference (cm) at 72 weeks
H1015,6:  superiorit y of pool ed tirzepatide 10 mg and 15 mg versus placebo for change in 
body  weight (kg) from rando mizat ion at 20 weeks 
H5,1:  superiorit y of tirzepat ide 5 mg versus placebo for p ercent change in body weight 
from randomization and percentage of participants who achieve ≥5% body  weight 
reducti on at 72 weeks
Hp,7:superi ority of tirzepati de (all  doses combined) versus placebo for change in systolic 
blood pressure (SBP) (mmHg) from rando mization at 72 weeks
Hp,8:superi ority of tirzepati de (all  doses combined) versus placebo for change in 
triglyceri des (m g/dL) from rando mizat ion at 72 weeks
Hp,9:superi ority of tirzepat ide (all doses combined) versus placebo for change in non -
high-densit y lipoprotein cho lesterol (non -HDL -cholesterol ) (mg/dL) from  rando mizat ion 
at 72 weeks
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 81Hp,10:  superiori ty of tirzepati de (all dose s combined) versus placebo for change in high -
densit y lipoprotein cho lesterol (HDL -cholesterol) (mg/dL) fro m rando mizat ion at 72 
weeks
Hp,11:  superi ority of tirzepat ide (all doses combined) versus placebo for change in fast ing 
insulin (pmo l/L) fro m rando mization at 72 weeks
H1015,12 :  superiorit y of pool ed tirzepatide [ADDRESS_318453] ioning domain score from rando mization at 72 weeks.
H15,13and H 10,13:superiorit y of tirzepat ide 10 mg and/or [ADDRESS_318454] acebo for change 
in percent body  weight from  randomizati on at 176 weeks (for participants with 
predi abetes at randomization).
Hp,14and H p,15:  superiori ty of tirzepat ide (all doses combined) versus placebo for 
delaying the onset of ty pe 2 di abetes m ellitus (T2DM) during 176 weeks or 193 weeks 
(for participants with prediabetes at randomizat ion).
The details o f family-wise type I error rate con trol strategy  and methods for the aforem entioned 
hypotheses will be provi ded in the statistical anal ysis pl an (SAP).
9.2. Sample Size Determination
Approximately  3429 participants will be screened to achieve 2400 rando mlyassigned to study  
intervent ion (600 participants per intervent ion group ).
The sample size determinat ion assumes that evaluation of superiorit y of 10-mg tirzepatide and 
tirzepat ide 15mg to placebo will be conducted in parallel, each at a [ADDRESS_318455] 11% m ean body  weight 
percentage reduction from randomizat ionat 72 weeks for 10-mg tirzepat ide and /ortirzepati de 
15mg compared withplacebo, a commo n SD of 10%, and a dropout rate of 25% are assum ed for 
statist ical power calculat ions.  Under the assumpt ions above, rando mizing 2400 participants in a 
1:1:1 :1ratio to tirzepati de 5 m g (600 ), tirzepat ide10 m g 
(600), ti rzepat ide 15 m g (600), and 
placebo ( 600) provides more than 90% power to demonstrate superiority o f tirzepat ide 10 m g 
and/or 15 m gto placebo. 
The chosen sample size and rando
mization ratio also provides >90% power to establish 
superi ority of 10-mg tirzepat ide and 15-mg tirzepatide doses to placebo in term o f percentage of 
participants achieving at least 5% body  weight reducti on at 7 2 weeks, conducted in parallel using 
a Fisher ’sexact test, each at a 2 -sided significance level of 0.025, assuming 25% placebo -
treated 
participants and 90% tirzepatide -treated parti cipants achi eving the goal  and a dropout rate of 
25%.   
In addition,assuming that approximately 60% of  the randomized populat ion will have 
predi abetes ,the study sample size will also provide more than 90% power to demonstrate 
superi ority of tirzepat ide (all doses combined) over placebo in term sof delaying the onset of
diabetes for participant swith predi abetes at study  entry .  It is based on the fo llowing
assum ption
s: 1.6% (corresponding to annual hazard rate of 0. 54%) of parti cipants randomized to
tirzepat ide and 6% of parti cipants randomized to placebo (corresponding to annual hazard rate of 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 822.1%)will progress to diabetes during the 3-year peri od; 49% of participants will drop out 
(corresponding to annual drop- out rate of 22%) during the same period; and the test will be 
conducted at a 2 -sided significance level of 0. 05.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 839.3. Populations for Analyses
For purposes of analysis, the following analysis sets are defined:
Analysis Set Description
Entered Participants all participants who sign informed consent
Randomized Participants all participants who are randomly assigned a study treatment
Modified Intent-to-T reat (mITT) all randomly assigned participants who are exposed to at least 1dose of study 
drug; p articipants will be included in the treatment group they were randomized 
to
Efficacy A nalysis Set(EAS) data obtained during treatment period from mITT, excluding data after 
discontinuation of study  drug (last dose date + 7 days)
Full analysis set (FAS) data obtained during treatment period from mITT, regardless of adherence to 
study drug.
Safety Analysis Set(SS) data obtained during the treatment period plus safety follow -up period from 
mITT, regardless of adherence to study drug
9.4. Statistical Analyses
9.4.1. General Statistical Considerations
Statistical analysis o f this study  will be the respons ibilit y of Lilly orits designee.  Any change to 
the data analysis methods described in the protocol will require an amendment ONLY if it 
changes a principal feature of the protocol.  Any  other change to the data analysis methods 
described in the protocol, and the just ificat ion for making the change, will be described in the 
SAP or the Clinical Study Report (CSR) . Additional exploratory data analyses may be 
conducted as deemed appropriate.
Unless otherwise noted, all tests of treatment effects will be conducted at a 2 -sided alpha level o f 
0.05,and the confidence interval will be calculated at 95%, 2 -sided.  In stati stical summaries and 
analyses, data will be analyzed as rando mized.
Unless specified otherwise, efficacy and safet y will be assessed using the modified intent ion-to-
treat (mITT) populat ion.  Baseline will be defined as the last available non -missing measurement 
during Visit 1 to Visit 3 .  Unless specified otherwise, safet y assessments will be guided by [CONTACT_261763] y of tirzepat ide doses with placebo irrespective of adherence to study  
drug. Thus, safety analysis will be conducted using safety analysis set(SS).  
Summary  statistics for continuous m easures will  includesample size, mean, SD, median, 
minimum, and maximum.  T heanalysis model to make compar isons amo ng treatment groups
relative to continuous measurements assessed over time will include a mixed model for repea ted 
measures (MMRM), with terms of treatm ent, visi t, and treatm ent-by-visit interact ion,
stratificat ion factors , and baseline measurement as a covariate.  
Kaplan -Meier m ethod will be used for estimation of cumulat ive event -freesurvival  rates over 
time, and Cox proporti onal hazards regressio n analysis will be used to compare hazard rates 
among treatm ents.
Summary  statistics for categorical measures (including categorized continuous measures) will 
include sample size, frequency, and percentages.  Logist ic regressio n will be used to examine the 
treatm ent difference in binary  efficacy  outcomes if there is a nee d to adj ust for covariates . 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 84Otherwi se, Fisher’s exact test will be used to examine the treatment difference in categorical 
outcom es. 
Summary  statistics for discrete coun t measures will include sample size, mean, SD, median, 
minimum, and maximum.  The ne gative bino mial regressio n model will be used for the treatment 
comparison of discrete count measures. 
Other stati stical methods may be used, as appropriate, and details will be described in the SAP.
9.4.2. Treatment Group Comparability
[IP_ADDRESS]. Participant Disposition
A detailed description o f participant disposit ion will be provided at the end of the study . 
Frequency coun ts and percentages of all part icipants screened, randomized, and receiving at least 
1 dose of study  drug will  be presented by  [CONTACT_82400].  Of t heparticipants in the m ITT 
popul ation, frequency  counts and percentages of participan ts who completed the study , 
prem aturely  discontinued the study (and/or study  drug) , including reason for premature 
discontinuat ion, will be presented by  [CONTACT_82400].   
A Kaplan -Meier analysis o f time fro m rando mizat ion to premature discontinuat ion from study  by 
[CONTACT_82401].
[IP_ADDRESS]. Participant Character istics
Dem ographics and other baseline characteristics (including years of educat ion)will be 
summarized by [CONTACT_134116].
[IP_ADDRESS]. Concomitant Therapy 
Concomitant medicat ions, includi ng previous therapy , will  be summarized by  [CONTACT_261764].  
[IP_ADDRESS]. Treatment Compliance 
Frequency counts and percentages of partici pants com pliant to study drug wil l be summarized by 
[CONTACT_261765] ( FAS).
9.4.3. Efficacy Analyses
[IP_ADDRESS]. Primary Analyses
There will be 2estimands o f interest in comparing efficacy o f tirzepati dedoses wi th placebo . 
For obj ectives controlled for Ty pe1 error at 72 weeks :
1) T he “efficacy” estimand, defined as the average treatment effect of tirzepat ide 
relative to placebo at [ADDRESS_318456] ivity, in the rando mized participants had they remained on thei r 
rando mized treatment for the ent ire planned 72 weeks treatm ent durati on.
2) T he “hybrid ”estimand, defined as the average treatment effect of tirzepat ide relat ive 
to placebo at [ADDRESS_318457] to a reduced -calorie diet and increased physical
activit y, for the randomized participants regardless of the adherence to study drug .  
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 85Forobjectives controlled for Ty pe 1 error assessed after 72 weeks: 
1) T he “efficacy” estimand, defined as the treatment effect of tirzepat ide relat ive to 
placebo at 176/[ADDRESS_318458] ivity, in the rando mized participants with prediabetes at randomizat ion 
had they  remained on thei r randomized treatm ent for the ent ire planned 176 weeks 
treatm ent durati on.  
2) T he “hybrid ”estimand, defined as the average treatment effect of tirzepat ide relat ive 
to placebo at 176/[ADDRESS_318459] ivity, for the randomized participants with prediabetes at randomizat ion 
regar dless of the adherence to study  drug .  
For the F ood and Drug Administration , the primary  efficacy analysis will be guided by  [CONTACT_261766]. This assessment will analyze percent change in 
body  weight obtained at the 72-week visit using an analysis o f covari ance (ANCOVA) and the 
percentage of parti cipants achieving at least 5% body  weight reducti onobtained at the 72-week 
visit using a logistic regressio n model. Both m odels will  include terms oftreatm ent, 
stratificat ionfactors, and baseline body  weight as a covariate .  Missing data at the 72 -week visit
will be imputed and a nalysis will be conducted with mult iple imputations (see details in the 
SAP). 
Since the mean percent change in body weight and percentage of parti cipants wi th ≥5% 
body  weight reducti on objectives need to be achieved at the same time, no mult iplicit y 
adjustm ent is planned for these 2 tests. 
For all other purpose s, the primary efficacy analysis will be guided by [CONTACT_941] “e fficacy” est imand 
and conducted using the efficacy analysis set (EAS ).  Theprimary analysis model will be a n
MMRM forbody weight percent change over time and logist ic regressio n for percentage of 
participants achieving at least 5% body  weight reducti on over time . Deta ils of the stati stical 
modeling will be provi ded in the SAP.
[IP_ADDRESS]. Key Secondary Analyses
superi ority of pooled tirzepat ide 10 m g and 15 m gto placebo for change in body  
weight (kg) from rando mizat ion at 20 week svisit
superi ority of QW tirzepat ide 5 mg to placebo for percent change in body weight 
from randomization AND percentage of parti cipants who achieve ≥5% body weight 
reducti on at 72 weeks visit
superi ority of each ti rzepat ide dose (10 m g and 15 mg) to placebo for the percentage
of study  parti cipants who achieve ≥10% body  weight reducti on at 72 weeks visit
superi ority of each ti rzepat ide dose (10 m g and 15 mg) to placebo for the percentage
of study  parti cipants who achieve ≥15% body  weight reducti on at 72 weeks visit
superi ority of each tirzepat ide dose (10 m g and 15 mg )toplacebo for thepercentage 
of study  participants who achieve ≥20% body  weight r eduction at 72 weeks visit
superi ority of each ti rzepat ide dose (10 m g and 15 mg) to placebo for change from 
rando mizat ionin waist circumference (cm) at 72 week svisit
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 86superi ority of pooled tirzepat ide 10 mg and 15 mg to placebo for change from 
rando mizat ion in SF -36v2 acute form physical  functi oning dom ain score at 72 weeks 
visit
superi ority of tirzepat ide (all doses combin ed) to placebo for change from 
rando mizat ion in triglycerides (mg/dL) at 72 weeks visit
superi ority of tirzepat ide (all doses combined) to placebo for change fro m 
rando mizat ion in non-HDL -cholesterol (mg/dL) at 72 weeks visit 
superi ority of tirzepat ide (all doses combined) to placebo for change fro m 
rando mizat ion in HDL -cholesterol (mg/dL) at 72 weeks visit
superi ority of tirzepat ide (all doses combined) to placebo for change fro m 
rando mizat ion in SBP (mmHg) at 72 weeks visit
superi orityof tirzepat ide (all doses combined) to placebo for change fro m 
rando mizat ion in fasting insulin (pmo l/L) at 72 weeks visit
superi ority of each tirzepat idedose (10 m g and 15 mg ) to placebo for change from 
rando mizat ionin percent change of body  weight at 176week svisit (for participants 
with predi abetes at randomizat ion)
superi ority of tirzepat ide (all doses combined) to placebo in delaying the onset of 
diabetes during 176 weeks treatm ent peri od(for participants with prediabetes at 
rando mizat ion)
superi ority of tirzepat ide (all doses combined) to placebo in delaying the onset of 
diabetes during 193 weeks study  period (for participants with prediabetes at 
rando mizat ion)
Addit ional details, including ana lysis methods for key  secondary endpo intsand the strategy  for 
control ling overall t ype 1 error rate at a 2 -sided al pha of 0.05 of primary and key  secondary  
endpo int evaluat ion, will be provided in the SAP.
9.4.4. Safety Analyses
Unless specified otherwise, s afety assessments will be guided by  [CONTACT_261767]. Thus, safet y analysis 
will be conducted using SS.  
[IP_ADDRESS]. Study Drug Exposure
Exposure to each study  treatm ent will  be calculated for each participant and summ arized by
[CONTACT_3227].
[IP_ADDRESS]. Adverse Events
Adverse events will be coded from the actual term using the Medical Dict ionary for Regul atory  
Activities (MedDRA) and reported with preferred terms and system organ class.  Counts and 
percentage s of parti cipants e xperi encing events will be reported for each treatment group, and 
Fisher’s exact test will be used to compare the treatment groups.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 87The percentage of participants experiencing TEAE , SAE, discont inuat ion due to AE will be 
summarized by [CONTACT_3227].
[IP_ADDRESS]. Adverse Event of Special Interest
This sect ion includes areas of interest whether due to observed safet y findings, potential findings 
based on drug class, and agreed upon consultation with regulatory  agencies for the reasons 
previously mentioned.
The fo llowing AEs are AEs of special interest (AESI) for this study:
severe hypoglycemia
major adverse cardi ovascular events (adjudicated )
;includes , but not limited to 
cardi ovascular death, nonfatal MI, nonfatal  stroke, and hospi [INVESTIGATOR_140756]
treatm ent-emergent supraventricular arrhyt hmias and cardiac conducti on disorders
hepatobiliary  disorders ; includes biliary  colic, cholecyst itis, and other gallbladder 
disease
severe GIevents
acute renal  events
MDD /suicidal behavi or and ideati on  
pancreat it is (adjudicated)
c-cell hyperpl asia and thy roid malignancies
allergic/ hypersensit ivity reactions; includes injection si te reacti ons and ADA
formation.
Summa ries and analyses for incidence of AESIs will be provided by [INVESTIGATOR_24258]. The details of 
analysis of AES I will be provided in the SAP.
[IP_ADDRESS]. Other Adverse Event Assessment s
[IP_ADDRESS].1. Gastrointestinal Events
Summaries and analyses for incidence and severit y of nausea, vo miting,and diarrhea will be 
provi ded by [CONTACT_91014].  
[IP_ADDRESS].2. Events Related to Potential Abuse Liability
Toident ify AE term s suggest ive of potential abuse liabilit y, narrow terms fro m SMQ of Drug 
abuse and dependence (20000101) will be used .  
Summa ries and analyses for incidence of potential abuse liabilit y terms will  be provi ded by
[INVESTIGATOR_24258]. The details will be provided in theSAP.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 [IP_ADDRESS].3. Depression, Suicidal Ideation, and Behavior
In addit ion to the summary  of TEAEs, suicidal  ideati on and b ehavi orwill be assessed by C-
SSRS, and depression -related symptom s will be assessed using PHQ -9. 
The analy sis details will be provided in the SAP.
[IP_ADDRESS].4. Central Laboratory Measures, Vital Signs, and Electrocardiograms
Actual  values and change fro m rando mizat ionto post randomizat ionvalues of central laboratory  
measures, vital signs, and s elected ECG parameters will be summarized at each scheduled visit.  
Change from randomizat ionto postrando mizat ionvalue will be summarized for participants who 
have both a randomizat ionand at least 1 postrandomizat ionresul t.  
The percentages of partici pants with treatm ent-emergent (TE) abnormal, high, or low measures 
(including lab oratory , vital, and ECG parameters) will be summarized and co mpared between 
treatm ent groups using Fisher’s exact test.  
The analysis details will be provi ded in the SAP.  
9.4.5. Pharmacokinetic/Pharma codynamic Analyses
Tirzepati de concentrati on data will be analyzed using a populat ion PK approach using nonlinear 
mixed -effects m odeling techniques implemented on the NONME M®software.  The 
relationships between tirzepat ide dose and/or concentration and selected efficacy, tolerabilit y, 
and safet y endpo ints will be characterized. Addit ionally, the impact of intrinsic and extrinsic 
participant factors such as age, weight, gender, and renal funct ion on tirzepat ide PK and/or PD 
param eters may be examined.  I f ADA titers are detected from  immunogenicit y testing, then the 
impact of immunogenicit y titers on ti rzepat ide PK or any relevant PD parameters may also be 
examined.
9.4.6. Evaluation of Immunogenicity
The frequency and percentage of participants with preexist ingADA and with TE ADA+ to 
tirzepat idewill be tabulated . Treatment -emergent ADAs are defined as those with a titer 2- fold 
(1 dilut ion) greater than the minimum required dilution (1:10) of the ADA assay  if no ADAs 
were detected at baseline (treatment -induce d ADA) or those with a 4 -fold (2 dilut ions) increase 
in titer com pared with baseline if ADAs were detected at baseline (treatment -boosted ADA).  
Details of the analyses will be provided in the SAP.
9.4.7. Other Analyses
[IP_ADDRESS]. Subgroup Analyses for Primary Outcome
Details o f the subgroup analyses will be shown in the SAP.  
The following subgroup variables will be considered (but not limited to) :
age(<65 y ears and ≥65years )
sex (female and male)
baseline BMI ( <30, ≥30 and <35, ≥35 and <40, ≥40kg/m2)
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 89race 
ethnicity 
glycemic status at randomization ( normoglycemia vs prediabetes) 
The outcome measures forthe subgroup analyses will include :
percent change in body  weight from  
randomizat ionat 72 weeks
percentage of parti cipants achieving at least 5% body  weigh t reducti onat [ADDRESS_318460] of 5- , 10-, and 15 -mg doses of 
tirzepat ide co mpared to placebo on HR .  The timing of the 36- week interim analysis will be 
triggered by  [CONTACT_261768] a 24-hour ambulatory  monitoring sub-study ; specifically , after 
approximately  [ADDRESS_318461] either com pleted 36 weeks of treatm entor discont inued earlier . A
nindependent
data m onitoring committee (DMC) will have the responsibilit y to review unblinded interim 
analysis results .  A stati stical analysis center independent fro mthe Sponsor will perform the data 
analysis for the DMC.  
The thi rd unblinded safet y interim analysis will occur approximately [ADDRESS_318462] access to the unblinded data from the interim and/or 
primary  database l ockprior to the final database lock (after all rando mized participants complete 
the ent ire study ).Inform ation that m ay unbli nd the study  after the interim or primary database 
lockwill not be communicat ed to study  sites or blinded study  team  prior to final database lock, 
unless it i s deemed necessary  for parti cipant safet y.  Details will be specified in the 
blinding/ unblinding plan and in the DMC charter.  
  
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 9010. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversigh t 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
oConsensus ethical principles derived from international guidelines including 
the Decl aration of Helsinki and Council for Internati onal Organizati ons of  
Medical Sciences (CIOMS) International Ethical Guidelines
oApplicable The International Council for Harmoni zation of  Technical  
Requi rements for Pharmaceut icals for Hum an Use (ICH) Good Clinical 
Practi ce (GCP )Guidelines
oApplicable laws and regulations
The protocol, protocol amendments, ICF, invest igator’s brochure , and other relevant 
docum ents ( for example , advert isements) must be submitted to an IRB/IEC by [CONTACT_52009]/IEC before the study is init iated.
Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study  design, except for changes necessary  to 
eliminate an immediate hazard to study  parti cipants.
The invest igator wi ll be responsible for the fo llowing:
oProvi ding wri tten summaries of the status of the study  to the ERB annually or 
more frequent ly in accordance wit h the requirements, policies, and procedures 
established by  [CONTACT_1201]/IEC
oNotifying the IRB/IEC of SAEs or oth er significant safet y findings as required 
by [CONTACT_261769] 21 CFR, ICH guidelines, the IRB/IEC , European regulat ion 
536/2014 for clinical studies (if applicable) , and all  other applicable l ocal 
regul ations
10.1.2. Informed Consent Process
The invest igator or his or her representative will explain the nature of the study , 
including risks and benefits, to the study participant or his /her legally authori zed 
representative an d answer all questi ons regarding the study .
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 91Study  participants must be informed that their participat ion is vo luntary.Study  
participants or thei r legally authori zed representative will be required to sign a 
statement of informed consent that meets the re quirements of [ADDRESS_318463] 
(HIPAA) requirements, where applicable, and the IRB/IEC or study  center.
The m edical  record m ust include a statem ent that wri tten inform ed conse nt was 
obtained before the study  participant was entered into the trialand the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.
Study  participants m ust be reconsented to the most current version of the ICF(s) 
during th eir parti cipat ion in the trial.
A copy  of the ICF(s) m ust be provi ded to the study participant or the study  
participant’s l egally authori zed representati ve.
10.1.3. Data Protection
Study  parti cipants will be assigned a unique ident ifier by [CONTACT_3170] .Any study  
participant records ,datasets , or ti ssue samples that are transferred to the Sponsor will 
contain the ident ifier only; study  participant names or any  information which would 
make the study  participant i dentifiable will not be transferred.
The study  parti cipant m
ust be inform ed that hi s/her personal trial -related data will be 
used by [CONTACT_9324]. The l evel of 
disclosure m ust al so be explained to the study  partici pant.
The stu dy parti cipant must be inform ed that hi s/her m edical records may  be examined 
by [CONTACT_17080] y Assurance auditors or other authorized personnel appo inted by  [CONTACT_429] , by [CONTACT_17081]/IEC members, and by  [CONTACT_261770].
10.1.4. Committees Structure
Prospective adjudicat ion of incident diabetes events as well as major adverse cardiovascular 
events and pancreat ic AEs will be performed by [CONTACT_261771] .  
More details on adjudication o f incid ent diabetes events can be found in Sect ion [IP_ADDRESS] .
Secti on 10.3 Appendix 3 outlines addit ional informat ion on pancreat ic and cardiovascular 
adjudicat ion commit tees. 
Anindependent DMC for the interim analysis (Secti on 9.5) will include members with no 
conflict of financial interest.
10.1.5. Dissemination of Clinical Study Data
Requi red clinical  trial registri es (for example, ClinicalTrials.gov) will be updated with the results 
from registered clinical trials regardless of the research outcome in accordance wit h local laws 
and regulations. 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 92All CSRs, amendments ,and addenda will be submitted to external regulatory  authori ties, 
external partners (as applicable) ,and sites. 
The publicat ion policy for Study  I8F-MC-GPH K(SURMOUNT -1)is outlined in Sect ion 10.1.10
and further described in the Clinical Trial Agreement.
10.1.6. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will
provi de instructi onal materi al to the study  sites, as appr opriate
provi de sponsor start- up training to instruct the invest igators and study  coordinators.
This training will provi deinstructi on on the protocol, the completion o f the eCRFs, 
and study  procedures
make periodic visit s to the study  site
be available f or consul tation and stay  in contact [CONTACT_47556], 
telephone, and/or fax , and
review and verify  data reported to detect potential errors .
In addit ion, Lilly or its representatives will periodically check a sample of the participant data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_47551] i ts 
representatives and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of a ll ori ginal  source data.  Thi s might include laboratory  
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the Sponsor , 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
10.1.7. Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the Sponsor . 
An electronic data capture (EDC) system  will be used in this study  for the collect ion of CRF 
data. The investigator maintains a separate source for the data entered by  [CONTACT_32864] -provided EDC system. The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  [CONTACT_17094] .
Addit ionally , clinical  outcom e assessment data (scales, self -reported di ary data) will  be collected 
by [CONTACT_423]/invest igator site personnel via a paper source document and will be tra nscribed by 
[CONTACT_261772].
Data collected via the sponsor- provided data capture systems will be stored at third parties. The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem s.Prior to decommissio ning, the invest igator will receive an archival 
copy  of pertinent data for retention.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 93Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’ s database system and electronic transfers will be provided to the invest igator 
for review and re tention.Data will subsequently be transferred fro m the central  vendor to the 
Lilly data warehouse.
Data from co mplaint forms submitted to Lilly will be encod ed and stored in the global product 
complaint m anagement sy stem .
10.1.8. Source Documents
Source documents provide evidence for the existence of the study  participant and 
substant iate the integrity  of the data collected. Source documents are filed at the 
investig ator’s si te.
Data reported on the CRF or entered in the eCRF that are transcribed fro m source 
docum ents m ust be consistent with the source documents or the discrepancies must be 
explained. The investigator may  need to request previous medical records or t ransfer 
records, depending on the trial.Also, current medical records must be available.
10.1.9. Study and Site Closure
[IP_ADDRESS]. Discontinuation of Study
The study  will be di scontinued ifLilly or i ts desi gnee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
[IP_ADDRESS]. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator, or the ERB
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
10.1.10. Publication Policy
The Sponsor will co mply with the requi rements for publicat ion of study  resul ts. 
Authorship w ill be determined by [CONTACT_134128] h Internat ional 
Committee of Medical Journal Editors authorship requirements.
The publicat ion policy for Study  I8F-MC-GPHK (SURMOUNT -1)is described in the 
Clinical Trial Agreement.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 9410.2. Appendix 2: Clinical Laboratory Tests
The tests detailed below will be performed by [CONTACT_261773].
Local  laboratory  resul ts are only  required in the event that the central laboratory  resul ts 
are not available in t ime for response evaluat ion.  If a local sample is required, it is 
important that the sample for central analysis is obtained at the same 
time. Addit ionally, if the local laboratory  resul ts are used to m ake ei ther a study  
intervent ion decisio n or response evaluat ion, the results must be entered into the eCRF.
Protocol -specific requirements for inclusio n or exclusio n of participants are detailed in 
Secti on5of the protocol.
Addit ional tests may be performed at any  time during the study  as determined necessary  
by [CONTACT_261774].
Refer to Section 5.1(Inclusion Criteria) for screening pregnancy  criteria.  
Invest igators must document their review of each laboratory  safety  report.
Laboratory /analy te resul ts that coul d unblind the study  will not be reported to invest igative sites 
or other blinded personnel until the study  has been unblinded.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 95Clinical Laboratory Tests
HematologyaClinical Chemistrya
Hemoglobin
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Bicarbonate
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocy tes Aspartate aminotransferase (AST)
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acid
Platelets Calcium
Glucose, fasting
Urine ChemistriesaAlbumin
Albumin
CreatinineTotal Cholesterol
Triglycerides
Creatine kinase (CK)
Nonpharmacogenetic Stored Samples
Serum
EDTA plasma
P800 plasmaHormones (females)
Pregnancy Testa,serum and/or urineb
Follicle -stimulating hormone (FSH)d
Pharmacokinetics sample sa,e,f,g
Pharmacogen etics Sample
Whole blood (EDTA)Calculations
eGFR (calculated by [CONTACT_9289] -EPI [INVESTIGATOR_10908])a,c
UACR (urine albumin mg/dL/creatinine g/dL=UACR 
mg/g)
Pancreas (exocrine)a
Pancreatic amylase
Oral Glucose Tolerance Test (glucose ,insuline, 
c-peptidee)Lipase
Cystatin -Ca
HbA1caImmunogenicitya,e,g
Anti-tirzepatide antibod ies
EndocrineaAnti-tirzepatide antibody neutralization
Calcitonin
Thyroid-stimulating hormone (TSH) Lipid Panela
LDL -C
Insuline
C-peptideeHDL -C
VLDL -C
  
Free Fatty Acidse
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 96Abbreviations: ADA = antidrug antibody; ALT = alanine aminotransferase ; ALP = a lkaline phosphatase ; AST =
aspartate aminotransferase ; BUN = blood urea nitrogen; CK= creatinine kinase , CKD -EPI=Chronic Kidney 
Disease -Epi[INVESTIGATOR_623]; eGFR =estimated glomerular filtration rate; EDTA =ethylenediaminetetraacetic acid ; 
FSH = follicle -stimulating hormone; HbA1c =hemoglobin A1c; HDL =high-density lipoprotein; IWRS = 
interactive web -response sy stem; LDL =low-density lipoprotein; PK =pharmacokinetics; RBC = red blood 
cells;TSH =thyroid-stimulating hormone; UACR = urine albumin/creatinine ration; VLDL =very low -density  
lipoprotein ; WBC = white blood cells .
aAll tests will be performed by a Lilly -designated central laboratory, unless otherwise noted .
bA serum pregnancy test will be performed at Visit [ADDRESS_318464] 
injection of study drug(s) for women of childbearing potential only. Additional pregnancy tests (beyond those 
required per the Schedule of Activities [Section 1.3]) should be performed at any  time during the trial if a 
menstrual period is missed, there is clinical suspi[INVESTIGATOR_51940], or as required by [CONTACT_51967] .
cEstimated glomerular filtration rate will be calculated by [CONTACT_261775].
dFollicle -stimulating hormone test performed at Visit [ADDRESS_318465] had spontaneous amenorrhea for more than 1 year 
without an alternative medical cause .
eResults will not be provided to the investigative sites.
fPK samples will be collected at these visits at time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hour s
postdose, as assigned by [CONTACT_10966]. Dependent on the time -
windows to which a participant gets assigned, they may 
be required to come to site for PK -specific visits.
gIn the eve nt of sy stemic drug hy persensitivity reactions (immediate or nonimmediate), additional blood samples 
will be collected including ADA, PK, and exploratory biomarker sample s. PK samples for immunogenicity must 
be taken prior to drug administration.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 97Selected tests m ay be obtained in the event of anaphylaxis or systemic allergic/hypersensit ivity 
reacti ons
.
Hypersensitivity Testsa
Anti-LY antibodies (immunogenicity) Tryptaseb
LY concentration (PK) N-methy lhistamineb
Drug Specific IgEb
Basophil Activation Testb
Complements
Cytokine Panel
Abbreviation s:  LY = LY3298176 ; IgE = immunoglobulin E; PK = pharmacokinetic s.
aAssay ed by [CONTACT_11007] -designated laboratory .
bWill be performed if a validated assay is available.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 9810.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -Up, and Reporting
Please refer to Section 8.3Adverse Events and Serious Adverse Even ts.
10.3.1. Special Safety Topi[INVESTIGATOR_1102]
[IP_ADDRESS]. Hypoglycemia 
Upon ICF signing , all parti cipants will be educated about signs and symptoms of hypoglycemia , 
how to treat hy poglycemia, and how to collect appropriate informat ion for each epi[INVESTIGATOR_159982] .
Hypoglycemia may  be identified by [CONTACT_105418] 
(whether confirmed or unconfirmed by [CONTACT_261776]) or by  [CONTACT_261777] (BG) 
samples co llected during study visits. 
All participants who develop diabetes d uring the study  will be provi ded wi th glucometers.  
Parti cipants wi thout di abetes m ay, at the invest igator’s discretion, be given gluco meters to assist 
in the evaluat ion of reported symptoms consistent with hypoglycemia. Participants receiving 
glucometers will be provided a diary  to record rel evant informat ion (for example, glucose values, 
symptoms).
Hypoglycemic epi[INVESTIGATOR_134055] a specific eCRF andshoul d not be recorded as AEs 
unless the event meets serious criteria . If a hypoglycemic event m eets severe criteria(see 
definit ion below) , it shoul d be recorded as serious on the AE and SAE eCRF s, and reported to 
Lilly as an SAE.
Invest igators should use the fo llowing definit ions and criteria when diagnosing and categorizing 
an epi[INVESTIGATOR_261716] t o be rel ated to hy poglycemia (the plasma Glucose values in this sect ion 
refer to values determined by  a laboratory  or Internat ional Federation of Clinical Chemistry  and 
Laboratory  Medicine blood -equivalent glucose meters and strips) in accordance with the 2019
American Diabetes Associat ion posi tion statem ent on glycemic targets (American Di abetes 
Associ ation
2019a ):
Glucose Alert Value (Level 1):
Documented symptomatic hypoglycemia is defined as any time a pat ient feels that 
he or she is experiencing symptoms and/or signs associated with hypoglycemia and 
has a BG level o f <70 m g/dL ( ≤3.9 mmo l/L).
Documented asymptomatic hypoglycemia is defined as any event not accompanied 
by [CONTACT_11017][INVESTIGATOR_105398], but with a measured BG <
70mg/dL 
(≤3.9 mmo l/L).
Documented unspecified hypoglycemia is define d as any  event wi th no inform ation 
about symptoms of hypoglycemia available, but with a measured BG <70mg/dL 
(≤3.9 mmo l/L).
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 99Clinically Significant Hypoglycemia (Level 2):
Documented symptomatic hypoglycemia is defined as any time a participan t feels 
that he or she is experiencing symptoms and/or signs associated with hypoglycemia 
and has a BG level o f <54 m g/dL (<3.0 mmo l/L).
Documented asymptomatic hypoglycemia is defined as any  event not accom panied 
by [CONTACT_11017][INVESTIGATOR_10922] a measured BG <54 m g/dL 
(<3.0 mmo l/L).
Documented unspecified hypoglycemia is defined as any event with no informat ion 
about symptoms of hypoglycemia available but with a measured BG <54 m g/dL 
(<3.0 mmo l/L).
Severe hypoglycemia (Level 3):
Severe hypoglycemia is defined as an epi[INVESTIGATOR_261717], 
glucagon, or other resuscitative act ions.  These epi[INVESTIGATOR_105400]. Blood gl ucose measurements 
may not be available during such an event, but neurological recovery attributable to 
the restoration of BG to normal is considered sufficient evidence that the event was 
induced by  a low BG concentrati on.
To avoid duplicate reporting, all consecutive BG values ≤70mg/dL (3. 9mmo l/L) occurring 
within a 1- hour period may be considered to be a single hypoglycemic event 
(Weinberg etal.2010; Danne et al. 2013).  
[IP_ADDRESS]. Pancreatitis 
Acute pancreat itis is defined as an AE of interest in all trials with t irzepat ide, including this trial.  
Acute pancreat itis is an acute inflammatory  process of the pancreas that may  also involve 
peripancreat ic tissues and/or remote organ sy stems (Banks and Freeman 2006).  The diagnosis of 
acute pancreatit is requires 2 of the fo llowing 3 features:
abdo minal pain, ch aracteri stic of acute pancreat itis (generally located in the 
epi[INVESTIGATOR_82347] )(Banks and 
Freeman 2006; Ko izumi et al . 2006); the pain is often associated with nausea and 
vomiting);
serum  amylase (total a nd/or pancreatic) and/or lipase ≥3XULN
characterist ic findings of acute pancreat itis on computed tom ography  (CT) scan or 
magnet ic resonance imaging (MRI).
If acute pancreat itis is suspected, appropriate laboratory  tests (including levels of pancreat ic 
amylase and lipase) should be obtained via the central laboratory  (and l ocally, if needed).  
Imaging studies, such as abdo minal CT scan with or without con trast, MRI, or gallbladder 
ultrasound, should be performed. Abdo minal ultrasound may be used as an alte rnative method 
only if CT and MRI cannot be performed. If laboratory  values and/or abdominal imaging 
support the diagnosis of acute pancreat itis, the participant must discont inue therapy wit h 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 100tirzepat ide,but will cont inue in the study . A review of the participant ’s conco mitant m edicati ons 
shoul d be conducted to assess any  potenti al causal  relationship with pancreat itis.
Each AE of pancreat itis must be reported.  If ty pi[INVESTIGATOR_82348]/or symptoms of pancreatit is are 
present and confirmed by [CONTACT_82382] (lipase or amylase [total and/or pancreatic]) and 
imaging studies, the event must be reported as an SAE.  For a potential case that does not meet 
all of these cri teria, it is up to the invest igator to determine the seriousness o f the case (AE or 
SAE) and the relatedness of the event to study  drug(s).
Each participan t will have measurements of p- amylase and lipase (assessed at the central 
laboratory ) as shown on the Schedule of Activities (Section 1.3)to assess the effects of the 
investigat ional doses of tirzepatide on pancreat ic enzyme levels.  Serial measure ment s of 
pancreat ic enzymes have limited clinical value for predict ing epi[INVESTIGATOR_261718] s (Nauck et al. 2017; Steinberg et al. 2017a , 2017b ).  Thus, further 
diagnosti c follow-up of  cases of asymptomat ic pancreatic hyper enzy memia (lipase and/or 
pancreat ic amylase ≥3XULN) i s not m andated but may  be perform ed based on the invest igator’s 
clinical judgment and assessment of the participant ’s overall clinical con dition.Only cases of 
pancreat ic hyperenzy memia that undergo ad ditional diagnosti c follow-up and/or are 
accompanied by [CONTACT_261778].
All suspected cases of acute or chronic pancreat itis will be adjudicated by  [CONTACT_82384]. In addi tion, AEs of severe or serious abdo minal pain o f unknown 
etiology will also be submitted to the adjudicat ion committee to assess for possible pancreat itis 
or other pancreat ic disease. Relevant data from participant s with acute or chronic pancreat itis 
and those wi th severe or seri ous abdo minal pain will be entered into a specifically designed 
eCRF page. The adjudication co mmittee representative will enter the results of adjudicat ion in a 
corresponding eCRF page.
[IP_ADDRESS]. Thyroid Malignancies and C- Cell Hyperplasia 
Individuals with personal or family history  of MTC and/or MEN -2 will be excluded from the 
study .  Parti cipants who are diagnosed with MTC and/or MEN -[ADDRESS_318466].
The assessment of thy roid saf ety during the tri al will include reporting of any  case of  thyroid 
malignancy (including MTC and papi[INVESTIGATOR_10928] )and measurements of calcitonin. This 
data will be captured in specific eCRFs.   The purpose of calcitonin measurements is to assess the 
potenti al of tirzepati de to affect thy roid C-cell functi on, which may  indicate development of 
C-cell hyperplasia and neoplasms. 
[IP_ADDRESS]. Calcitonin Measurement s
If an increased calcitonin value (see definit ions below) is observed in a participan t who has been 
administered a medicat ion that is known to increase serum calcitonin , then this medicat ion 
shoul d be stopped and calcitonin levels should be measured after an appropriate washout period.
For participan tswho require addit ional endocrine assessment because of increased calcitonin 
concentration as defined in this sect ion, data fro m the fo llow-up assessment will be co llected in 
the specific sect ion of the eCRF.
Calcitonin Measurements in Participants with eGFR ≥60 mL/min /1.73m2
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 101A significant increase in calcitonin for participants with eGFR ≥60mL/min is defined below.  If 
a partic ipant ’s laboratory  resul tsmeet th esecriteria, these clinically significant lab oratory  resul ts
shoul d be recorded as an AE.  
calcitonin value ≥20 ng/L and <35 ng/L AND ≥50% increase from the screening 
value .  These participants will be asked to repeat th e measurement wi thin 1 month.  If 
this repeat value is increas ing (≥10% increase), study  drug shoul d be stopped ,andthe 
participant encouraged to undergo addit ional endocrine assessment and longer -term 
follow
-up by  [CONTACT_221054] a nyserious adverse effect on the thyroid.
calcitonin value ≥35 ng/L AND ≥50% over the screening value .  In these participants , 
study  drug shoul d be stopped ,and the participant recommended to immediately 
undergo addit ional endocr ine assessments and longer -term follow
-up by [CONTACT_134110].  
Calcitonin Measurement in Participants with eGFR <60 mL/min /1.73m2
A significant increase in calcitonin for participants with eGFR <60 mL/min/1.73m2is defined as 
a calcitonin value ≥35ng/L AND ≥50% over the screening value.  If a participant ’s labs meet 
thesecriteria, these clinically  significant l abs should be recorded as an AE.  
In these participants, study  drug shoul d be di scontinued (after first confirming the value) and the 
participan t recommended to immediately undergo addit ional endocr ine assessments and 
longer-term follow
-up by [CONTACT_261779].
[IP_ADDRESS]. Major Adverse Cardiovascular Events
Deaths and nonfatal cardi ovascular AEs will be adjudicated by  a commi ttee of  physicians 
external to Lilly with cardio logy experti se.  Thi s commi ttee will be blinded to treatment 
assignment.  The nonfatal cardi ovascular AEs to be adjudicated include
myocardial  infarct ion
hospi [INVESTIGATOR_261719]
hospi [INVESTIGATOR_226360]
coronary  intervent ions (such as coronary  artery  by[CONTACT_261780]), and 
cerebrovascular events, including cerebrovascular accident (stroke) and transient 
ischemic attack.
[IP_ADDRESS]. Supraventricular Arrhythmias and Cardiac Conduction Disorders
Treatment -emergent cardiac conduction disorders will be further evaluated. Participants who 
develop any event from these groups of disorders should undergo an ECG ,which should be 
submitted to the central reading center. The specific diagnosi s will  be recorded as an AE.  
Events that meet criteria for serious conditions as described in Section 8.3must be reported as 
SAEs. 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 [ZIP_CODE].3.1.7. Hypersensitivity Events
All allergic or hy persensi tivity react ions will be reported by [CONTACT_261781] ,or if 
any serious criterion is met, as SAEs.
In the event of suspected drug hy persensi tivity reacti ons (immediate or nonimmediate) in 
subjects who experience moderate -to-severe injectio n reactions as assessed by [CONTACT_3170], 
unscheduled blood samples will be collected for PK and ADA analyses at the following t ime 
points:  
as close as possible t o the onset of the event
at the resolut ion of the event
30 (±3) day s following the event.  
Addit ionally , unscheduled serum  samples for immune safet y laborator y testing (including, but 
not limited to β try ptase, total  IgE, com plement ,and cy tokine panel  testing) shoul d also be 
collected at approximately [ADDRESS_318467] ion and treatment received, will be co llected on any AEs or 
SAEs that the investigator deems related to study drug(s) via theeCRF created for this purpose.  
Study  drug(s) should be temporarily  interrupted in any individual  suspected of having a severe or 
serious allergic reaction to study  drug(s).  Study  drug(s) m ay be restarted when/if it is safe to do 
so, in the opi[INVESTIGATOR_3078] n of the invest igator.  
[IP_ADDRESS]. Injection Site Reactions
Inject ion site reacti ons will  be collected on theeCRF separate from the hypersensit ivity react ion 
eCRF. At the time of AE occurrence, samples will be collected for measurement of tirzepat ide
ADA and tirzepat ideconcentrati on.
[IP_ADDRESS]. Anti
drug Antibodies
The occurrence of ADA formation will be assessed as outlined in Section 8.7.
[IP_ADDRESS]. Hepatobiliary Disorders
All events of TE biliary  colic, chol ecyst itis, or oth er suspected events related to gallbladder 
disease shoul d be evaluated and addit ional diagnostic tests performed, as needed.   In cases of 
elevated liver m arkers, hepati c monitoring shoul d be ini tiated as outlined in Sect ion 7.
[IP_ADDRESS]. Severe Gastrointestinal Adverse Events
Tirzepati de m ay cause severe GI AEs, such as nausea, vomit ing, and diarrhea.  Informat ion 
about severe GI AEs as well as antiemetic/antidiarrheal use will be co llected in the eCRF/AE 
form.  For detailed information concerning the management of GI AEs, plea se refer to 
Secti on6.6.2 .
[IP_ADDRESS]. Acute Renal Events
Renal safety  will be assessed based on repeated renal funct ional assessment as well as 
assessment of AEs suggest ive o f acute or worsening of chronic renal failure. Gastrointestinal
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 103AEs have been reported with tirzepat ide, including nausea, diarrhea, and vomit ing. This is 
consistent with other GLP -1Ragonists (Aroda an d Ratner 2011). The events may lead to 
dehydrat ion, which could cause a deterioration in renal function, including acute renal failure.
Parti c
ipants shoul d be advised to notify invest igators in case of severe nausea, frequent vomit ing, 
or symptoms of dehydration.
[IP_ADDRESS]. Depression , Suicidal Ideation, or Behavior Monitoring
Parti cipants will be m onitored f or depressi on and sui cidal i deati on or behavior through AE
collect ionand by[CONTACT_10540] C -SSRS and the PHQ -9.  Parti cipants will be referred to a nMHP if,
in the opi[INVESTIGATOR_3078] n ofthe invest igator ,it isnecessary  for the safe ty of the parti cipant ,or if the 
participant had any of the fo llowing:
a PHQ -9 score ≥15
C-SSRS responses of
oA “yes”answer to ei ther Questi on 4 (Act ive Suicidal Ideation wit h 
Some Intent to Act, Without Specific Plan) 
oor
oA “yes”answer to Question 5 (Act ive Suicidal Ideation with Specific 
Plan and Intent) on the “Suicidal  Ideat ion”porti on of  the C -SSRS 
oor 
oA “yes”answer to any  of the suici de-related behaviors (actual attempt, 
interrupted attempt, aborted attempt, preparatory act ,or behavior) on 
the “Suicidal  Behavi or”porti on of  the C -SSRS.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 [ZIP_CODE].4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of Childbearing Potential
A wo man is considered fertilefollowing menarche and unt il beco ming postmenopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (for example; amenorrhea in adol escents or athl etes) and a m enstrual  cycle 
cannot be confirmed before first dose of study  intervent ion, addi tional evaluat ion shoul d be 
considered.
Women in the fo llowing categori es are not considered women of childbearing p otential
Article I. Prem enarchal
Article II. Prem enopausal  female wi th 1 of the f ollowing:
Docum ented hysterectomy
Docum ented bilateral  salpi[INVESTIGATOR_1656]
Docum ented bilateral  oophorectomy
For individuals wit h perm anent infert ility due to an alternate medical cause other than the 
above, (for example; Mullerian agenesis, androgen insensit ivity), invest igator discretion 
shoul d be applied to determining study  entry .
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examinat ion, or m edical history  interview.
Article III. Postmenopausal  female
A postm enopausal  state is defined as eit her
oA wo man at l east [ADDRESS_318468] 1 year without an alternative 
medical cause, AND a follicle-stimulating hormone (FSH) ≥40 m IU/mL; or 
oA wo man [ADDRESS_318469] 12 m onths 
of spontaneous am enorrhea; or 
oA wo man at l east 55 years of age with a diagnosis of menopause prior to 
starting hormone replacem ent therapy . 
Females on HRT and whose menopausal status is in doubt will be required to use one 
of the nonestrogen hormonal highly effect ive contraception methods if they wish to 
continue their HRT during the study . Otherwise, they must discont inue HRT to allow 
confirmat ion of postmenopausal status before study enrollment.
Contraception Guidance:
Contraceptive use by [CONTACT_261782] d be consistent with local regulat ions regarding the 
methods of contraception for those participat ing in clinical studie s.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 105Two forms of effect ive contraception, where at least 1form is highly  effect ive, will be used. 
Effect ive contraception may be used as the second therapy . Barrier protecti on methods wi thout 
concomitant use of a spermicide are not a reliable or acceptable method. The use of male and 
female condo ms as a double barrier method is not considered acceptable due to the high failure 
rate when these methods are combined. 
Highly Effective Methods of Contraception:
Combined oral contraceptive pi[INVESTIGATOR_10917]
NuvaRing
Implantable contraceptives
Injectable contraceptives (such as Depo -Provera®)
Intrauterine device (such as Mirena®and ParaGard®)
Contraceptive patch –ONLY women <198 pounds or 90 kg
Total  abstinence (if this is their preferred and usual lifestyle) or in a same -sex 
relationship with no sexual relationship with males (as part of their preferred and 
usual lifest yle), and agrees to maintain this status throughout trial fo llow-up 
Note:   periodic abstinence ( for example , calendar, ovulat ion, symptothermal, and 
postovulat ion methods), declarat ion of abst inence just for the duration of a trial, and 
withdrawal  are not acceptabl e methods of contraception
Vasectomy  –for men in clinical studies
Note :Implantable contraceptives and injectable contra ceptives (such as Depo Provera) 
are only permitted if started more than 18 months prior to scr eening. Participants shoul d 
not start these methods of contraception after being enrolled in the study .
Effective Methods of Contraception (must use combination of 2 methods):
Male condom wit h spermicide
Female condo m with spermicide
Diaphragm  with spermicide
Cervical sponge
Cervical cap wit h spermicide
Men, regardless of their fertilit y status, with nonpregnant women of childbearing potential 
partners must agree to either remain abstinent (if this is their preferred and usual lifest yle) or use 
condoms plus 1additional highly  effect ive (less than 1% failure rate) method of contraception 
(such as co mbinat ion oral  contraceptives, implanted contraceptives, or intrau terine device) or 
effect ive method of contraception (such as diaphragms wit h spermicide or cervical sponge) for 
the duration of the study  and for [ADDRESS_318470] ion. Periodic a bstinence ( for example , calendar, ovul ation, 
symptothermal, and postovul ation methods), decl aration of  abst inence just for the duration of a 
trial, and wi thdrawal are not acceptable methods of contraception .
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 106Men wi th pregnant partners should use condoms du ring intercourse for the duration of the study  
and until the end of est imated relevant potential exposure in women of childbearing potential. 
Men who are abstinent (if this is co mplete abst inence, as their preferred and usual lifest yle) or in 
a sam e-sex r elationship (as part of their preferred and usual lifestyle) must agree to either remain 
abstinent or stay  in a same -sex relati onship wi thout sexual relationships with females ( usual 
lifest yle). In these situat ions,menare not required to use contracepti on. 
Men should refrain fro m sperm  donat ion for the durati on of  the study  and f or [ADDRESS_318471] ion. 
Collection of Pregnancy Information
Male part icipants wi th partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male 
participant’s female partner who beco mes pregnant while the male participant is in 
this study . 
After obtaining the necessary  signed informed consent from the pregnant female 
partner direct ly, the invest igator will record pregnancy informat ion on the appropriate 
form and submi t it to the Sponsor within 24 hours of learning of the partner’s 
pregnancy. The female partner will also be fo llowed to determine the outcome of the 
pregnancy. Inform ation on the status of the mother and child will be forwarded to the 
Sponsor .Generally, the fo llow-up will be no longer than 6 to 8 weeks fo llowing the 
estimated delivery  date. Any terminat ion of the pregnancy  will be reported regardl ess 
of fetal status (presence or absence of ano malies) or indicat ion for the procedure. 
Female Participants who become pregnant
The invest igator will co llect pregnancy information o n any female participant who 
beco mes pregnant while participat ing in this study . Informat ion will be recorded on 
the appropriate form and submitted to the Sponsor within 24 hours of learning of a 
participant ’s pregnancy . 
The parti cipant will be fo llowed to determine the outcome of the pregnancy . The 
investigator will co llect fo llow-up inform ation on the participant and the neonate and 
the informat ion will be forwarded to the Sponsor .Generally, fo llow-up will not be 
requi red for longer than 6 to 8 weeks beyo nd the estimated delivery date. Any 
termination o f pregnancy will be reported, regardless of fetal status (presence or 
absence of ano malies) or indicat ion for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complicat ion or el ective terminat ion of a pregnancy  will be reported as an AE or 
SAE. A spontaneous abortion is always considered to be an SAE and will be reported 
as such. Any poststudy  pregnancy -related SAE considered reasonably related to the 
study  interventi on by  [CONTACT_261783]8.3.2 . While the investigator is not obligated to actively seek this informat ion 
in former study  partici pants, he or she m ay learn of an SAE through spontaneous 
reporting.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 107Any female part icipant w ho becomes pregnant while participat ing in the study  will 
discontinue study  interventi on andbe withdrawn from the study .
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 [ZIP_CODE].5. Appendix 5 : Liver Safety: Suggested Actions and Follow -Up 
Assessments
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Antinuclear antibody a
AST
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT =alanine aminotransferase; AST =aspartate aminotransferase; CPK =creatinine 
phosphokinase; GGT =gamma -glutamyl transferase; Ig =immunoglobulin; INR =internatio nal no rmali zed 
ratio; RBC =red blood cells; WBC =white blood cells.
aAssay ed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 [ZIP_CODE].6. Appendix 6 : Medical Device Incidents: Definition and Procedures 
for Recording, Evaluating, Follow-U p, and Reporting
Definitions of a Medical Device Incident
The detec tion and docum entati on procedures described in this protocol apply  to all  sponsor 
medical devices provided for use in the stud y.
Medical Device Incident Definition
A medical device incident is any malfunct ion or deteri oration in the characteri stics 
and/or performance of a device as well as any inadequacy in the labeling or the 
instructi ons for use which, directly or indirectly, might lead to or might have led to a 
serious injury, death of a participant/user/other person ,or to a serious deterioration 
in his/her state of health.
Not all incidents lead to death or serious deterioratio n in healt h. The nonoccurrence of 
such a result might have been due to other fortunate circumstances or to the 
intervent ion of health care personnel.
It is sufficient that:
An incident associated with a device happened.
AND
The incident was such that, if it occurred again, might lead to death or a serious 
deteri oration in health.
A serious deterioration in state of health can include any  of the f ollowing:
Life-threatening illnes s
Perm anent impairment of body  functi on or perm anent dam age to body  structure
Condi tion necessitat ing medical or surgi cal intervent ion to prevent one of the above
Fetal  distress, fetal death, or any  congeni tal abnormali ty or bi rth defects
Examples of Incid ents
A participant, user, caregiver, or health care professional is injured as a result of a 
medical device failure or its misuse.
A participant’s study  interventi on is interrupted or compromised by a medical 
device failure.
A misdiagnosis due to a medicaldevice failure leads to inappropriate treatment.
A participant’s healt h deteriorates due to a medical device failure.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 110Documenting Medical Device Incidents
Medical Device Incident Documenting
Any medical device incident occurring during the study will b e docum ented in the 
participant’s m edical  records, in accordance wit h the invest igator’s normal clinical 
practi ce, and on the appropriate form of the eCRF.
For incidents fulfilling the definit ion of an AE or an SAE, the appropriate AE/SAE 
eCRF page will be completed as described in Section 8.3.
A product complaint must be submitted describing the issue or deficiency  that m ay 
have led to the incident or AE.
The eCRF will be completed as thoroughly  as possible and signed by [CONTACT_261784].
It is very  important that the investigator provides his/her assessment of causalit y 
(relationship to the medical device provided by [CONTACT_1034]) at the time of the init ial 
AE or SAE report and describes any corrective or remedial act ions taken to prevent 
recurrence o f the incident.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 [ZIP_CODE].7. Appendix 7: Protocol GPHK Standardized Protocols fo r the 
Measurement of Height, Weight , 
Waist Circumference , 
Vital Signs , Electrocardiogram, and Oral Glucose 
Tolerance Test
The fo llowing inform ation has been adapted fro m standardized physical measurement protocols 
for the World Healt h Organization’s STEPwise approach to Surveillance (STEPS) (WHO 2008) 
(Available at:
https://www.who.int/ncds/surveillance/steps/Sect ion%204%20S tep%202%20Physical%20Measu
rements.pdf ) Accessed January  17, 2019.
Measuring Height
Step 1. Ask the participant to rem ove thei r footwear and any  headgear (light headgear worn for 
religious reasons can remain, but this should be worn by [CONTACT_134138] m easured).
Step 2. Ask the participant to stand on the calibrated height measuring board (stadiometer) or 
against a wall wit h their feet together and their knees straight with their heels against the 
backboard, the stadiometer,or the wall .
Step 3. Ask the participant to look s traight ahead wi thout til ting thei r head up.
Step 4. Ask the participant to breathe in and stand tall. Measure and record the participant’s 
height in cent imeters (cm) to [ADDRESS_318472].
Measuring Weight
Body  weight m easurements shoul d be done in a consistent manner using a calibrated 
electroni c scale capable of measuring weight in kilograms (kg) to [ADDRESS_318473] .
All weights for a given participant shoul d be m easured using the same scale, 
whenever possible, at approximately the same time in the morning after evacuat ion of 
bladder contents.  
Body  weight m ust be m easured i n fasting state.  If the participant is not fast ing, the 
participant shoul d be called in for a new visit wit hin the visit window to have the 
fasting body  weight measured.
Step 1 .Ask the participant to empt y their pockets, remove their footwear, outerwear (coat, 
jacket, etc .), and any headgear (light headgear worn for religious reaso ns can remain, but thi s 
shoul d be worn by  [CONTACT_226430] t when weight i s measured).
Step 2 .Make sure the scale is placed on a firm, flat, even surface (not on carpet, on a slopi[INVESTIGATOR_126154], or a rough, uneven surface).
Step [ADDRESS_318474] weight in kilograms 
(kg) to the nearest one-tenth kg.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 112Measuring Waist Circumference
Waist circumference shoul d be measured in the horizontal plane and at the midpoint 
between the lower margin o f the last pal pable rib and the top of the iliac crest .
Measurements should be taken at the end of a normal expi[INVESTIGATOR_134067] a 
nonstretchable measuring tape .  The tape should lie flat against the skin without 
compressing the soft tissue.
The waist ci rcumference shoul d be m easured twi ce, rounded to the nearest 0.5 cm .
The m easuring tape should be removed between the 2measurements. Both 
measurements will be recorde d in the eCRF. If the difference between the 2
measurements exceeds 1 cm, this set of measurements should be discarded and the 2
measurements repeated.
Step 1 .Ask the participant to wear light clothing (if available, patient gowns could also be used) .
Step 2.Ask the participant to stand with their feet close together, arms at their side, body  weight 
evenly distributed.
Step 3 .Ask the participant to relax and m easure the parti cipant’s waist circumference.
Vital Sign Measurements (blood pressure and heart rate)
Vital sign m easurements (blood pressure and heart rate, measured by [CONTACT_117682]) shoul d be 
taken before obtaining an ECG tracing and before collect ion of blood samples for 
laboratory  testing
The parti cipant shoul d sit quietly for 5 minutes before vit al signs measurements are 
taken
For each parameter, 3measurements will be taken using the same arm , pref erably  the 
nondo minant arm
The recordings should be taken at least 1 minute apart. Each m easurement of sitting 
pulse and BP needs to be recorded in the eCRF
Blood pressure must be taken with an automated blood pressure instrument
If blood pressure and pulse measurements are taken separately, pulse should be taken 
prior to bl ood pressure. 
Note: In the event pulse measurement cannot be taken via an autom ated bl ood pressure 
instrument, t he preferred location for measurement of pulse is the radial artery .
Electrocardiogram
All digital ECGs will be obtained using centrally provided ECG machines and will be 
electroni cally transmitted to a designated ce ntral ECG laboratory.
12-lead ECGs should be obtained after the subject has rested in a supi[INVESTIGATOR_226354] 10 minutes .
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 113Electrocardiograms should be co llected at least [ADDRESS_318475] ion of 
blood sam ples for l aboratory  testing, inclu ding PK sam ples.
Triplicate ECGs (obtained at Week 0 and Week 36) should be obtained 
approximately  [ADDRESS_318476]
Parti cipants shoul d maintain adequate carbohydrate intake for 3 day s prior to the 
scheduled 2-hour OGTT.
In the [ADDRESS_318477] ivity.
Parti cipants shoul d fast for approximately  [ADDRESS_318478] is complete.
Placement of a venous cannula, preferably  in an antecubital vein, is recommend ed to 
simplify  collect ion of mult iple blood sam ples for glucose, insulin, and C -pepti de at 
time 0, 30, 60, 90, and 120 minutes.
Note : Placement of a venous cannula may not be required when a 2-hour OGTT is repeated to 
confirm the diagnosis of diabetes (s ee Secti on [IP_ADDRESS] ), and only samples at 0 and 120 minutes 
for glucose m easurement willbecollected.
Immediately after collection of the time [ADDRESS_318479] approved for this use (and in a total vo lume 
of not m orethan 350 m L).
The parti cipant shoul d consume the glucose l oad wi thin 5 minutes.
The patient should remain minimally act ivefor the durati on of  the test.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 [ZIP_CODE].8. Appendix 8:  Suggested Visit Structure
Abbreviations:  AE s= adverse event s
;ECG =electrocardiogram ;OGTT = 2-hour oral glucose tolerance test ;PK= 
pharmacokinetic s
;PRO = patient -reported outcomes ; SOA = schedule of activities .

CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 [ZIP_CODE].9. Appendix 9:  Management of Gastrointestinal Symptoms
Abbreviations:  GI = gastrointestinal; IWRS = interactive web -response sy stem.

CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 [ZIP_CODE].10. Appendix 10:  Provisions for Changes in Study Conduct During 
Exceptional Circumstances
There m ay be times of except ionalcircumstances , such as pandemics or natural disasters , which 
may cause disrupt ions to the conduct of the study .Possible disruptions are limitat ions in the 
abilit y to conduct study  procedures or abilit y to have on -site visi ts occur by  [CONTACT_183568] .
To mit igate the risk of participants missing visits, to allow participants to safely cont inue in the 
study , and to m aintain the data integrit y of the study  in the case of an except ional circumstance , 
sites m ay implement changes to the conduct of the study  on a case -by-case basis fo llowing 
Sponsor’s written approval  (if permitted by  [CONTACT_54019]).Good clinical pract icecompliance 
and minimizat ion of risks to study  integrity are important considerations. Ensuring the safet y of 
study  participants is the prevailing consideration.
Additional written guidance will be provi ded by  [CONTACT_261785] .
The fo llowing changes in study  conduct captured in this Appendix will not be considered 
protocol  deviat ions. Mi ssing data will be captured as protocol deviat ion(s).
1.Remote visit (telephone/telemedicine)
Telephone or IT -assisted virtual visits (telemedicine) to complete appropriate assessments are 
acceptable. The study  site shoul d capture the visit location and method with a specific 
explanat ion for any  data missing because o f missed in -person site visits in source document 
and eCRF. Examples o f assessments to be completed in this manner include AEs and product 
complaints, concomitant medicat ions, review study participant diary ( including study  drug 
compliance ),review diet an d exercise goals, C -SSRS (Since Last Visit Version), Self -Harm  
Suppl ement Form , Self -Harm  Follow-up Form  (if applicable), and PHQ -9.
2.Mobile home health visit
Mobile visits may be performed at participants’ homes when participants cannot travel to the 
site due to exceptional circumstances. These will be performed by a qualified ho me nursing 
service provider ortrained site personnel , following Sponsor writtenapproval (if permitted 
by [CONTACT_24550]).Procedures performed may include, but are not limited to, weight 
measurement, taking bl ood sam ples, conduct ing physical assessments, administering PROs, 
and co llecting health informat ion. Please note that requirements related to the reporting of 
SAEs remain unchanged. Every effort shoul d be made for the parti cipant to return to on-site
visits as soon as reasonably  possible, while ensuring the safety  of the parti cipant and 
investigat ional site staff. 
Addit ional consent fro m the parti cipant will  be obtained for those who participate in home 
healt h services.
3.Investigational product and ancillary supplies (including participant diaries)
In cases when a participant is unable to come to site to receive trial supplies during normal 
on-site visi t, the si te shoul d work wi th the Sponsor to determine appropriate actions to 
receive trial supplies . This m ayinclud ea parti cipant coming to the site to receive trial 
supplies only fro m site staff wi thout full co mpletion of a visit, a participant -approved 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 117designee coming to the site to receive trial supplies on a participant’s behalf, or delivery to a 
participant’s ho me.
The fo llowing requi rements m ust be m et:
Sponsor approves the alternat ive method of delivery , taking l ocal regulatory  
requi rements into considerat ion
participant consents verbally  to al ternate m ethod of delivery   
site/Sponsor confirms the participant’s receipt of the trialsuppli es
site/Sponsor confirm appropriate ethics review board notificat ion
alternate delivery  of investigat ional product should be performed in a manner that 
does not com promise treatm ent blinding and ensures product integrit y.The exist ing 
protocol  requi rements for product accountabilit y remain unchanged 
when delivering supplies to a participant’s home:
oparticipant consent must include provisio n of any  personal  informat ion
oinvestigator/S ponsor shoul d ensure oversight of the shippi[INVESTIGATOR_261720] y and product qualit y (i.e., storage condit ions and intact 
packaging upon receipt)
additional instructi ons shoul d be provi ded to the parti cipant on how to return any  
unused or co mpleted tri al supplies
4.Local laboratory option
In exceptional circumstances, to ensure partic ipant safet y and wi th the Sponsor's prior written 
approval , local laboratory  testing m ay be conducted in lieu of central laboratory  testing. The 
local laboratory  must be qualified in accordance wit h local regulat ions. Clinically significant 
laboratory  findings m ust be recorded as an adverse event in the AE eCRF . 
5.Screening period guidance 
To ensure safet y of study  participants, l aboratory values and other eligibilit y assessments 
taken at Visit [ADDRESS_318480] ive, non -rando mized status due to 
exceptional circumstances:   
Paused for less than 90 days fro m Visit 1 to Visit 3: the participant will proceed to the 
next study  visit per the schedule of act ivities in the protocol and Visit 3 
(randomization visit) must be conducted within 90 days from Visit 1. 
oThe site should proceed with the next visit if eligibil ity criteria are confirmed 
and docum ent the reason for delay  in the eCRF.
oDue to the pause in screening, sites should also reconfirm each participant’s 
consent and document in the source documentation.
Paused for more than 90 days fro m Visit 1 to Vi sit 3: The participant must be 
discontinued fro m the study  and rescreened. The screening procedures per the 
schedule of act ivities in the protocol should be fo llowed (starting at Visit 1) to ensure 
participant eligibilit y by [CONTACT_261786] (Visit 3). Before rescreening, the 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 118participant m ust si gn a new ICF and receive a new identificat ion number through 
IWRS .
6.Increasing visit window(s) for primary and secondary endpoint visits
Parti cipants shoul d complete primary endpo int visit (Visit 21 or 99) and the final 
study endpo int visit ( Visit 116 or 199) as per original schedule whenever possible and 
safe to do so, at the invest igator’s discretion. However, in order to maximize the 
abilit y for such on -site visi ts, minimize missing data, and preserve the intended 
cond uct of the study , the visi t windows m ay be brought forward no sooner than 
14days or extended up to 28 days, upon specific guidance fro m the Sponsor.
For the fo llowing 2 secondary  endpoint visi ts, Visit 8 (the key secondary endpo int 
visit) and Visit 12 (th e 36-week interim analysis endpo int visit), the visit windows 
may be brought forward no sooner than 7 days or extended up to 7 days, upon 
specific guidance fro m the Sponsor.
For parti cipants requiring the visit window sto be extended, addit ional study  drug
may need to be provided to avoid study  drug interrupti on and maintain overall 
integrity of the tri al.Addit ional consent fro m the parti cipant per l ocal regul ations will 
be obtained for those participants who will be dispensed addit ional study  drug during 
the extended treatment period.
7. Documentation
a.Changes tostudy conduct
Changes to study  conduct will be docum ented as the fo llowing:
Sites will need to ident ify and document the details of how all part icipants, visits ,
methods, and activit ies conducted were affected by [CONTACT_261730] . All 
dispensing/shipment records of IP and rel evant communicat ions, including delegat ion, 
shoul d be filed wi th site trial  records .
The site should document the participant’s verb al consent for having remote visits
andremote di spensing of IP, ancillaries, and di aries, prior to im plementati on of  these 
activit ies.
Source document(s) that are generated at participant’s ho me should be part of the 
investigator’s source documentation a nd shoul d be transferred to the site in a secure 
and timely manner. 
b.Missing data and other protocol deviations 
The study  site shoul d capture specific explanat ion for any missing data and other protocol 
deviat ions in source documents and eCRF. While proto col deviat ions m ay be 
unavo idable in an except ional circumstance , documentati on of  deviat ions and missing 
data will be important for data analysis and reporting.
8.Informing ethical review boards (ERBs)
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 119The Sponsor and study  investigators will notify ERBs as early as possible to 
communicate implementation of changes in study  conduct due to exceptional
circumstances. To protect the safety of study  parti cipants, urgent changes may be 
implemented before such co mmunicat ions are made, but all changes will be reported as 
early as possible fo llowing implementati on.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 [ZIP_CODE].11. Appendix 1 1:  Abbreviations
Term Definition
ADA antidrug antibodies
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an a bnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
AESI adverse events (AEs) of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
BG blood glucose
BMI body mass index
BMR basal metabolic rate
BP blood pressure
CHF congestive heart failure
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CONSORT Consolidated Standards of Reporting Trials
CRF case report form
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CSR Clinical Study Report
C-SSRS Columbia -Suicide Severity Rating Scale
CT computed tomography
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 121CVD cardiovascular disease
DMC data monitoring committee
DPP-[ADDRESS_318481]
FAS full analy sis set
FG fasting glucose
FSH follicle -stimulating hormone
GCP good clinical practice
GI gastrointestinal
GIP glucose -dependent insulinotropic polypeptide
GIPR glucose -dependent insulinotropic polypeptide receptor
GLP-1 glucagon -like peptide -1
GLP-1R glucagon -like peptide -1 receptor
GPGA Study I8F -MC -GPGA
GPGB Study I8F -MC -GPGB
GPGF Study I8F -MC -GPG F
GPHK (SURMOUNT -1) Study I8F-MC -GPHK
HbA1c hemoglobin A1c
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 122HDL high-density lipoprotein
HR heart rate
HRT hormonal replacement therapy
IB Investigator’s Brochure
ICF informed consent form
ICH The International Council for Harmoni zation of Technical Requirements for 
Pharmaceuticals for Human Use
Informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the patient’s decision to participate.  Informed consent is documented by 
[CONTACT_3553] a written, sig ned,and dated informed consent form .
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
INR internatio nal no rmalized ratio
IP investigational product: Apharmaceutical form of an active ingredient or placebo 
being tested or used as a reference in a clinical trial, including products already on the 
market when used or assembled (formulated or packaged) in a way different from the 
autho rized form, or market ed products used for an unauthorized indication, or marketed 
products used to gain further information about the authorized form.
IRB/IEC Institutio nal Review Boards /Independent Ethics Committees 
ITT intention to treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by [CONTACT_41445] a patient (that is, the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that patients allocated to a treat ment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.
IWQOL -Lite- CT Impact o f Weight on Quality of Life -Lite-Clinical trials
IWRS interactive web -response system
LDL low-density  lipoprotein
Lilly Eli Lilly and Company
MAD multiple ascending dose
MDD Major Depressive Disorder
MedDRA Medical Dictionary for Regulatory Activities
MEN multiple endocrine neoplasia
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 123MHP mental health professional
MI myocardial infarction
mITT modified intention -to-treat
MMRM mixed- model for repeated measures
MRI magnetic resonance imaging
MTC medullary thyroid carcinoma
NYHA [LOCATION_001] Heart Association
OGTT oral glucose tolerance test
PC Product Complaints
PGIS Patient Global Impression of status for physical activity
PHQ -9 Patient Health Questionnaire -9
PK/PD pharmacokinetics/pharmacodynamics
PRO s/ePRO patient -reported outcomes
QW once weekly
SAD single ascending dose
SAE serious adverse event
SAP Statistical Analysis Plan
SBP systolic blood pressure
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SD standard deviation
SF-36v2 Short-Form -36 Health Survey (SF -36), versio n 2
SMQ standardized MedDRA queries
SS safety  analy sis set
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
T1DM type 1 diabetes mellitus
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 124T2DM type 2 diabetes mellitus
TBL total bilirubin level
TE treatment emergent
TEAE treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
TEE total energy exposure
TSH thyroid-stimulating hormone
ULN upper limit of normal
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 [ZIP_CODE].12. Appendix 1 2: Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
Amendment a: (24-July-2020 )
Overall Rationale for the Amendment
The GPHK clinical protocol  has been amended to extend the safet y follow-up peri od in order to 
better characterize the glycemic status of study  parti cipants.   The overall changes and rationale 
for the changes made to this protocol are described in the fo llowing table. Note that minor edits 
have been made throughout the protocol, which are not captured in the amendment summary 
table.
Section # and Name [CONTACT_23688]
1.[ADDRESS_318482] ivities 
changed Visit 802 to 17 weeks 
posttreatment period The safet y follow-up period has 
been extended to 17 weeks to 
address regulatory  feedback 
from Type C advice meet ing 
with FDA (26 June 2019).
9.[ADDRESS_318483] ives and 
Endpoint
9.1 Stati stical 
Hypothesis
[IP_ADDRESS] Key  Secondary  
AnalysesAkey secondary  objective was 
added (time to onset of T2DM 
during the ent ire study ) with the 
associ ated endpoint and statist ical 
hypothesis An addit ional key secondary  
objective was added per FDA 
request from Ty pe C advice 
meet ing with FDA (26 June 
2019).
10.10 Appendix 10 An appendix describing mit igation 
for extenuat ing circumstance s was 
added as Section 10.10  Appendix 
10
The Abbreviat ion Appendix 10 is 
now Appendix 11Language was added to address 
extenuat ing circumstan ces due to 
unforeseen widespread 
emergencies (such as pandemics 
or natural disasters) .
[IP_ADDRESS] Primary Asentence rel ated to sel ection of 
variance -covariance structure in The details will be provided in 
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 126Section # and Name [CONTACT_261789].
1.3 Schedule of 
ActivitiesAllowable deviat ion (days) for 
Visit21 was changed fro m 
+7days to ±[ADDRESS_318484] 
circumference data for 
participants who discont inue the 
study  treatm ent early but come 
to the 3- year endpo int visit. 
[IP_ADDRESS].3 Continued 
Follow-up for 
Parti cipants wi th 
Predi abetes (Vi sits 101 
through 116)Measurement of waist 
circumference added to list of visit 
proceduresThe text was added to align wit h 
changes in the Schedule of 
Activities regarding 
measurement of waist 
circumference at Vi sit 199.
1.[ADDRESS_318485] ivity entitled “register 
study  visit in IWRS”The a ctivit y was added to the 
SOA to ensure all visits are 
registered.  Thi s allows 
monitoring of study  activities 
using real -time IWRS reports.
10.[ADDRESS_318486] ion of 
Pregnancy InformationAdded text “more than 18 months” Thesentence was revised to 
maintain consistency  with the 
text fro m the exclusio n criteria.
10.[ADDRESS_318487] imulat ing 
horm one l evels used to confi rm a 
postm enopausal state in wom en
has been deleted The note could lead to 
misinterpretation of inclusion 
criterion 4.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 [ZIP_CODE]. References
Adams T D, Davidson LE, Litwin SE, Ki mJ, Ko lotkin RL, Nanjee MN, Guti errez JM, Frogley 
SJ, Ibel e AR, Brinton EA, Hopkins PN, McKinlay  RM., Si mper SC, Hunt SC. Weight and 
metabo lic outcomes 12 years after gastric by[CONTACT_6476]. N Engl J M ed.2017;377 (12):1143 -1155.
Allison DB ,Downey M ,Atkinson RL ,Billington CJ ,Bray GA ,Eckel RH ,Finkelstein EA, 
Jensen MD, Tremblay A .Obesit y as a disease: a white paper on evidence and arguments 
commissioned by [CONTACT_261787] .Obesity (Silver 
Spring ).2008; 16(6):1161 -1177 .
American Diabetes Associat ion. In Standards of Medical Care in Diabetes -2019. Glycemic 
Targets: Standards of Medical Care in Diabetes -2019. Diabetes Care . 2019 a;42(suppl 1):S61 -
S70.
American Diabetes Associat ion. In Standards of Medical Care in Diabetes -2019.  Classificat ion 
and Diagnosis of Diabetes: Standards of Medical Care in Diabetes -2019.  Diabetes Care 
2019b; 42(suppl 1): S 13 -S28.
[AMA] American Medical Association. American Medical Association House of Delegates 
Resolution : 420 (A -13) Recognit ion of Obesit y as a Di sease, 2013 pp 1-7. Available at:  
https://www.npr.org/documents/2013/jun/ama -resol ution-obesit y.pdf  Accessed August 30, 
2019.
Aroda VR, Ratner R. The safety and tol erabilit y of GLP -1 receptor agonists in t he treatment of 
type 2 di abetes : a review. Diabetes Metab Res Rev . 2011;27(6):528 -542. 
Baggi
o LL, Drucker DJ. Bi ology of incretins: GLP -1 and GIP. Gastroenterol.
2007;132(6):2131 -2157. 
Banks PA, Freeman ML ; Practi ce Parameters Com mittee of the American Co llege of 
Gastroenterology .Practi ce gui delines in acute pancreatit is. Am J Gastroenterol.
2006;101(10):[ADDRESS_318488], Gimeno RE, D’Alessio DA, 
Haupt A. LY3298176, a novel dual GIP and GLP -[ADDRESS_318489] for the treatment of ty pe 2 
diabetes m ellitus: From discovery  to clinical  proof  of concept. Mol Metab . 2018 ;18:3 -14.
Council on Science and Public Health. Report of the Council on Science and Public Healt h. Is 
obesit y a disease? (Reso lution 115 -A-12). Council on Science and Public Health. Report
number: 3-A-13, 2013.
Danne T, Philotheou A, Goldman D, Guo X, Pi[INVESTIGATOR_007] L, Cali A, Johnston P. A randomized trial 
comparing the rate of hypoglycemia – assessed using continuous glucose monitoring – in 125 
preschool children with ty pe 1 diabetes treated with insulin glargine or NPH insulin (the
PRESCHOOL study ). Pediatr Diabetes . 2013;14(8):593 -601. Erratum in: Pediatr Diabetes . 
2015;16(6):462.
Dolan P. Modeling valuations for EuroQol Healt h States. Medical Care 1997; 35(11):1095 -1108.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 128Dombrowski SU, Knittle K, Avenell A ,Araújo -Soares V, Sniehotta FF. Long term  maintenance 
of weight loss wi th non-surgical interventions in obese adults: systemat ic review and 
meta -analyses o f randomiz ed controlled trials. BMJ .2014;348: g2646.
[EMA] European Medicines Agency.  G uideline on clinical evaluation of medicinal products 
used in weight management .  Committee for Medicinal Products for Human Use.  June 2016.  
http://www.ema.europa.eu/docs/en_GB/document_library /Scient ific_guideline/2016/07/WC50
0209942.pdf   Accessed Novem ber 19, 2018 .
EuroQoL Group. EQ -5D- 5L User guide : basic inform ation on how to use the EQ -5D- 5L 
instrum ent. Versi on 2.1. Available at: 
https://euroqol.org/wp -content/upl oads/2016/09/EQ -5D- 5L_UserGuide_2015.pdf. Published
April 2015 . Accessed January  22, 2019.
FAO/WHO/UNU. Human energy  requi rements. Report of a joint FAO/WHO/UNU expert , 
Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WHH, Temelkova -Kurktschiev T, for the 
REWIMND consultat ion. FAO: food and nutri tion technical report series 1. Rome: 
FAO/WHO/UN U;2004.
[FDA] Food and Drug Administration. Guidance for Industry. Developi[INVESTIGATOR_261721].  February 2007 .Available at: 
https://www.fda.gov/downloads/Drugs/Guidances/ucm071612.pdf .Accessed November 19, 
2018.
Frias JP, Nauck MA, Van J , 
Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, 
Robins D, Haupt A . Efficacy and safet y of LY3298176, a novel dual GIP and GLP -[ADDRESS_318490], in pat ients with type 2 di abetes: a randomi sed, placebo -controlled and act ive 
comparator -controlled phase 2 trial. Lancet .2018;392([ZIP_CODE]) :[ADDRESS_318491] igators. Dulaglut ide and cardiovascular outcomes in t ype 2 diabetes 
(REWIND): a double -blind, randomized placebo -controlled trial. Lancet
2019;394 ([ZIP_CODE]):[ADDRESS_318492] 
VS, Jakicic JM, Ku shner RF, Loria CM, Millen BE, Nonas CA, Pi -Sunyer FX, Stevens J, 
Stevens VJ, Wadden TA, Wo lfe BM, Uanovski SZ. Executive summary: guidelines (2013) 
for the m anagement of overweight and obesit y in adul ts: a report of the American Co llege o f 
Cardi ology/American Heart Associat ion Task Force on Practice Guidelines and the Obesit y 
Society published by [CONTACT_134141] y Society and Ameri can Co llege of Cardio logy/American 
Heart Associ ation Task Force on Practice Guidelines. Based on a sy stematic review from the 
Obesi ty Expert Panel , 2013. Obesity .2014;22: (suppl 2 ):S5-S39.
Knowl er WC, Barrett -Connor E, Fowler SE, Hamman R F, Lachin JM, Walker EA, Nathan DM ;
Diabetes Prevent ion Program  Research Group. Reduction in the incidence of ty pe 2 di abetes 
with lifestyle interventi on or m etformin. N Engl J Med .2002;346 (6):393-403.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 129Koizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, 
Kimura Y, [COMPANY_005] K, Isaji S, Otsuki M, Matsuno S; JPN. JPN Guidelines for the management 
of acute pancreatit is: diagnost ic criteria for acute pancreat itis. J Hepatobiliary Pancreat Surg . 
2006;13(1):[ADDRESS_318493] of Weight on Qualit y of Life -Lite questi onnaire (IWQoL -Lite Clinical  
Trials Versi on):  resul ts from two qualitat ive studies. Clin Obes .2017;7(5):290 -299. 
Kolotkin RL, Williams V, Ervin, CM, Meincke HH, Qin S, Smit h LvH, Fehnel SE. Validat ion of 
a new measure of qualit y of life in obesit y trials: IWQOL –Lite Clinical Tri als Versio n. 
Poster presented at: Obesit yWeek 2018; November 13, 2018; Nashville, TN.
Kroenke K, Spi[INVESTIGATOR_626] R L, Williams JB. The PHQ -9: validit y of a brief depressio n severi ty 
measure. J Gen Intern Med. 2001;16(9) :606- 616.
leRoux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding 
JPH, Skj oth TV, Manning LS, Pi -Sunyer X for the SCALE Obe sity Prediabetes NN8022 -1839 
Study  Group. 3 years of liraglut ide versus placebo for ty pe 2 di abetes ri sk reducti on and 
weight management in individuals with prediabetes: a randomized, double -blind trial. Lancet .
2017;389 ([ZIP_CODE]) :[ADDRESS_318494] yle intervent ion for people wit h impaired glucose 
tolerance i n the Da Qing Diabetes Prevent ion Study: a 23 -year follow
-up study . Lancet 
Diabetes Endocrinol .2014;2(6):474 -480.
Luppi[INVESTIGATOR_4276], de Wit LM, Bouvy  PF, Stijnen T, Cu ijpers P, Penninx BW, Zit man FG. 
Overweight, obesit y, and depressio n: a systemati c revi ew and meta -analysis o f longitudinal 
studi es. Arch Gen Psychiatry .2010;67(3):220 -
229.
Marso SP, Daniels GH, Brown -
Frandsen K, Kirstensen P, Mann JFE, Nauck MA, Nissen SE, 
Pocock S, Poulter NR, Tavn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal  RM, Buse 
JB. For the LEADER Steering Committee.  Liraglutide and cardiovascular outcomes in ty pe 2 
diabetes. N Engl J Med 2016a ; 375:[ADDRESS_318495] AG, Pettersson J, Vilsbo ll T, for the 
SUSTAIN -6 Investigators.  Semaglut ide and cardiovascular outcomes in patients with type 2 
diabetes. N Engl J Med 2016b ; 375:1834 -1844.
Maruish ME, ed. User’s manual for the SF -36v2 Heal th Survey .3rd ed. Linco ln, RI: Qualit y
Metri c Incorporated; 2011 .
Mertens IL, Van Gaal LF. Overweight, obesit y, and bl ood pressure: the effects of modest weight 
reducti on. Obes Res. 2000;8 (3):270-278.
Nauck MA, Meier JJ, Schmidt WE. Incretin -based glucose -lowering medicat ions and the risk o f 
acute pancreatit is and/or pancreati c cancer: Reassuring data from cardio -vascular outcome 
trials. Diabetes Obes Metab . 2017;19(9):1327- 1328.
CONFIDENTIAL Protocol  I8F-MC-GPHK (b)
LY3298176 130SAXENDA® [ EMA summary  of product characteri stics (SmPC)]. Novo Nordis k, Bagsvaerd, 
Denmark .Available at: 
https://ec.europa.eu/healt h/documents/communit y-register/2015/20150323131125/anx_13112
5_en.pdf .  Accessed April 10, 2019.
SAXENDA® [package insert ] Novo Nordisk, Bagsvaerd, Denmark. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf. 
Accessed March 2, 2019.
Skow MA, Bergmann , NC, Knop FK. Di abetes and obesit y treatm ent based on dual incret in 
receptor acti vation: “twincret ins”. Diabetes Obes Metab .2016;18(9) :847- 854.
Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD
, Nauck MA; LEADER Steering 
Committee; LEADER Tri al Invest igators. Amylase, lipase, and acute pancreat itis in peopl e 
with type 2 diabetes treated with liraglut ide: results from the LEADER Rando mized Trial.
Diabetes Care .2017a;40(7):[ADDRESS_318496] of 
liraglutide on amylase, lipase, and acute pancreat itis in part icipants wi th overwei ght/obesi ty 
and normoglycemia, pred iabetes, or ty pe 2 di abetes: secondary  analyses of pooled data from 
the SCALE clinical development program. Diabetes Care. 2017b;40(7):839 -848.
Tomlinso n B, Hu M, Zhang Y, Chan P, Liu ZM. An overview of new GLP -1 receptor agonists 
for type 2 di abetes. Expert Opin Investig Drugs . 2016;25(2):145 -
158. 
van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of 
glucagon -like peptide 1 on appetite and body  weight: focus on the CNS. J Endocrinol . 
2014;221(1):T1
-T16.
Warkent in LM, Das D, Majumdar SR, Johnson JA, Padwal RS. The effect of weight loss on 
healt h-related qualit y of life: system atic review and meta -analysis of rando mized trials . Obes 
Rev.2014;15 (3):169-182.
Weinberg ME, Bacchetti P, Rushakoff RJ. Frequent lyrepeated gl ucose m easurements 
overestimate the incidence of inpatient hy poglycemia and severe hyperglycemia. J Diabetes 
Sci Technol . 2010;4(3):577 -
582.
Leo Document ID = 8dd79a8d-d134-4b80-afb3-6ce848a2570c
Approver: 
Approval Date & Time: 01-Oct-2021 16:14:59 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 04-Oct-2021 15:48:26 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]